ΕΛΛΗΝΙΚΗ ΝΕΥΡΟΛΟΓΙΚΗ ΕΤΑΙΡΕΙΑ
ΑΛΚΜΑΝΟΣ 10, 115 28, ΑΘΗΝΑ
ΕΝΤΥΠΟ ΚΛΕΙΣΤΟ ΑΡ. ΑΔΕΙΑΣ 815/94 ΚΕΜΠ ΚΡ.
ΚΩΔΙΚΟΣ ΕΝΤΥΠΟΥ: 017159

ISSN: 2732-9119

ΕΛΛΗΝΙΚΗ ΝΕΥΡΟΛΟΓΙΚΗ ΕΤΑΙΡΕΙΑ
HELLENIC NEUROLOGICAL SOCIETY
www.enee.gr

Αρχεία Κλινικής Νευρολογίας

www.jneurology.gr

ΕΠΙΣΗΜΟ ΠΕΡΙΟΔΙΚΟ ΤΗΣ ΕΛΛΗΝΙΚΗΣ ΝΕΥΡΟΛΟΓΙΚΗΣ ΕΤΑΙΡΕΙΑΣ

Τόμος 31 - Τεύχος 3

Vol. 31 - Issue 3

ΚΕΙΜΕΝΟ ΟΜΟΦΩΝΙΑΣ / CONSENSUS DOCUMENT

ΑΡΘΡΑ / ARTICLES

Μάιος - Ιούνιος 2022 / May - June 2022

Διμηνιαία έκδοση της
Ελληνικής Νευρολογικής Εταιρείας
Αλκμάνος 10, Αθήνα 115 28
Τηλ.: 210 72.47.056 - Fax: 210 72.47.556
www.enee.gr info@jneurology.gr

Κωδικός Διεύθυνσης Εποπτείας ΜΜΕ:
7159ISSN 1106 - 3106

Αρχεία Κλινικής Νευρολογίας

www.jneurology.gr

Τόμος 31, Τεύχος 3, Μάιος - Ιούνιος 2022

Περιεχόμενα

ΑΡΘΡΑ

Official Journal of the
Hellenic Neurological Society
10, Alkmanos str., Athens
Tel.: 210 72.47.056 - Fax: 210 72.47.556
www.enee.gr info@jneurology.gr
e-submission: submission@jneurology.gr

OWNER

HELLENIC NEUROLOGICAL SOCIETY
10 Alkmanos str, Athens
115 28 - Greece

PRINTED EDITION AND PDFs

Lychnia S.A.
7 Andravidas str., Athens
136 71, Hamomilo Aharnon
Tel.: 210 34.10.436 - 1, Fax: 210.34.25.967
www.lyhnia.com

SUBSCRIPTION FEES

HNS Members Free

Archives of Clinical Neurology

www.jneurology.gr

Volume 31:3 May - June 2022

Contents

ARTICLES

"Our dream, our effort…" – Editorial

Is there a need for another neuroscience journal, given the continuously growing number of options available in which to publish your research efforts? The announcement of the rename to "Archives of Clinical Neurology" of the official journal of the Hellenic Neurological Society last autumn, came at a time of great competition between neuroscience journals. Consideringthe increasing numbers of journals offering different publishing options for authors, some of which are of great quality, it is almost a dream for us to launch a serious, quality oriented journal in this environment.

After several months of preparatory work, taking into consideration the broad spectrum of the article types that we want to publish, we have created a large Editorial Board representing all the areas of clinical and basic neurosciences, and we have appointed section editorial teams for all the relevant subspecialties.

Currently, we are delighted to release the present issue containing five non-invited articles written in English language that have been submitted to our journal by various Departments of Neurology in Greece. Moreover, we are happy from the positive response and constructive feedback from the Hellenic Neurological Scientific Community. The first article is a consensus paper for the management of spasticity in patients with Multiple Sclerosis; the article was written in collaboration by the Hellenic Neurological Society, the Hellenic Academy of Neuroimmunology and the Hellenic Society of Physical and Rehabilitation Medicine.The second article is a guidance paper for the accreditation of the existing Hellenic Stroke Units according to the European Stroke Organization requirements. The other three are three interesting and clinical relevant case reports.

We sincerely hope that you find these articles interesting, and of high scientific quality. To reach our goals for the journal, we need your support. Our readership is small but growing and we continue to invite reviews on new developments and perspectives, and we welcome submissions of research articles and interesting case reports.
Please continue to support us to make Archives of Clinical Neurology an influential voice publishing content with international scientific impact.
.

Sotirios Giannopoulos, MD, PhD
National & Kapodistrian University of Athens

Συντακτική Ομάδα (Editorial Board)

Συντακτική Ομάδα (Editorial Board)

25. Χ. Κρόγιας (Ruhr University of Bochum, Bochum, Germany)
26. Β. Λιούτας (Harvard University, Boston, USA)
27. Π. Μήτσιας (Πανεπιστήμιο Κρήτης, Ηράκλειο & Wayne State University, Detroit, USA)
28. Γ. Ρούντολφ (Γενικό Νοσοκομείο Παπαγεωργίου, Θεσσαλονίκη)
29. Α. Σαφούρης (Νοσοκομείο Metropolitan, Πειραιά)
30. Κ. Σπέγγος (Νοσοκομείο Υγεία, Αθήνα)
31. Γ. Τσιβγούλης (Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών & University of Tennessee Health Sciences Center, Memphis, USA)

Παιδονευρολογία
1. Β. Δάρας (Harvard University, Boston, USA)
2. Α. Ευαγγελίου (Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης, Θεσσαλονίκη)
3. Δ. Ζαφειρίου (Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης, Θεσσαλονίκη)
4. Α. Παπαβασιλείου (Ιασώ Παίδων, Αθήνα)

Κλινική Νευροφυσιολογία
1. Ε. Αναγνώστου (Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών, Αθήνα)
2. Π. Ζης (Πανεπιστήμιο Κύπρου, Λευκωσία, Κύπρος)
3. Ι. Καράκης (Emory University, Atlanta, USA)
4. Β. Κιμισκίδης (Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης, Θεσσαλονίκη)
5. Π. Κοκότης (Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών, Αθήνα)
6. Α. Κωδούνης (251 Γενικό Νοσοκομείο Αεροπορίας, Αθήνα)
7. Α. Μπονάκης (Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών, Αθήνα)
8. Μ. Παπαδοπούλου (Πανεπιστήμιο Δυτικής Αττικής)
9. Χ. Πιπερίδου (Δημοκρίτειο Πανεπιστήμιο Θράκης, Αλεξανδρούπολη)
10. Ε. Σταμπουλής (Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών, Αθήνα)
11. Δ. Τσίπτσιος (Δημοκρίτειο Πανεπιστήμιο Θράκης, Αλεξανδρούπολη)
12. Ε. Χρόνη (Πανεπιστήμιο Πάτρας, Πάτρα)

Άνοια
1. Π.Ιωαννίδης (Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης, Θεσσαλονίκη)
2. Ε.Καπάκη (Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών, Αθήνα)
3. Χ.Μπούρας (University of Geneva, Geneva, Switzerland)
4. Γ.Παρασκευάς (Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών, Αθήνα)
5. Ν.Σκαρμέας (Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών, Αθήνα)
6. Μ.Τσολάκη (Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης, Θεσσαλονίκη)

Επιληψία
1. M. Reuber (University of Sheffield, UK)
2. Α. Αγαθονίκου (Γενικό Νοσοκομείο Αθηνών ΚΑΤ, Αθήνα)
3. Α. Αρζιμάνογλου (University Hospital of Lyon, Lyon, France)
4. Ι. Καράκης (Emory University, Atlanta, USA)
5. Β. Κιμισκίδης (Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης, Θεσσαλονίκη)
6. Μ. Κουτρουμανίδης (Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom)
7. Χ. Πιπερίδου (Δημοκρίτειο Πανεπιστήμιο Θράκης, Αλεξανδρούπολη)
8. Π. Πολυχρονόπουλος (Πανεπιστήμιο Πάτρας, Πάτρα)
9. Αικ.Τερζούδη (Δημοκρίτειο Πανεπιστήμιο Θράκης, Αλεξανδρούπολη)

Συντακτική Ομάδα (Editorial Board)

Κεφαλαλγία
1. Χ.Αρβανίτη (Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών, Αθήνα)
2. Θ. Αβραμίδης (Γενικό Νοσοκομείο Αθηνών Ερυθρός Σταυρός, Αθήνα)
3. Μ. Βικελής (Αθήνα)
4. Κ. Γυμνόπουλος (Γενικό Νοσοκομείο Θεσσαλονίκης Άγιος Λουκάς, Θεσσαλονίκη)
5. Π. Μήτσιας (Πανεπιστήμιο Κρήτης, Ηράκλειο & Henry Ford Hospital - Wayne State University, Detroit, USA)
6. Δ. Μητσικώστας (Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών, Αθήνα)
7. Γ. Ρούντολφ (Γενικό Νοσοκομείο Παπαγεωργίου, Θεσσαλονίκη)

Ιστορία της Νευρολογίας
1. Α. Καράβατος (Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης, Θεσσαλονίκη)
2. Λ. Τριάρχου (Πανεπιστήμιο Μακεδονίας, Θεσσαλονίκη)

Επεμβατική Νευρολογία
1. N. Goyal (University of Tennessee Health Sciences Center, Memphis, USA)
2. A. Sarraj (The University of Texas McGovern Medical School, Houston, USA)
3. Α. Σαφούρης (Νοσοκομείο Metropolitan, Πειραιά)

Κινητικές Διαταραχές
1. Μ. Αρναούτογλου (Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης, Θεσσαλονίκη)
2. Ζ.Μ. Κεφαλοπούλου (Πανεπιστήμιο Πάτρας, Πάτρα)
3. Σ. Κονιτσιώτης (Πανεπιστήμιο Ιωαννίνων, Ιωάννινα)
4. Σ. Μποσταντζοπούλου (Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης, Θεσσαλονίκη)
5. Μ. Πολίτης (University of Exeter, UK)
6. Μ. Σταμέλου (University of Marburg, Germany)
7. Λ. Στεφανής (Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών, Αθήνα)

Νευρογενετική
1. K. Kleopa (Cyprus Institute of Neurology and Genetics, Cyprus)
2. Ε. Δαρδιώτης (Πανεπιστήμιο Θεσσαλίας, Λάρισα)
3. Γ. Κούτσης (Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών, Αθήνα)
4. Δ. Μόνος (University of Pennsylvania, Philadelphia, USA)
5. Γ. Ξηρομερίσιου (Πανεπιστήμιο Θεσσαλίας, Λάρισα)
6. Γ. Χατζηγεωργίου (Πανεπιστήμιο Κύπρου, Λευκωσία, Κύπρος)

Νευροανοσολογία
1. R. Gold (Ruhr University of Bochum, Bochum, Germany)
2. M. Hadjivassiliou (University of Sheffield, UK)
3. Κ. Βουμβουράκης (Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών, Αθήνα)
4. Ν. Γρηγοριάδης (Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης, Θεσσαλονίκη)
5. Ε. Δαρδιώτης (Πανεπιστήμιο Θεσσαλίας, Λάρισα)
6. Γ. Δερετζή (Γενικό Νοσοκομείο Παπαγεωργίου, Θεσσαλονίκη)
7. Ε.Μ. Ευαγγελοπούλου (Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών, Αθήνα)
8. Ι. Ηλιόπουλος (Δημοκρίτειο Πανεπιστήμιο Θράκης, Αλεξανδρούπολη)
9. Λ. Κάππος (University of Basel, Basel, Switzerland)
10. Κ. Κυλιντηρέας (Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών, Αθήνα)
11. Δ. Μόνος (University of Pennsylvania, Philadelphia, USA)
12. Μ. Μποζίκη (Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης, Θεσσαλονίκη)
13. Τ. Ντόσκας (Ναυτικό Νοσοκομείο Αθηνών, Αθήνα)
14. Π. Παπαθανασόπουλος (Πανεπιστήμιο Πάτρας, Πάτρα)

15. Γ. Τζάρτος (Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών, Αθήνα)
16. Γ. Χατζηγεωργίου (Πανεπιστήμιο Κύπρου, Λευκωσία, Κύπρος)

Νευροεντατική
1. J. Chang (MedStar Washington Hospital Center)
2. T. Steiner (University of Heidelberg, Heidelberg, Germany)
3. Π. Βαρελάς (Albany Medical College, Albany, USA)
4. Κ. Δημητριάδης (Ludwig-Maximillians University Munich, Germany)
5. Δ. Κάζης (Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης, Θεσσαλονίκη)
6. Χ. Κρόγιας (Ruhr University of Bochum, Bochum, Germany)
7. Γ. Ρούντολφ (Γενικό Νοσοκομείο Παπαγεωργίου, Θεσσαλονίκη)

Εκπαίδευση στη Νευρολογία
1. Θ. Αβραμίδης (Γενικό Νοσοκομείο Αθηνών Ερυθρός Σταυρός, Αθήνα)
2. Κ. Βαδικόλιας (Δημοκρίτειο Πανεπιστήμιο Θράκης, Αλεξανδρούπολη)
3. Π. Βαρελάς (Albany Medical College, Albany, USA)
4. Κ. Βουμβουράκης ((Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών, Αθήνα)
5. Ν. Γρηγοριάδης (Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης, Θεσσαλονίκη)
6. Ε. Δαρδιώτης (Πανεπιστήμιο Θεσσαλίας, Λάρισα)
7. Γ. Δερετζή (Γενικό Νοσοκομείο Παπαγεωργίου, Θεσσαλονίκη)
8. Π. Ζης (Πανεπιστήμιο Κύπρου, Λευκωσία, Κύπρος)
9. Κ. Κυλιντηρέας (Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών, Αθήνα)
10. Π. Μήτσιας (Πανεπιστήμιο Κρήτης, Ηράκλειο & Henry Ford Hospital - Wayne State University, Detroit, USA)
11. Ι. Μυλωνάς (Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης, Θεσσαλονίκη)
12. Γ. Ρούντολφ (Γενικό Νοσοκομείο Παπαγεωργίου, Θεσσαλονίκη)
13. Λ. Στεφανής (Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών, Αθήνα)
14. Γ. Τσιβγούλης (Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών & University of Tennessee Health Sciences Center, Memphis, USA)
15. Γ. Χατζηγεωργίου (Πανεπιστήμιο Κύπρου, Λευκωσία, Κύπρος)

Νευρομυϊκές διαταραχές
1. C. McDermott (University of Sheffield, UK)
2. Θ. Αβραμίδης (Γενικό Νοσοκομείο Αθηνών Ερυθρός Σταυρός, Αθήνα)
3. Π. Δαβάκη (Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών, Αθήνα)
4. Θ. Ζαμπέλης (Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών, Αθήνα)
5. Β. Ζούβελου (Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών, Αθήνα)
6. Π. Ζης (Πανεπιστήμιο Κύπρου, Λευκωσία, Κύπρος)
7. Ι. Μαυρομάτης (Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης, Θεσσαλονίκη)
8. Γ. Παπαδήμας (Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών, Αθήνα)
9. Α. Παπαδημητρίου (Πανεπιστήμιο Θεσσαλίας, Λάρισα)
10. Δ. Παρίσης (Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης, Θεσσαλονίκη)
11. Ε. Σταμπουλής (Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών, Αθήνα)
12. Ν. Τάσκος (Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης, Θεσσαλονίκη)

Νευρο-ογκολογία
1. Α. Κυρίτσης (Πανεπιστήμιο Ιωαννίνων, Ιωάννινα)

Νευρο-οφθαλμολογία
1. Ε. Αναγνώστου (Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών, Αθήνα)
2. Ι. Ευδοκιμίδης (Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών, Αθήνα)

Συντακτική Ομάδα (Editorial Board)

3. Ι. Ηλιόπουλος (Δημοκρίτειο Πανεπιστήμιο Θράκης, Αλεξανδρούπολη)

Νευροψυχολογία – Νευροψυχιατρική
1. Γ. Δελατόλας (Universite Paris Descartes, Paris, France)
2. Ε. Καπάκη (Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών, Αθήνα)
3. Α. Καράβατος (Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης, Θεσσαλονίκη)
4. Χ. Μπακιρτζής (Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης, Θεσσαλονίκη)
5. Χ. Μπούρας (University of Geneva, Geneva, Switzerland)
6. Ν. Ρομπάκης (Mounti Sinai, New York, USA)
7. Μ. Συγγελάκης (Γενικό Νοσοκομείο Παπαγεωργίου, Θεσσαλονίκη)

Νευροακτινολογία και Νευρουπερηχογραφία
1. M. Rubiera (Hospital Universitari Vall d'Hebron, Barcelona, Spain)
2. M. Rubin (University of Tennessee Health Sciences Center, Memphis, USA)
3. Ν. Αρτέμης (Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης, Θεσσαλονίκη)
4. Κ. Βαδικόλιας (Δημοκρίτειο Πανεπιστήμιο Θράκης, Αλεξανδρούπολη)
5. Α. Βαλαβάνης (University of Zurich, Zurich, Switzerland)
6. Ν. Βλαϊκίδης (Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης, Θεσσαλονίκη)
7. Σ. Γιαννόπουλος (Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών, Αθήνα)
8. Ι. Ηλιόπουλος (Δημοκρίτειο Πανεπιστήμιο Θράκης, Αλεξανδρούπολη)
9. Θ. Καραπαναγιωτίδης (Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης, Θεσσαλονίκη)
10. Α. Κατσάνος (McMaster University, Hamilton, Canada)
11. Σ. Κόλλιας (University of Zurich, Zurich, Switzerland)
12. Χ. Κρόγιας (Ruhr University of Bochum, Bochum Germany)
13. Β. Λιούτας (Harvard University, Boston, USA)
14. Π. Μήτσιας (Πανεπιστήμιο Κρήτης, Ηράκλειο & Henry Ford Hospital - Wayne State University, Detroit, USA)
15. Μ. Πολίτης (University of Exeter, UK)
16. Θ. Τέγος (Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης, Θεσσαλονίκη)
17. Γ. Τσιβγούλης (Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών & University of Tennessee Health Sciences Center, Memphis, USA)
18. Α.Χαριτάντη-Κουρίδου (Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης, Θεσσαλονίκη)

Πόνος
1. A. Paladini (L'Aquila University, Italy)
2. G. Varrassi (Paolo Procacci Foundation, Italy)
3. Π. Ζης (Πανεπιστήμιο Κύπρου, Λευκωσία, Κύπρος)

Ιατρική του Ύπνου
1. Α. Βγόντζας (Πανεπιστήμιο Κύπρου, Λευκωσία, Κύπρος)
2. Π. Μπαργιώτας (Πανεπιστήμιο Κύπρου, Λευκωσία, Κύπρος)
3. Α. Μπονάκης (Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών, Αθήνα)
4. Αικ. Τερζούδη (Δημοκρίτειο Πανεπιστήμιο Θράκης, Αλεξανδρούπολη)

Διεθνής Εκπροσώπηση
1. Π. Ζης (Πανεπιστήμιο Κύπρου, Λευκωσία, Κύπρος)
2. Α. Κατσάνος (McMaster University, Hamilton, Canada)

Editorial Board

Editorial Board

Editorial Board

15. Tzartos J (National & Kapodistrian University of Athens, Athens, Greece)
16. Voumvourakis K (National & Kapodistrian University of Athens, Athens, Greece)

Neurointensive care

1. Dimitriadis K (Ludwig-Maximillians University Munich, Germany)
2. Chang J (MedStar Washington Hospital Center)
3. Kazis D (Aristotle University of Thessaloniki, Thessaloniki, Greece)
4. Krogias C (Ruhr University of Bochum, Bochum, Germany)
5. Rudolf J (Papageorgiou Hospital, Thessaloniki, Greece)
6. Steiner T (University of Heidelberg, Heidelberg, Germany)
7. Varelas P (Albany Medical College, Albany, USA)

Neurology Education

1. Avramidis T (Red Cross Hospital, Athens, Greece)
2. Dardiotis E (University of Thessaly, Larissa, Greece)
3. Deretzi G (Papageorgiou Hospital, Thessaloniki, Greece)
4. Grigoriadis N (Aristotle University of Thessaloniki, Thessaloniki, Greece)
5. Hadjigeorgiou GM (University of Cyprus, Nicosia, Cyprus)
6. Kilidireas K (National & Kapodistrian University of Athens, Athens, Greece)
7. Milonas I (Aristotle University of Thessaloniki, Thessaloniki, Greece)
8. Mitsias P (University of Crete, Heraklion, Greece & Wayne State University, Detroit, USA)
9. Rudolf J (Papageorgiou Hospital, Thessaloniki, Greece)
10. Stefanis L (National & Kapodistrian University of Athens, Greece)
11. Tsivgoulis G (National & Kapodistrian University of Athens, Athens, Greece & University of Tennessee Health Sciences Center, Memphis, USA)
12. Vadikolias K (Democritus University of Thrace, Alexandroupolis, Greece)
13. Varelas P (Albany Medical College, Albany, USA)
14. Voumvourakis K (National & Kapodistrian University of Athens, Athens, Greece)
15. Zis P (University of Cyprus, Nicosia, Cyprus)

Neuromuscular disorders

1. Avramidis T (Red Cross Hospital, Athens, Greece)
2. Chroni E (University of Patras, Patras, Greece)
3. Davaki P (National & Kapodistrian University of Athens, Greece)
4. McDermott C. (University of Sheffield, UK)
5. Mavromatis I (Aristotle University of Thessaloniki, Greece)
6. Papadimas G (National & Kapodistrian University of Athens, Athens, Greece)
7. Papadimitriou A (University of Thessaly, Larissa, Greece)
8. Parissis D (Aristotle University of Thessaloniki, Greece)
9. Stamboulis E (National & Kapodistrian University of Athens, Athens, Greece)
10. Taskos N (Aristotle University of Thessaloniki, Greece)
11. Zouvelou V (National & Kapodistrian University of Athens, Athens, Greece)
12. Zis P (University of Cyprus, Nicosia, Cyprus)

Neurooncology

1. Kyritsis A (University of Ioannina, Ioannina, Greece)

Neuro-opthalmology

1. Anagnostou E (National & Kapodistrian University of Athens, Athens Greece)
2. Evdokimidis I (National & Kapodistrian University of Athens, Athens, Greece)
3. Iliopoulos I (Democritus University of Thrace, Alexandroupolis, Greece)

ΚΕΙΜΕΝΟ ΟΜΟΦΩΝΙΑΣ

«Η δημοσίευση άρθρων στο περιοδικό "ΑΡΧΕΙΑ ΚΛΙΝΙΚΗΣ ΝΕΥΡΟΛΟΓΙΑΣ" δεν δηλώνει αποδοχή των απόψεων και θέσεων του συγγραφέα από την Συντακτική Επιτροπή ή την ΕΝΕ»

«Το περιεχόμενο των καταχωρήσεων είναι ευθύνη των εταιρειών που αναφέρονται και οφείλει να ακολουθεί τις προβλεπόμενες νόμιμες προϋποθέσεις»

«Η χρήση εργαλείων, κλιμάκων και λογισμικού που αναφέρεται στις εργασίες είναι ευθύνη των συγγραφέων, οι οποίοι πρέπει να έχουν εξασφαλίσει τις σχετικές άδειες και να τις κρατούν στο προσωπικό τους αρχείο»

MANAGEMENT OF SPASTICITY IN MULTIPLE SCLEROSIS: A CONSENSUS STATEMENT OF THE HELLENIC NEUROLOGICAL SOCIETY, THE HELLENIC ACADEMY OF NEUROIMMUNOLOGY AND THE HELLENIC SOCIETY OF PHYSICAL AND REHABILITATION MEDICINE

Georgios Tsivgoulis MD[1], Maria-Ioanna Stefanou MD[1], Athanasios Tsivgoulis MD[1, 2], Eleftheria Antoniadou MD[3], Jobst Rudolf MD[4], Efthimios Dardiotis MD[5], Theodoros Avramidis MD[6], Athanasios Tychalas MD[4], Dimitra Veltsista MD[7], Ioannis Iliopoulos MD[8], Triantafyllos Ntoskas MD[9], Konstantinos Melanis MD[1], Sygkliti-Henrietta Pelidou MD[10], Georgios M. Hadjigeorgiou MD1[1], Panagiotis Papathanasopoulos MD[12], Constantinos Kylintireas MD[13], Odysseas Kargiotis MD[1, 14], Markos Sgantzos MD[5], Nikolaos Ananidis MD[15], Zoi Dalivigka MD[16], Aikaterini Kotroni MD[17], Maria-Eleni Manola MD[18], Panoraia Mitsostergiou MD[18], Filomeni Armakola MD[16], Konstantinos Voumvourakis MD[1], Konstantinos Vadikolias MD[8], Nikolaos Grigoriadis MD[19], Konstantina Petropoulou MD[18]

[1] *2nd Department of Neurology, "Attikon" University Hospital, School of Medicine, National and Kapodistrian University of Athens*
[2] *Animus Rehabilitation Clinic, Larisa*
[3] *Physical Medicine and Rehabilitation Department Patras University Hospital, Patras*
[4] *Department of Neurology, Papageorgiou General Hospital, Thessaloniki*
[5] *Department of Neurology, University Hospital of Larissa, University of Thessaly, Larissa*
[6] *Department of Neurology, Red Cross Hospital, Athens*
[7] *Department of Neurology, School of Medicine, University of Patras, Patra*
[8] *Department of Neurology, Democritus University of Thrace, Alexandroupolis*
[9] *Department of Neurology, Athens Naval Hospital, Athens*
[10] *Department of Neurology, University of Ioannina, Ioannina*
[11] *Department of Neurology, Medical School, University of Cyprus, Nicosia*
[12] *University of Patras Medical School, Patras*
[13] *1st Department of Neurology, "Eginition" Hospital, School of Medicine, University of Athens, Athens*
[14] *Stroke Unit, Metropolitan Hospital, Piraeus*
[15] *1st Department of Physical Medicine and Rehabilitation, National Rehabilitation Center, Athens*
[16] *Pediatric Rehabilitation Unit, Children's Hospital "Aglaia Kyriakou", Athens*
[17] *Department of Physical Rehabilitation Medicine, KAT Hospital, Athens*
[18] *2nd Department of Physical Medicine and Rehabilitation, National Rehabilitation Center, Athens*
[19] *2nd Department of Neurology, AHEPA University Hospital, Aristotle University of Thessaloniki, School of Medicine, Faculty of Health Sciences, Thessaloniki*

Abstract

Spasticity is a sensorimotor phenomenon characterized by velocity dependent hypertonia, involuntary muscle spasms or contractions, and is a common cause of disability and quality of life (QoL) impairment in multiple sclerosis (MS). Epidemiological evidence points towards a very high prevalence of MS-related spasticity (MSS) of up to 80% among MS patients. MSS is characterized by a wide spectrum of clinical manifestations and related complications, that contribute to worsening of motor deficits and loss of independence of MS patients, while if left without prompt treatment, MSS may lead to permanent joint deformities, muscle contractions, pain, involuntary movements, and skin complications. The diagnosis and clinical follow-up of MSS requires implementation of well-established clinical scales (Ashworth Scale, modified Ashworth scale, Tardieu Scale), but also requires use of functional scales that incorporate patient-relevant outcomes. The management of MSS should be initiated by multidisciplinary teams consisting of Neurologists and Physical Medicine and Rehabilitation (PM&R) physicians. Therapeutic goals include the overall clinical and functional improvement of the patient, the prevention of complications and contractures, as well as the facilitation of nursing and patient care. MSS treatments include non-pharmacological approaches such as rehabilitation sessions with specialized techniques, and pharmacotherapies, including administration of oral antispastics, intrathecal muscle relaxants, and intramuscular injections of botulinum toxin. The present consensus paper summarizes the current evidence on pharmacological and non-pharmacological MSS treatments, providing recommendations of an expert panel on the diagnostic approach and therapeutic management of MSS.

Key words: spasticity, multiple sclerosis, muscle relaxants, intrathecal baclofen, Botulinum toxin

ΑΝΤΙΜΕΤΩΠΙΣΗ ΤΗΣ ΣΠΑΣΤΙΚΟΤΗΤΑΣ ΣΤΗΝ ΠΟΛΛΑΠΛΗ ΣΚΛΗΡΥΝΣΗ: ΚΕΙΜΕΝΟ ΟΜΟΦΩΝΙΑΣ ΤΗΣ ΕΛΛΗΝΙΚΗΣ ΝΕΥΡΟΛΟΓΙΚΗΣ ΕΤΑΙΡΕΙΑΣ, ΤΗΣ ΕΛΛΗΝΙΚΗΣ ΑΚΑΔΗΜΙΑΣ ΝΕΥΡΟΑΝΟΣΟΛΟΓΙΑΣ ΚΑΙ ΤΗΣ ΕΛΛΗΝΙΚΗΣ ΕΤΑΙΡΕΙΑΣ ΦΥΣΙΚΗΣ ΙΑΤΡΙΚΗΣ ΚΑΙ ΑΠΟΚΑΤΑΣΤΑΣΗΣ

Γεώργιος Τσιβγούλης MD[1], Μαρία-Ιωάννα Στεφάνου MD[1], Αθανάσιος Τσιβγούλης MD[1, 2], Ελευθερία Αντωνιάδου MD[3], Γιομπστ Ρούντολφ MD[4], Ευθύμιος Δαρδιώτης MD[5], Θεόδωρος Αβραμίδης MD[6], Αθανάσιος Τυχάλας MD[4], Δήμητρα Βελτσίστα MD[7], Ιωάννης Ηλιόπουλος MD[8], Τριαντάφυλλος Ντόσκας MD[9], Κωνσταντίνος Μελάνης MD[1], Συγκλητή-Ερριέτα Πελίδου MD[10], Γεώργιος Μ. Χατζηγεωργίου MD[11], Παναγιώτης Παπαθανασόπουλος MD[12], Κωνσταντίνος Κυλιντηρέας MD[13], Οδυσσέας Καργιώτης MD[1, 14] Μάρκος Σγάντζος MD[5], Νικόλαος Ανανίδης MD[15], Ζωή Δαληβίγκα MD[16], Αικατερίνη Κοτρώνη MD[17], Μαρία-Ελένη Μανωλά MD[18], Πανωραία Μητσοστεργίου MD[18], Φιλομένη Αρμακόλα MD[16], Κωνσταντίνος Βουμβουράκης MD[1], Κωνσταντίνος Βαδικόλιας MD[8], Νικόλαος Γρηγοριάδης MD[19], Κωνσταντίνα Πετροπούλου MD[18]

[1] Β΄ Νευρολογική Κλινική, Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών, Ιατρική Σχολή, Νοσοκομείο «Αττικόν», Αθήνα
[2] Animus Κέντρο Αποκατάστασης & Αποθεραπείας, Λάρισα
[3] Κλινική Φυσικής Ιατρικής & Αποκατάστασης, Πανεπιστημιακό Νοσοκομείο Πατρών, Πάτρα
[4] Νευρολογική Κλινική, Γενικό Νοσοκομείο Παπαγεωργίου, Θεσσαλονίκη
[5] Νευρολογική Κλινική, Πανεπιστήμιο Θεσσαλίας, Ιατρική Σχολή, Πανεπιστημιακό Νοσοκομείο Λάρισας, Λάρισα
[6] Νευρολογική Κλινική, Νοσοκομείο Ερυθρός Σταυρός, Αθήνα
[7] Νευρολογική Κλινική, Πανεπιστήμιο Πατρών, Ιατρική Σχολή, Πανεπιστημιακό Νοσοκομείο Πατρών, Πάτρα
[8] Νευρολογική Κλινική, Δημοκρίτειο Πανεπιστήμιο Θράκης, Ιατρική Σχολή, Πανεπιστημιακό Νοσοκομείο Αλεξανδρούπολης, Αλεξανδρούπολη
[9] Νευρολογική Κλινική, Ναυτικό Νοσοκομείο Αθηνών, Αθήνα
[10] Νευρολογική Κλινική, Πανεπιστήμιο Ιωαννίνων, Ιατρική Σχολή, Πανεπιστημιακό Γενικό Νοσοκομείο Ιωαννίνων, Ιωάννινα
[11] Νευρολογική Κλινική, Πανεπιστήμιο Κύπρου, Ιατρική Σχολή, Γενικό Νοσοκομείο Λευκωσίας, Κύπρος
[12] Ιατρική Σχολή Πανεπιστημίου Πατρών, Πάτρα
[13] Α' Νευρολογική Κλινική, Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών, Ιατρική Σχολή, Νοσοκομείο «Αιγινήτειον», Αθήνα
[14] Μονάδα Αντιμετώπισης Αγγειακών Εγκεφαλικών Επεισοδίων, Θεραπευτήριο Μετροπόλιταν, Πειραιάς
[15] Α΄ Κλινική Φυσικής Ιατρικής & Αποκατάστασης, Εθνικό Κέντρο Αποκατάστασης, Αθήνα
[16] Παιδιατρική Κλινική Αποκατάστασης, Νοσοκομείο Παίδων «Παναγιώτη & Αγλαΐας Κυριακού», Αθήνα
[17] Κλινική Φυσικής Ιατρικής & Αποκατάστασης, Νοσοκομείο «ΚΑΤ», Αθήνα
[18] Β΄ Κλινική Φυσικής Ιατρικής & Αποκατάστασης, Εθνικό Κέντρο Αποκατάστασης, Αθήνα
[19] Β΄ Νευρολογική Κλινική, Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης, Πανεπιστημιακό Νοσοκομείο ΑΧΕΠΑ, Θεσσαλονίκη

Περίληψη

Η σπαστικότητα είναι μια αισθητικο-κινητική διαταραχή που χαρακτηρίζεται από μια εξαρτώμενη από την ταχύτητα υπερτονία και αποτελεί μια κοινή αιτία αναπηρίας και διαταραχής της ποιότητας ζωής (QoL) στην πολλαπλή σκλήρυνση (ΠΣ). Επιδημιολογικά στοιχεία υποδεικνύουν έναν πολύ υψηλό επιπολασμό σπαστικότητας σε έδαφος πολλαπλής σκλήρυνσης (ΣΠΣ) έως και 80% μεταξύ των ασθενών με ΠΣ. Η ΣΠΣ χαρακτηρίζεται από ένα ευρύ φάσμα κλινικών εκδηλώσεων και σχετιζόμενων επιπλοκών, που συμβάλλουν στην επιδείνωση των κινητικών ελλειμμάτων και στην απώλεια της ανεξαρτησίας των ασθενών με ΠΣ, ενώ χωρίς έγκαιρη θεραπεία, η ΣΠΣ μπορεί να οδηγήσει σε μόνιμες παραμορφώσεις αρθρώσεων, μυϊκές συγκάμψεις, πόνο, ακούσιες κινήσεις και δερματικές επιπλοκές. Η διάγνωση και η κλινική παρακολούθηση της ΣΠΣ απαιτεί την εφαρμογή καθιερωμένων κλινικών κλιμάκων (Κλίμακα Ashworth, τροποποιημένη κλίμακα Ashworth, κλίμακα Tardieu), αλλά απαιτεί επίσης τη χρήση λειτουργικών κλιμάκων που ενσωματώνουν παραμέτρους σημαντικές για τον ασθενή. Η διαχείριση της ΣΠΣ θα πρέπει να συντονίζεται από διεπιστημονικές ομάδες που απαρτίζονται από Νευρολόγους και ιατρούς Φυσικής Ιατρικής και Αποκατάστασης. Οι θεραπευτικοί στόχοι περιλαμβάνουν τη συνολική κλινική και λειτουργική βελτίωση του ασθενούς, την πρόληψη επιπλοκών και συγκάμψεων, καθώς και τη διευκόλυνση της νοσηλευτικής φροντίδας του ασθενούς. Οι θεραπείες της ΣΠΣ περιλαμβάνουν μη φαρμακολογικές προσεγγίσεις όπως συνεδρίες αποκατάστασης με εξειδικευμένες τεχνικές, και φαρμακοθεραπείες, συμπεριλαμβανομένης της χορήγησης από του στόματος αντισπαστικών, ενδορραχιαίων μυοχαλαρωτικών και ενδομυϊκών ενέσεων αλλαντοτοξίνης. Το παρόν άρθρο ομοφωνίας συνοψίζει τα επιστημονικά δεδομένα σχετικά με τις φαρμακολογικές και μη φαρμακολογικές θεραπείες της ΣΠΣ, παρέχοντας συστάσεις μιας ομάδας ειδικών αναφορικά με τη διαγνωστική προσέγγιση και τη θεραπευτική διαχείριση της ΣΠΣ.

Λέξεις ευρετηρίου: σπαστικότητα, πολλαπλή σκλήρυνση, μυοχαλαρωτικά, ενδορραχιαία βακλοφαίνη, βοτουλινική αλλαντοτοξίνη

ΕΛΛΗΝΙΚΗ ΝΕΥΡΟΛΟΓΙΚΗ ΕΤΑΙΡΕΙΑ

1. Introduction

Multiple sclerosis (MS) comprises the most frequent inflammatory and neurodegenerative demyelinating disorder of the human central nervous system (CNS) [1]. Spasticity is a common cause of disability and quality of life (QoL) impairment in MS, with epidemiological evidence pointing towards a very high prevalence of MS-related spasticity (MSS) of up to 80% among MS patients [2-4]. MSS can be clinically defined as a type of hypertonia (involuntary muscle contraction), that presents with increased, speed-dependent resistance to stretching of skeletal muscles [5]. The underlying pathophysiological mechanisms of MSS are related to demyelinating lesions in the brain or spinal cord, that precipitate neuronal dysfunction and secondary axonal degeneration of descending corticospinal and/or rubro-/reticulospinal tracts, which result into disturbed inhibitory interneuronal spinal pathways and velocity-dependent increase of muscle tone [6, 7].

MSS is characterized by a wide spectrum of clinical manifestations. In MS patients, MSS manifests typically with concomitant "positive" upper motor neuron (UMN) signs, including clonus, co-contraction of antagonist muscles, and abnormal reflexes, and also with "negative" signs, including loss of coordination, weakness and fatigability of affected muscles (Table 1) [2, 8]. In the context of UMN syndrome, MSS results in motor impairment, as well as gait and balance impairment, limiting ambulation and functional independence of MS patients [9]. MSS can manifest clinically either in a tonic or a phasic form (i.e., with continuously or intermittently increased muscle tone, respectively), causing painful muscle spasms, which in turn precipitate sleep disorders and neuropsychiatric complications in MS patients [6]. Additionally, MSS may cause bladder dysfunction as a result of detrusor muscle and external urethral sphincter (spastic muscle) dyssynergia, resulting in detrusor overactivity with urinary incontinence, urinary retention (with mixed symptoms being the most predominant) and dysuria [10]. MSS may also result in bowel dysfunction by adversely affecting the function of muscles of the gastrointestinal tract/pelvic floor [11]. Notably, MSS is also implicated in the manifestation of dysphagia in MS patients [12]. Moreover, chronic spasticity may result in muscle shortening and limb deformities that contribute significantly to the deterioration of patient functional status [2]. MSS is thus, a complex phenomenon, and one of the major causes of disability in MS with negative impact on QoL and MS prognosis [8].

In fact, despite the tremendous advances in the development of immunomodulatory therapies for MS during the last years, a significant proportion of MS patients still experience moderate to severe MSS-related disability [2-4]. Early-implementation of targeted pharmacological and non-pharmacological treatments for MSS is thus, of paramount importance. Such interventions aim to improve QoL through preservation of mobility and functional independence, pain alleviation, and facilitation of nursing [6, 13]. In addition, because of the rising global incidence of MS as well as the increasing survival rates of MS patients [14, 15], MSS has been linked to increasing healthcare costs with detrimental implications for individual patients and healthcare systems worldwide [16]. There is consequently, an urgent need to raise awareness among clinicians regarding the necessity of early recognition and management

Table 1. Positive and negative signs of upper motor neuron syndrome (UMN)

Positive signs	Negative signs
Flexor and extensor muscle spasms	Fatigability
Clonus	Incoordination
Automatisms	Atrophy
Increased deep tendon reflexes	Lack of strength
Rigidity	Lack of motor control
Dystonia	Impaired fine movements
Athetosis	
Spasticity	
Spastic dystonia	
Babinski sign	
Primitive reflexes	
Muscle synergies	

Table 2. Clinical characteristics for the differential diagnosis of spasticity

Spasticity	• Lesions in the pyramidal tract or in vestibulo-/rubro-/ reticulospinal tracts • Velocity – dependent, also length-dependent in MS • Mainly affects muscles resisting gravity, in MS mostly in lower extremities • More resistance in one direction • Clasp knife phenomenon (more tone in the initial phase of movement)
Dystonia	• Involuntary, sustained or intermittent muscle contractions • Twisting or repetitive movements/ abnormal postures
Intrinsic hypertonia	• Soft tissue changes and overactivation of spindle afferents • Same resistance in all directions • Velocity independent
Spastic dystonia	• Uncontrolled muscle contractions, abnormal postures • Simultaneous activity of both agonist and antagonist muscle groups

of MSS, as well as a pressing need to establish interdisciplinary teams for optimal care of MS patients.

The present consensus paper of the Hellenic Neurological Society, the Hellenic Academy of Neuroimmunology and the Hellenic Society of Physical and Rehabilitation Medicine summarizes the current evidence on pharmacological and non-pharmacological MSS treatments, providing recommendations of an expert panel on the diagnostic approach and therapeutic management of MSS.

2. Definition and pathophysiology of MSS

Lance proposed in 1980 the more systematic definition of spasticity as "a motor disorder characterized by a velocity dependent increase in tonic stretch reflexes (muscle tone) with exaggerated tendon jerks, resulting from hyperexcitability of the stretch reflex, as one component of the UMN syndrome" [17]. Beyond the association of spasticity with UMN syndrome, Young expanded the definition of "spastic paresis" to include the presence of "extensor plantar responses, velocity-dependent increase in tonic stretch reflexes, exaggerated phasic stretch reflexes, increased autonomic reflexes, and abnormal postures" [18]. More recently, sensory aspects of spasticity have been acknowledged [19], which have contributed to our current understanding of spasticity as a sensorimotor phenomenon, associated with automatic movement responses to sensory inputs [8]. Spasticity is thus, defined as "a disorder of sensorymotor control caused by UMN lesions that manifests as intermittent or sustained activation of muscles" [20]. Accordingly, MSS occurs as a consequence of involuntary stimuli to muscle tissue to contract [21].

In patients diagnosed with MS [22, 23], CNS injury results in loss of descending inhibitory pathways and in increased excitability of dynamic gamma neurons and alpha motor neurons, that cause aberrant muscle activation [24]. Additional spinal tracts, including vestibulospinal and rubro-/reticulospinal pathways, may be overtly activated contributing to the disinhibition of stretch reflexes. MSS thus, arises as a consequence of CNS lesions and secondary neuroplastic changes, that induce an imbalance of supraspinal inhibitory and excitatory inputs directed to the spinal cord [7].

Even though MSS manifests as a consequence of neuroplastic adaptation to lesions of corticospinal or vestibulo-/rubro-/reticulospinal tracts, these neuroplastic changes lead to secondary effects on the neuromuscular system [7, 25]. Such effects include soft tissue changes (i.e., in muscles, tendons, and ligaments) and muscle contractures causing overactivation of spindle afferents, which in turn aggravate MSS. In contrast to the velocity-dependent MSS, muscle hypertonia due to soft tissue changes manifests clinically with increased resistance to passive movement of skeletal muscles that is not velocity-dependent, and is often referred to as non-reflex hypertonia or intrinsic hypertonia (Table 2) [26-28].

Clinically, besides the distinction of MSS from intrinsic hypertonia, it is important to differentiate MSS from dystonia, which refers to involuntary, sustained or intermittent muscle contractions, that cause twisting, repetitive movements, or abnormal postures (Table 2) [5]. Additionally, in MS patients, overlapping syndromes may occur, which include spastic dystonia that refers to the inability of a muscle to relax leading to spontaneous tonic contraction [29], and spastic co-contraction that implies the simultaneous activity of both agonist and antagonist muscle groups and is particularly profound in spastic paresis [8, 30]. We should also refer to the paroxysmal components of spastic dystonia, as they are of particular relevance for the treatment of spasticity in MS patients [31].

Concerning the evolution of spasticity over time, the pathophysiological correlates and course of spasticity are less well-characterized in MS compared

to other neurological disorders associated with spasticity, including stroke. In stroke, for example, a time-dependent manifestation of spasticity is described, with increasing prevalence of spasticity with increasing time from stroke onset: affecting 4-27% of patients in the early post-stroke period (1-4 weeks poststroke), 19-27% in the post-acute phase (1-3 months poststroke), and 17% to 43% of those in the chronic phase (>3 months poststroke) [32]. Due to several variables contributing to the development of MSS, its evolution over time is difficultly to assess in observational studies. Nonetheless, MSS is thought to follow a similar pattern of progression, occurring with a latency of weeks to months after a CNS insult, and typically reaching its clinical peak between 3 and 6 months following a clinical event [33]. Importantly, there is a significant correlation between MSS and disease duration, as well a significant association between MSS and progressive courses of the disease [33].

3. Clinical characteristics of MSS

With regard to the clinical features of MSS, it should be emphasized that MSS manifests not only as a velocity-dependent, but also as a length-dependent phenomenon [7]. For example, in the quadriceps muscles, greater spasticity is noted when the muscle is shorter (i.e., in the slightly flexed knee position) compared to when the muscle is longer (i.e., when the knee is fully flexed), a mechanism possibly underlying the so-called "clasp-knife" or "catch" phenomenon [34]. Conversely, in the upper limb flexors and ankle extensors (triceps surae), spasticity is greater when the muscle is longer [35, 36].

With respect to MSS distribution, it should be noted that MSS most frequently affects the flexor muscles in the upper limb and the ankle plantar flexors in the lower limbs [7]. Interestingly, a phylogenetic advantage associated with the preservation of human standing posture is thought to underlie this distribution of spasticity, as indicated by the fact that muscles resisting gravity are the ones most commonly affected in patients with UMN syndrome [28].

Another important feature of MSS is that, although MS can affect all levels of human CNS, the probability of impairment of a functional pathway is higher with increasing pathway length [27]. This observation has been confirmed by independent studies demonstrating a higher prevalence of MSS in the lower compared to the upper limbs of MS patients [37, 38]. For example, in an electrophysiological study including 59 MS patients, MSS was present in ankle extensors in 85%, in knee extensors in 44%, in knee flexors in 32%, in wrist flexors in 10%, in elbow flexors in 8%, and in elbow extensors in 3% of the patients [38]. In clinical practice, hip adductors are also predominantly affected in MS patients, limiting passive mobilization and affecting significantly patient care and hygiene.

According to the anatomical distribution, MSS can be classified as focal, multifocal, segmental, generalized spasticity and hemispasticity [39]. Focal and multifocal spasticity affect one and ≥2 non-contiguous body regions, respectively. Segmental spasticity affects ≥2 contiguous body regions. **Generalized spasticity affects** the trunk and ≥2 additional sites. In line with the previous definitions, a paraspasticity should be classified as a segmental and a tetraspasticity as a generalized spasticity form.

As indicated by the complex definitions, clinical presentations and classification schemes that were previously analyzed, it is difficult to approach spasticity in clinical practice without the use of standardized clinical assessment tools. Importantly, the implementation of clinical scales facilitates not only the clinical diagnosis and early-recognition of MSS, but also the conduction of epidemiological research in the MS patient population.

4. Clinical scales for MSS assessment

MSS is assessed in clinical practice using semi-quantitative scales, such as the Ashworth Scale (AS), the modified Ashworth Scale (MAS) and the Tardieu Scale (Table 3), which are based on the degree of resistance to passive movement of different body segments as perceived by the examiner, or by neurophysiological investigations such as the H-reflex and the Wartenberg pendulum tests, the latter being mostly used in research [40-45]. The REsistance to PAssive movement Scale (REPAS) has been developed from AS, requiring standardization of the clinical examination, and is thus, characterized by a higher reliability regarding spasticity assessment in different muscle groups [46]. Moreover, since MSS predominantly affects the hip adductors, standardized assessment of passive hip abduction (i.e., using protractor goniometer), measurement of the maximum distance between the knees during passive abduction and use of the Adductor Tone Rating Scale (ATRS) are recommended [47].

In clinical practice, there are four stages of clinical examination, including static and functional evaluation [48). *Stage 1*: Clinical observation - The image presented by the patient's body as they enter the examination room and when in a sitting and supine position. Any muscular atrophies and/or muscular spasms are also recorded. *Stage 2*: In a supine position the examination includes the range of joint motion with passive slow movement; the spasticity degree; the active movement; and the normal and pathological reflexes. At this stage we use the motor test, the MAS, the ATRS, and the Tardieu Scale. *Stage*

Table 3. Clinical scales for spasticity assessment

GRADING	SCALES			
		Ashworth	**Modified Ashworth**	**Modified Tardieu**
	0	No increase in muscle tone	No increase in muscle tone	No resistance throughout the passive movement
	1	Modest increase in tone giving catch in flexion and extension	+ catch and release or minimal resistance at the end of the range of motion	Modest resistance through the passive movement
	1+	–	+ catch followed by minimal resistance through the remainder of the range of motion, easy motion	–
	2	More noticeable increase in tone, but the limb is easily flexed	+ through most of the range of movement, easy motion	Clear catch at a specific angle, interruption of passive movement, followed by release
	3	Significant increases in tone, passive movement difficult	Significant increases in tone, passive movement difficult	Fatigable clonus (<10s with stable pressure), at a precise angle
	4	Limb rigid in flexion or extension	Limb rigid in flexion or extension	Unfatigable clonus (>10s with stable pressure) at a precise angle
	5	–	–	Fixed joint

Velocities' definition (according to modified Tardieu scale)	
V1	Very slow (slower than the limb drop under gravity)
V2	Same velocity as the limb falling under gravity
V3	Faster than the natural drop

3: Examination with the patient in a sitting position. Here the examination is supplemented by an upper limb motor skill test. *Stage 4*: Examination of body balance in upright position and walking for a short and longer distance. Fatigue is considered as a major factor of movement disturbance [48].

An overview of 24 clinically-used scales for measuring spasticity can be found in Platz et al. [41]. This systematic review showed that the methods most frequently used for the assessment of spastic muscle tone are the AS and MAS scales. These scales are easy to implement, but show varying degrees of interrater reliability across studies [41]. Besides the significant interrater variability, additional limitations of these scales comprise the lack of assessment of patients' MSS experience and the fact that none of these scales is designed to reflect how MSS affects patients' daily lives [49].

Patient-reported outcomes are thus, used both in clinical practice and research, including the Numerical Rating Scale (NRS), the Visual Analogue Scale (VAS) and the Multiple Sclerosis Spasticity Scale (MSSS-88) (Table 4) [40, 49]. Further assessment methods and QoL measuring instruments ("patient-related outcome measures, PROMs" and "health-related quality of life measures, HRQL") can also be implemented [50, 51], including: active and passive range of motion in motion segments (aROM, pROM), 10 m walking time, disability assessment scale (DAS), and Goal Attainment Scale (GAS) [52-55]. The GAS in particular, utilizes six goal areas under two domains: (a) body structure impairment: pain, involuntary movements, and range of movement and (b) activities/function: passive function (ease of caring), active function –transfers or standing, and active function– mobility, to evaluate achievement of treatment goals [56].

In clinical practice, it is advisable to monitor responsiveness to MSS therapies using both clinically standardized (AS scale, MAS, Tardieu, or REPAS scale) and functional scales, that incorporate patient-relevant symptoms and treatment-goals [51]. Nonetheless, it should be mentioned, that there is lack of consensus

Table 4. Overview of clinical scales and tools for patient-reported outcome assessment in MS patients with spasticity-related symptoms

Parameter	Tool	Characteristics
Tonus	REPAS, (modified) Ashworth Scale, (modified) Tardieu Scale, Numerical Rating Scale (NRS)	High inter-rater variability, low sensitivity regarding moderate changes
Paresis	BMRC-Grading of Muscle Strength	Assess in supine or resting position
Spasms	Spasms Frequency Rating Scale, Penn Spasm Frequency Scale	Variation during day
Pain	Visual Analogue Scale (VAS)	Useful to monitor treatment
Joint Mobility	Neutral Zero Method, Range of Movement	Useful for assessment of joint deformities or muscle contractures
Walking speed	10-meter walking test, 25-foot walking test	Easy to perform
Walking Distance	EDSS (ambulation)	Variation during day
Endurance	2-minute walking test (2MWT) 6-minute walking test (6MWT)	Easy to perform, highly reproducible
Daily walking distance	Pedometer or Accelerometer	Highly sensitive for clinical deterioration
Everyday Relevance	MSSS-88	Useful for evaluation of spasticity impact on daily activities

Abbreviations: REPAS: Resistance to Passive Movement Scale, BMRC: British Medical Research Council scale for muscle strength, EDSS: Expanded Disability Status Scale, MSSS-88: The 88-item Multiple Sclerosis Spasticity Scale.

on whether a particular combination of scales is superior to others. The use of variable tools for evaluating MSS limits the comparability of results obtained from different clinical trials and observational studies (e.g., on the efficacy of antispastic agents on MSS). Therefore, in clinical practice, the use of the same combination of scales is advisable for the follow-up of MS patients [57, 58].

5. Epidemiology of MSS

As noted in previous sections, the use of clinical scales for the evaluation of MSS is a prerequisite for the performance of epidemiological research in the MS patient population. Evidence from large epidemiological studies indicates that MSS is present in up to 80% of MS patients, while nearly all patients with progressive types of MS exhibit some degree of MSS [3, 4, 59]. In addition, approximately one third of MS patients suffer from moderate/severe MSS despite antispastic treatments [4, 33, 60], eliminating, thus, their daily activities [45, 59]. Several observational studies have shown that daily life is mostly affected as a consequence of motor impairment or MSS-related limb stiffness [61, 62].

Epidemiological evidence points toward an increasing incidence of MS in the Greek population during the last decades. The mean annual incidence rate of MS increased from 2.71/100,000 recorded during the period 1984-1989 to 10.73/100,000 in the 5-year period of 2002-2006 [63, 64]. Accordingly, Greece belongs to the high-risk geographical areas for MS [64]. In addition, electrophysiological evidence suggests a particularly high incidence of MSS among patients with progressive types of MS [65]. Interestingly, Greek observational studies indicate that MSS is frequently complicated by vesicourethral dysfunction, muscle spasms, pain and functional impairment in MS patients [66, 67].

With respect to risk factors, the presence of severe paralysis, sensory deficits, and pain have been linked to increased risk of spasticity [32, 68]. Crucially, MSS-aggravating factors (so-called spasticity triggers) have been identified specifically in MS patients, including immobility, pain, noxious stimuli, emotional tension, infections, urge to stool/urinate, pressure ulcers, thromboses and fractures [40, 69, 70].

While early-recognition of risk factors is pivotal for MSS therapy, it should be stressed that in accordance with the "NEDA" principle (No Evidence of Disease Activity) [71-73], the early implementation of disease modifying therapies (DMTs) for MS and the regular re-evaluation of indications to escalate DMTs comprise the cornerstone of MS but also MSS treatment [74]. Crucially, several studies corroborate the positive effect of DMTs on MSS progression [58], while vice

Figure 1. Diagnostic algorithm for multiple sclerosis spasticity



Abbreviations: MS: multiple sclerosis, QoL: quality of life, MSS: multiple sclerosis-related spasticity

versa MSS progression and accumulation of disability are linked to disease activity [75]. On the other hand, interferons have been reported to aggravate MSS [58, 76, 77], a fact that should be considered when prescribing DMTs in MS patients [58].

Furthermore, the effect of some antidepressants should be monitored closely in patients with MSS, since previous studies indicate that selective serotonin reuptake inhibitors may exacerbate MSS [78, 79], presumably due to serotonin effects on the motor neuron and reflex activity [78]. In addition, some anecdotal reports suggest a possible link between spasticity and antiepileptic drugs, such as lamotrigine [80]. Although associations between concomitant medication and MSS are poorly-characterized, regular assessment for potential drug-induced triggers of MSS is recommended, using patient-reported measures of MSS as described in previous sections [81].

6. Diagnostic and therapeutic approach to MSS

The initial approach of patients with MSS entails thorough assessment of their medical history. Besides the exclusion of potential triggers that may aggravate spasticity, concomitant disorders that may contribute to MSS should be explicitly evaluated (Figure 1). For example, MS patients are known to harbor an increased risk for cerebrovascular disease that may contribute to MSS; thus, assessment of presence of concomitant cerebral small vessel disease and cardiovascular risk factors is pivotal [82-84]. Moreover, as bladder dysfunction in MS patients is very frequently complicated by urinary tract infections, prompt recognition and management of underlying urinary tract infections that may aggravate MSS is essential [10]. Besides history taking and clinical evaluation, ancillary testing may be indicated, including neuroimaging studies, neurophysiological studies, cerebrospinal fluid (CSF) analysis, laboratory or genetic/molecular testing in order to exclude other neurological diseases (e.g., progressive multifocal leukoencephalography in patients under DMTs, myelopathy, and hereditary spastic paraplegia among others) that could complicate or mimic MS, resulting in MSS [85-88]. Moreover, as discussed in previous sections, the diagnosis of MSS should include detailed assessment of different functional domains, including use of Multiple Sclerosis Functional Com-

Table 5. Overview of non-pharmacological interventions for MS-related spasticity (MSS)

Non-pharmacological treatment	Level of evidence
Physical exercises (except sports climbing with no evidence): muscle strengthening, stretches, balance exercises, gait training, endurance exercises, hydrotherapy, electronic bike training, robotic-assisted rehabilitation and virtual reality programs	Low, expert consensus to recommend for MSS
Occupational therapy, logotherapy, nutrition monitoring to prevent muscle wasting and osteoporosis, and psychological support	Low, expert consensus to recommend for MSS
Intermittent Theta Burst stimulation (iTBS), Repetitive Transcranial magnetic stimulation (rTMS)	Low, expert consensus to recommend for MSS
Transcranial direct current stimulation (tDCS)	No evidence of efficacy, not recommended for MSS
Transcutaneous electrical nerve stimulation (TENS)	No evidence of efficacy, only in selected patients
Whole body vibration (WBV)	No evidence of efficacy, not recommended for MSS

posite (MSFC) and Expanded Disability Status Scale (EDSS), and different organ systems, while taking into account potential complications of MSS, including bladder/bowel dysfunction, dysphagia, contractures and limb deformities, as well as pressure sores [2, 11, 12, 89-91].

Crucially, the therapeutic management of MSS should be individualized, while focusing on the establishment of treatment-goals collaboratively with patients, their carers and rehabilitation teams, prior to initiation of MSS treatment [92]. Clinically-relevant goals of MSS treatments include: improvement of motor performance, ambulation and functional disability; pain reduction; facilitation of nursing; and prevention of complications, such as contractures and pressure sores [6, 40, 48, 51]. Notably, MSS therapy should be provided by multidisciplinary teams, including neurologists, physical medicine and rehabilitation physicians, nurses, physiotherapists, speech therapists and other allied specialties, while typically, combination of different treatment modalities and rehabilitation techniques is warranted for optimal patient care [93-95]. In brief, MSS therapies encompass non-pharmacological therapies, including physical therapy, magnetic and electrical stimulation and peripheral nerve stimulation, and pharmacological therapies, including oral antispastic drugs, muscle injections with botulinum neurotoxins, and intrathecal administration of anti-spastic drugs, which will be separately presented in the following sections [6, 40].

7. Non-pharmacological therapies for MSS

Non-pharmacological interventions may be used alone or in combination with pharmacological agents to treat MSS [92]. To date, there is a striking gap in the scientific literature concerning optimal non-pharmacological treatments for MSS, as robust data from large, well-designed randomized-controlled clinical trials (RCTs) are scarce [96]. A systematic Cochrane review, summarized the available evidence on non-pharmacological treatments of MSS and compared them with any type of control intervention in adult MS patients [92]. The authors identified nine RCTs comprising 341 patients, which investigated various types and intensities of non-pharmacological MSS interventions. Among the studied interventions were: physical activity programs (including physiotherapy, structured exercise program, sports climbing); transcranial magnetic stimulation [intermittent Theta Burst Stimulation (iTBS), repetitive Transcranial Magnetic Stimulation (rTMS)]; transcranial direct current stimulation (tDCS), Transcutaneous Electrical Nerve Stimulation (TENS) and Whole-Body-Vibration (WBV). Notably, due to the high heterogeneity of included RCTs, a meta-analysis could not be performed, whereas further limitations of RCTs included small sample sizes, high risk of bias, short follow-up periods, variable outcome measures, and inclusion of diverse MS patient populations with diverse MSS symptoms. In particular, the authors reported that all studies scored 'low' on methodological quality assessment [92].

This systematic review concluded that there was 'low level' of evidence for physical activity programs used in isolation or in combination with other interventions for MSS (pharmacological or non-pharmacological), as well as 'low level' of evidence for intermittent/repetitive magnetic stimulation (iTBS/rTMS) with or without adjuvant exercise therapy to improve MSS in adults [92]. Conversely, no evidence of benefit was detected to support the use of TDCS, TENS, sports climbing and vibration therapy for MSS treatment (Table 5).

7a. *Physical activity programs*

With respect to physical activity programs, the

previous systematic Cochrane review [92] included 4 RCTs [97-100] that evaluated the impact of different types of physical therapy (including structured physiotherapy, exercise program and sports climbing) on MSS. Among them, 3 RCTs evaluated these therapies in conjunction with other interventions: botulinum neurotoxin (BoNT) [97], iTBS [98], and vibration therapy [99]. One RCT [97] with 38 secondary progressive MS patients, examined whether the addition of physiotherapy may enhance BoNT's efficacy in treating focal spasticity. The intervention group received BoNT and add-on daily physiotherapy for 15 days, encompassing passive, active and stretching exercises, while the control group received only BoNT. This RCT found a significant decrease in MSS in the combination treatment group compared to the group receiving only BoNT injections, as indicated by the significant reduction in MAS scores noted for up to 12 weeks following treatment. Another double-blind, sham-controlled clinical trial [98] investigated the effects of combined iTBS and exercise therapy on motor disability in MS patients. Thirty patients were randomized into 3 groups: iTBS plus exercise therapy, sham stimulation plus exercise therapy, and iTBS alone. There was a significant improvement in MAS scores, MSSS-88, fatigue and QoL scores in the iTBS plus exercise therapy group, but not in the sham stimulation plus exercise therapy group. A significant reduction in MAS score was also noted in the iTBS group, while other measures of MS-related disability remained unaffected in this treatment group. One trial [99] evaluated the efficacy of WBV on muscle tone, muscle force, sensation and functional ability in MS. Sixteen participants were randomly allocated into two groups: the first group underwent 4 weeks of WBV plus exercise 3 times per week, 2 weeks of no intervention and then 4 weeks of exercise alone 3 times per week; the second group underwent these treatment interventions in the reverse order. The exercise program had positive effects on muscle force and well-being, but there was insufficient evidence that the addition of WBV provided any additional benefit, while no significant differences in MAS scores were detected from either intervention. Nevertheless, for each group, the combination of WBV with exercises showed significant reductions on MSSS-88 sub-scales of muscle spasms and pain. Some non-significant improvements in functional abilities were also noted, including 10-meter walk and Timed Up and Go Test. The fourth RCT [100] included in the systematic Cochrane review [92], investigated the effects on MSS, fatigue, cognitive impairment and mood of two different aerobic physical activities: sports climbing and yoga. This trial included 20 participants with relapsing remitting or progressive MS, which were randomly allocated to a 10-week intervention period. No significant improvements in MSS were found from either intervention (measured using MAS). It is however worth noting, that in the sports climbing group, there was a significant reduction in EDSS pyramidal functions score, while in the yoga group there was a significant increase in selective attention performance.

Despite the lack of robust evidence from RCTs in MSS, there is a strong expert consensus that, in clinical practice, rehabilitation programs aiming to improve passive and active motor function should be recommended [51, 96]. However, caution is warranted to avoid unwanted increase in muscle tone. Sustained passive muscle stretching with extended positions of the extremities may improve the passive range of motion [51, 101]. In addition, there is promising evidence that the damage-oriented training ("Impairment-Oriented Training"), which includes the systematic repetitive training of a paretic limb, as well as modified "Constraint-Induced Movement Therapy" protocols, may have beneficial effects on motor function while attenuating spasticity in paretic extremities [51, 102, 103]. Similarly, device-assisted physiotherapy should be considered in passive and passive-active therapy protocols [51]. Finally, it should be stressed that besides physical therapy, occupational therapy, logotherapy (speech therapy), nutrition monitoring to prevent muscle wasting and osteoporosis, as well as psychological support should all be included in multimodal programs tailored for MSS patients (Table 5).

7b. *Casting, splints and orthotic devices*

Splints, casts and orthotic devices can be classified as aids used in extremities with spastic paralysis for tone and posture regulation as well as for contracture prophylaxis. They may be used alone or in combination with other MSS therapies [51]. The term "casting" or "serial casting" refers to the sequential use of several casts for the treatment of a spastic contracture (with restricted passive range of motion: pROM). A therapeutic improvement of the pROM in the affected extremity is achieved by means of individualized casts made serially in specific joint angles. Previous studies have shown that splint/casting treatment is ineffective for the prevention of spasticity and contractures [104].

However, for cases with chronic spasticity, positive effects have been described by the use of various types of splints at the elbow, wrist [105, 106], ankle and foot [107]. Interestingly, a positive effect has also been reported with combined use of casting and BoNT therapy in patients with spastic contractures [108]. Moreover, with respect to orthotic devices, ankle-foot orthoses (AFO) are frequently used in patients with MSS. AFO by covering the foot and ankle area, can either be completely rigid to immobilize

the ankle or may encourage movement in certain directions. The dynamic AFO helps in controlling foot drop, facilitating normal posture in an upright position, improving the gait pattern, and preventing falls. Although the criteria according to which casting, splints and orthotics should be used in clinical practice are not sufficiently addressed or described in clinical studies, there is expert consensus that these aids may be considered especially for patients with severe forms of MSS with concomitant contractures. The serial application of plaster casts (closed casting) may also be considered, for example in the ankle, to facilitate posture correction [109].

Consequently, aided positioning in pain-free stretching position is advisable for spastic muscles, whereas for severe forms of MSS with incipient spastic contractures (i.e., in the ankle or in the finger flexors) the serial application of closed casts and plaster casts can be recommended, alone or in conjunction with pharmacological therapies (including BoNT therapy) [51].

7c. *Repetitive magnetic stimulation and transcranial direct current stimulation*

Repetitive transcranial magnetic stimulation (rTMS) comprises a non-invasive brain stimulation technique that is painless and well-tolerated, and can induce changes in cortical excitability both at the site of stimulation and at remote sites, while resulting in either facilitation or inhibition of neuronal networks depending on the frequency and pattern of pulses [110, 111]. The effects of rTMS are mediated by induction of short-term and long-term synaptic plasticity. Therapeutic protocols of rTMS are currently implemented in several neurological disorders [111]. Intermittent theta burst stimulation (iTBS) is a recently developed high-frequency and short-duration rTMS protocol, which induces long-lasting effects while being well-tolerated in clinical practice [112]. The use of rTMS in MSS treatment has been systematically reviewed in the literature by independent research groups and expert panels [40, 113]. In a recent systematic review assessing MSS interventions using the GRADE approach (Grades of Recommendation, Assessment, Development and Evaluation) [40, 114], 5 rTMS trials were evaluated [115-119], 3 of which were double-blind sham-controlled randomized controlled trials [116, 118, 119] and 2 were pseudo-randomized sham-controlled trials [115, 117]. With respect to MSS outcomes measured with MAS, a treatment effect was observed with real but not sham stimulation in 3 out of 4 trials [115, 117, 118], whilst one trial [116] found improvement in MAS in both groups, without significant between-group differences. In the fifth trial [119], a significant benefit of real versus sham stimulation was noted on MSS outcome measures, as well as on QoL outcomes. Due to inherent methodological limitations of these trials, a weak recommendation in favor of rTMS for the treatment of MSS was formulated based on the previous data [40]. Similar recommendations have been issued in the recently published consensus paper of evidence-based guidelines for the therapeutic use of rTMS in MSS, suggesting a probable benefit of rTMS (iTBS protocols) applied over the primary motor cortex (level B evidence) [113]. Moreover, there are indications that in patients with incomplete paraplegia, high-frequency rTMS (or iTBS) of the parasagittal motor cortex (leg representation area) may improve leg spasticity, especially when combined with gait training [120, 121].

Peripheral repetitive magnetic stimulation (prMS), applied directly over the nerve roots (paraspinal stimulation targeting the spastic muscles in the upper or lower extremities), may also be used for spasticity treatment. Whether a clinically-relevant treatment effect can be achieved by prMS is still unclear from the available observational studies [122]. A Cochrane Review reported that there is currently inadequate evidence to permit any conclusions regarding the routine use of rPMS in patients with spasticity after stroke [123], while the potential utility of prMS in MSS treatment has not been systematically studied. Nonetheless, expert recommendations suggest that prMS has an excellent safety profile and may be considered especially for patients with persistent MSS despite the combined use of other pharmacological and non-pharmacological interventions, provided that the practitioner is competent in implementing this technique [51].

With respect to transcranial direct current stimulation (TDCS) there are currently insufficient data to recommend its use in MSS treatment. A large number of published TDCS studies suffer from major methodological limitations, precluding any inferences regarding the potential benefits of TDCS in MSS treatment. In particular, 13 TDCS studies were assessed in a recent systematic review using GRADE analysis [40]; a total of 12 were excluded for a variety of methodological reasons, including outcomes unrelated to MSS (n = 2), non-comparable drug/interventions (n = 6), unspecified study type (n = 3), review (n = 1). Only one study was finally included in the GRADE analysis [124], a single-center, randomized, double-blind, sham-controlled trial with MAS as the primary end-point. This trial failed to detect any benefit of TDCS [124].

7d. *Transcutaneous electrical nerve stimulation (TENS)*

Transcutaneous electrical nerve stimulation (TENS) of the antagonists of spastic muscles has been suggested to reduce spasticity and to enhance the pas-

sively restricted range of motion (pROM) of affected muscles [125]. In addition, application of TENS on the muscle-tendon junction of spastic gastrocnemius can improve functional gait parameters [126]. A systematic review of RCTs using TENS as spasticity treatment, comprising 207 post-stroke patients, 84 MS patients, and 39 patients with paraplegia, concluded that, although TENS may be useful in clinical practice because of its low cost, ease of use, and absence of adverse reactions, the high variability of therapeutic clinical study protocols precludes any robust conclusions regarding TENS efficacy [127]. Similar results were obtained from a systematic review using GRADE assessment, which concluded that there is currently insufficient evidence to support the use of TENS for MSS treatment [40, 128]. Notably, in clinical practice, the effects of TENS on spasticity appear to be stronger when TENS is combined with active therapy (e.g., exercise and task-related training) [129].

Functional electrical stimulation (FES) is a technique that combines electrical stimulation with intended or partially self-performed activities (e.g. grasping and manipulating or walking) and has been suggested to improve spasticity, motor and walking ability [130]. Notably, FES devices generate low level electrical impulses that stimulate nerves to generate muscle contractions and have the ability to target specific muscles at a specific time. Furthermore, electroacupuncture has been suggested to improve motor performance, spasticity and activities of daily living [131]. Currently, there are no robust data from large RCTs on FES or electroacupuncture to support their use in MSS.Their potential utility should be individually assessed in selected patients [51].

7e. *Other non-pharmacological interventions*

Currently, there is insufficient evidence to recommend the use of thermal stimuli for MSS treatment [51]. A study using alternating daily heating and cooling in hemiplegic upper extremities failed to document any lasting effects on muscle tone [132]. Similarly, as already mentioned in previous sections, there is no evidence to support the use of whole body vibration (WBV) for MSS treatment [133]. Nonetheless, WBV may be associated with reductions of muscle spasms and pain in MS patients [99], and has been suggested that it may alleviate spasticity for short periods of time in patients with paraplegia [134]. Finally, there are insufficient data to date in support of the use of extracorporeal shock wave therapy (ESTW) in MSS [135]. Nonetheless, as ongoing research on the aforementioned modalities will expectedly facilitate the optimization of therapeutic protocols, the utility of these therapeutic interventions should be assessed in the future in the context of well-designed RCTs in MSS patients.

8. Pharmacological therapies for MSS

The selection of pharmacological therapies for MSS should take into account the distribution of MSS (focal, multifocal, segmental, generalized), the type of MSS (continuous or paroxysmal), MSS complications and MSS-related symptoms. Individualized risk-benefit assessment is recommended, as most pharmacotherapies have distinct adverse-effect profiles that should be evaluated when deciding to initiate or modify MSS treatment. Particular caution is warranted when choosing pharmacological therapies for patients with MSS and predominantly brain-localized MS lesions. In contrast to patients with spinal cord lesions, MS patients with high brain lesion-load typically have reduced tolerance to central side effects of oral antispastic treatments [51]. The most frequent pharmacological therapies used for MSS include centrally-acting oral antispastics, such as baclofen, tizanidine, benzodiazepines, gabapentin and nabiximols; the peripherally-acting oral antispastic dantrolene; intrathecally applied antispastics, including baclofen; as well as intramuscular treatments with various BoNT regimens. In the following sections, an overview of the pharmacological therapies for MSS will be presented, along with recommendations for their use in clinical practice.

8a. *Oral agents for MSS treatment*

The oral agents most frequently used in clinical practice to treat MSS are baclofen (gamma-amino-butyric acid [GABA]-B agonist), tizanidine (central alpha-2 agonist), benzodiazepines (GABA-A agonists), gabapentin (GABA analogue), and dantrolene (muscle relaxant inhibiting the release of calcium ions in the muscle) [93, 136]. Of those, dantrolene is the only antispasticity treatment acting primarily on muscles, decreasing the excitation-coupling reaction involved in muscle contraction through inhibition of the calcium release from the sarcoplasmic reticulum [93]. In addition, an oromucosal spray (Sativex®) consisting of 2 cannabis derivatives (tetrahydrocannabinol [THC] and cannabidiol [CBD] in a ratio of 50% THC to 50% CBD) has been recently approved for the treatment of spastically increased muscle tone in MS, and is particularly effective against painful spasms [51, 137-140] (Table 6). This oromucosal spray, acts as a partial agonist at cannabinoid receptors exerting both central and peripheral effects, which are mediated by inhibitory neurotransmitters that cause muscle relaxation [141].

Independent studies using MSS assessment scales (e.g. AS, MAS), have provided preliminary evidence supporting the beneficial effects of oral antispastics on MSS; however, MSS reduction does not always translate into clear functional benefits or QoL improvement (i.e., improvement in daily activities) [4, 142]. In fact, discrepancies between spasticity

Table 6. Overview of pharmacological agents used for MS-related spasticity (MSS)

Active ingredient	Dosing	Mechanism of action	Side effects
Baclofen	10-100 mg/d	GABA-B agonist	Fatigue, dizziness, muscle weakness, falls, dependency, epileptic seizures, risk for misuse
Tizanidine	6-36 mg/d	Alpha-2 adrenergic receptor agonist	Fatigue, dizziness, hypotension and bradycardia, constipation, xerostomia, liver dysfunction
Gabapentin	300-3600 mg/d	GABA- agonist, voltage-gated calcium channels	Fatigue, dizziness, headache, hypotension
Diazepam	5-30 mg/d	GABA-A agonist	Fatigue, dizziness, ataxia, hypotension, muscle weakness with falls, constipation, bladder dysfunction, dependency especially in night spasticity
9-delta-THC / cannabidiol	32.4/30 mg/d & 10.8/10 mg/d respectively	CB1/2 receptor agonist	Fatigue, dizziness, weakness, nausea, depression, psychotropic properties
Intramuscular botulinum toxin	In Table 7	Inhibition the acetylcholine release	Local irritation, bleeding, muscle weakness, incontinence
Intrathecal baclofen	25-1200 μg/d	GABA-B agonist	Bladder and sexual dysfunction, nausea, vomiting, hypotension, respiratory failure, epileptic seizures

Abbreviations: GABA: Gamma aminobutyric acid, THC: Tetrahydrocannabinol, CB1/2 receptor: Cannabinoid receptors subtypes 1/2.

reduction and functional outcomes have been reported in patients suffering from spasticity following initiation of antispastic treatments. For example, a recent meta-analysis of 7 RCTs on systemically-acting antispastic drugs versus placebo, comprising 403 patients with spasticity, failed to detect between-group differences in functional outcome measures [143). Conversely, a significant risk of adverse events per participant was observed in the treatment compared to the placebo group (risk ratio (RR): 1.65, 95% CI 1.12 to 2.42) [143). These data indicate that adverse effects of systemically acting antispastic therapies may hamper the potential benefits of these drugs on functional improvement.

Centrally-acting oral pharmacotherapies exert their antispastic effects by decreasing the excitability of spinal interneurons and motor neurons [51]. Consequently, the limitations of oral MSS treatments are associated with adverse effects on mobility, which are typically dose-dependent, and most frequently involve a decrease in muscle strength [6, 57, 144, 145]. In addition and especially in patients with significant motor impairments, antispastic drugs may significantly affect gait and reduce ambulation [51]. Conversely, immobile patients (e.g., patients with paraplegia or generalized spasticity) are most likely to benefit from oral antispastic therapies, which aim to reduce pain and muscle spasms, while facilitating active-passive mobilization and nursing [6, 40, 51].

Sedation and neuropsychiatric side effects, including depression and cognitive disorders, represent additional side effects of oral antispastic drugs [146, 147]. The clinical indications for MSS treatment, as well as the selection of antispastic agents should be critically assessed on an individual patient basis. A gradual dose titration of antispastic medication is recommended. In order to optimize the tolerability and efficacy of oral antispastic drug treatments it is important to develop individualized dosage regimens. For instance, if a patient has difficulties in getting out of bed, the drugs should be preferably administered after arousal, whereas in patients with predominant nocturnal muscle spasms, increasing night-time doses can be useful [93]. Further aspects need to be considered for a tailored antispastic treatment. For example, as previously noted, MS patients with significant brain lesion-load may exhibit more frequently adverse effects related to sedation compared to those with spinal cord lesions [51]. Thus, these patients should be closely monitored for adverse effects of centrally-acting antispastic drugs, while alternative pharmacological therapies (such as BoNT) or the peripherally-acting antispastic dantrolene may be indicated in selected patients [51].

The most frequent side-effects and recommended dosages of oral antispastic drugs have been summarized in **Table 6**. Briefly, among the centrally-acting oral antispastics, baclofen has predominantly seda-

tive and strength-reducing properties. Typical side effects of tizanidine include xerostomia and drowsiness, while combination of tizanidine with antihypertensive drugs may cause significant decreases in blood pressure [148, 149]. Moreover, tizanidine has been linked to increased risk of hepatic dysfunction; thus, it is recommended that liver function monitoring is performed monthly for the first 6 months of treatment and periodically thereafter. Furthermore, predominant sedative effects are typically noted in patients treated with benzodiazepines, gabapentin and nabiximols, while dantrolene has been associated with a substantial risk for hepatotoxicity (0.7-1%; severe hepatitis or liver failure 0.1-0.2%) [150]; thus, strict monitoring of patients undergoing dantrolene treatment is advisable. It should be stressed that adherence to recommendations concerning dosing and monitoring is advisable in accordance with the Summary of Product Characteristics (SPC) of each approved pharmacotherapy. In the following sections, the efficacy of different oral drugs used in MSS will be briefly presented.

8a-1. *Oral baclofen*

Oral baclofen is a structural GABA-analogue, which binds to pre- and postsynaptic GABA receptors, decreasing activity in motor neurons and interneurons [136]. In clinical practice, symptom control is typically achieved with doses up to 60 mg, with a maximum daily dose of 100 mg. The effects of oral baclofen have been systematically examined in a recent systematic review of RCTs and observational studies in patients with MSS [136]. In this systematic review, evidence on MSS treatments was assessed using prespecified levels of certainty (class I, II, III and IV) [151]. The use of oral baclofen for MSS was examined in 9 randomized [152-160] and one non-randomized [161] controlled clinical trials. Six out of 7 placebo-controlled trials [152, 154, 156, 159-161] found a significant improvement in MSS in patients treated with oral baclofen compared to placebo, while one identified study, with a lower sample size, found no between-group differences [157] (class II/III evidence). In addition, baclofen was found to significantly improve muscle spasms and clonus [154, 159] (class III evidence). In 3 studies comparing baclofen with diazepam, no significant between-group differences were detected using the AS or other MSS scales [153, 155, 158]. Similarly, no differences were detected with respect to the frequency of reported muscle spasms between the two drugs [155, 158] (class III evidence). Additionally, high versus low doses of baclofen (30 or 60 mg) and diazepam (15 or 30 mg) were assessed in one trial [153]. Even though both doses of both drugs showed a significant change in the AS score pre- and post-treatment, there was a marked improvement in patients who were able to tolerate higher doses (class III evidence). In the majority of analyzed trials, baclofen showed an improvement in spasticity compared to placebo, with no differences compared to diazepam. However, side effects, including weakness, drowsiness, paresthesia and xerostomia were common (10%-75%) limiting the maximum tolerated dose, but were fewer in patients treated with oral baclofen compared to diazepam [162].

In line with the previous findings, another recently published systematic review and consensus paper on the use of pharmacological therapies for MSS [40], included 4 double-blind, placebo-controlled studies, analyzing the effects of oral baclofen therapy on AS scores and spasticity NRS, in a GRADE analysis [152, 156, 157, 161]. The authors concluded that the quality of evidence was very low; there was however a consensus for a weak recommendation for the use of oral baclofen for MSS treatment [40].

8a-2. *Tizanidine*

Tizanidine is a short-acting muscle relaxant which acts via stimulation of the central alpha-2-adrenergic receptors, and leads to attenuated release of excitatory neurotransmitters at spinal and supraspinal levels [136]. Tizanidine is typically started at a dose of 2 mg daily, and can be increased up to a maximum dose of 36 mg daily with an average effective dose between 12 and 24 mg [107]. In a systematic review of pharmacological therapies for MSS, 13 trials that examined tizanidine for MSS treatment were identified: two assessing tizanidine in a single dose compared to placebo [42, 163] and 11 assessing the medium-term use of the drug (5-15 weeks) compared to placebo [164-167], diazepam [168] or baclofen [169-174]. A detailed analysis of the results of these trials can be found in the systematic review by Otero-Romero et al. [136]. In summary, this systematic review showed that tizanidine was superior in reducing MSS in the short and medium-term compared to placebo, while being equally effective to diazepam or baclofen. Among the reported side effects of tizanidine, which were mostly related to its alpha-2-adrenergic activity, drowsiness and xerostomia were the most prevalent, while a dose-dependent effect was reported. Moreover, decreases in heart rate and blood pressure were observed, and tizanidine was also related to transient increases in the levels of transaminases, which returned to normal levels after discontinuation of treatment [175].

In accordance with the previous findings, a recent meta-analysis assessing the effects of tizanidine on MSS compared to placebo, included 6 studies in a GRADE analysis [40], 5 double-blind, placebo-controlled trials [42, 167, 168, 176, 177], and one double-blind, double-dummy, two-way crossover,

placebo-controlled RCT [178]. The authors concluded that there were various methodological limitations in the identified studies. Therefore, this study group concluded that there was consensus for a weak recommendation for the use of tizanidine in MSS [40].

*8a-3. **Benzodiazepines***

Given the side-effect profile of benzodiazepines, including their addiction potential and the associated increased risk for misuse and abuse, these drugs should be considered as second-line treatments in MSS [179]. Diazepam is known to enhance the effect of the neurotransmitter GABA and contributes to muscle relaxation via suppression of neuronal activity in the reticular formation [136]. The maximum recommended dose is 30 mg/day, with an average dose of 15 mg. In a systematic review of clinical trials on pharmacological treatments for MSS [114], diazepam was shown to have a comparable efficacy to baclofen with respect to MSS, although more sedation was observed with diazepam (class III evidence) [153, 155, 158]. In comparison to dantrolene, tizanidine or ketazolam, a similar reduction of MSS was observed with diazepam (class II/III evidence) [168, 180-182].

In another systematic review, 3 clinical studies were included in a GRADE analysis [153, 155, 168], two of which compared diazepam to baclofen [153, 155], and the third was a RCT comparing diazepam to tizanidine [168]. The authors reported that diazepam was associated with significant reductions in muscle tone; however, there were no significant differences compared to the efficacy of tizanidine and oral baclofen. Accordingly and based on the reported effects of oral diazepam, which were not superior to the comparator (oral baclofen or tizanidine) and the limited tolerability of the drug, the authors agreed on a weak recommendation for the utilization of benzodiazepines for MSS treatment [40].

8a-4.*Gabapentin*

Gabapentin represents a structural analogue of GABA, which exerts GABAergic activity by binding to receptors in the neocortex and hippocampus [136]. The normal starting dose is 300 mg/day, which can be escalated up to a maximum daily dose of 3600 mg. A systematic review of studies assessing the effects of gabapentin on MSS, included two randomized, placebo-controlled short-duration crossover RCTs [183, 184].

The higher dose study [183] (up to 900 mg gabapentin per os 3 times daily over a 6-day period) found a significant reduction in all physician-assessed measures and subject-reported MSS outcomes. The lower dose study [184] (400 mg gabapentin per os three times daily for 48 hours) reported also a reduction in the modified AS scores, but no effect on clonus, reflexes or response to noxious stimuli (class II evidence). The main adverse effects included drowsiness, somnolence and dizziness, albeit treatment was generally well tolerated, with no serious side effects reported [183, 184].

The same RCTs were included in a systematic review using GRADE analysis [40], prompting the authors to agree on a weak recommendation for using gabapentin to reduce spasticity in MS patients.

8a-5. *Dantrolene*

Dantrolene exerts its effects on the contractile mechanism of skeletal muscle via reduction of calcium release [136]. Treatment is usually started at 25 mg once daily and increased gradually to a maximum of 400 mg divided into four doses. In the previously presented systematic review by Otero-Romero et al. [136], 3 clinical studies assessing dantrolene for MSS were identified: two small studies comparing dantrolene with placebo [185, 186], starting at 50 or 25 mg four times daily, respectively, and titrated to a maximum of 100 mg. A significant reduction in MSS was noted using semi-quantitative scales in 42% of patients on dantrolene and 27% on placebo [186]. In addition, a third trial was included in this systematic review, that compared dantrolene to diazepam [180]. Although both dantrolene and diazepam reduced MSS at low and high doses, this reduction was significantly greater in patients treated with dantrolene at higher doses. The patients reported subjective improvement for two symptom-categories (muscle spasms or cramps and stiffness), while no statistical differences were detected between drugs.

This review concluded that the use of dantrolene is superior to placebo using objective and subjective measures, albeit this conclusion was based on studies with low-quality of evidence [136]. It should be noted that in clinical practice the use of dantrolene is restricted due to the high frequency of side effects, including gastrointestinal symptoms, weakness, fatigue, sedation and dizziness. Moreover, as already discussed in previous sections, the risk of hepatotoxicity is a major limiting factor that necessitates monitoring of liver function prior and during therapy [51, 136, 150]. Taken together, the previous results suggest that the use of dantrolene should be restricted only to patients who show lack of MSS improvement despite treatment with oral pharmacotherapies, including baclofen, tizanidine or gabapentin (Figure 2). Also, since weakness is a frequent side effect of dantrolene, this drug may be reserved for non-ambulatory patients [136].

8a-6. *Nabiximols*

Nabiximols (Sativex®) is an oromucosal spray of cannabis extract containing THC and CBD and is currently the only approved cannabis-based drug for MSS

Figure 2. Therapeutic algorithm for multiple sclerosis spasticity



Abbreviations: MS: multiple sclerosis, MSS: multiple sclerosis-related spasticity, BoNT: botulinum neurotoxin

treatment [136, 187]. Therapy usually starts with a 2-week dose titration phase, up to a maximum daily dose of 12 sprays. Nabiximols has been tested during the past years against placebo in MS patients with a variety of symptoms (spasticity, spasms, tremor, bladder problems, or pain). A systematic review and meta-analysis including 3 randomized, placebo-controlled, double-blind parallel group studies in 666 patients with MSS, demonstrated that nabiximols is well tolerated and reduces MSS significantly compared to placebo [138].

Many RCTs have corroborated to date the superiority of nabiximols compared to placebo in reducing MSS, while nabiximols has also been associated with improved spasm frequency, reduced sleep disruption and improved functional outcomes [188]. In the systematic review by Otero-Romero et al. [136], nabiximols was found to have a positive effect on MSS without serious adverse effects, when used as an add-on therapy. Nevertheless, an increased incidence of non-serious adverse events was noted, with dizziness being the most frequently reported symptom [189].

In another systematic review, 13 studies on nabiximols for MSS treatment were included in a GRADE analysis [40], in which different outcomes including AS, MAS, NRS, MSSS-99 and spasticity VAS were evaluated. The expert panel of this consensus paper agreed that evidence exists to recommend cannabinoids, and particularly oromucosal spray of nabiximols, for the treatment of MSS and based on the analyzed evidence, the strength of recommendation was strong.

Taken together, the previous evidence supports the use of nabiximols for MSS treatment, especially in patients with a suboptimal therapeutic response or poor tolerance of other pharmacotherapies [136]. It should be stressed, however, that close monitoring of the therapeutic response is warranted, as approximately only half of treated patients respond to nabixomols treatment, and discontinuation should be considered in case of absence of net clinical benefit or if significant side effects are present [125]. It should be noted that a position paper issued by the National Institute for Health and Care Excellence (NICE) [190]supported the efficacy and safety of nabiximols in MSS. Nevertheless, a final recommendation against the use of nabiximols in clinical practice was made due to unmet cost-efficacy requirements. Thus, the possibility of reimbursement should also be considered when prescribing nabiximols in clinical practice.

8a-7. *Summary of recommendations on oral pharmacotherapies*

Taken together, the previous evidence on oral pharmacotherapies for MSS indicates that there are limited data from RCTs to guide the choice of antispastic treatments in MSS, while most oral antispastic drugs have a narrow therapeutic range requiring cautious titration and close patient monitoring [191]. In clinical practice, there is consensus that in patients who experience non-focal MSS, with significant impact on daily life (i.e., interference with activities of daily living or MSS-related pain), oral baclofen should be considered as one of the first treatment options [51, 136]. Given the potential risk for dose-dependent side effects, baclofen therapy should be initiated at low dose (5-10 mg daily) and gradually titrated upwards to a maximum of 100 mg/day. We recommend the use of tizanidine as an alternative to baclofen, given the similarities in efficacy between the two drugs. To minimize dose-dependent side effects of tizanidine, initiation of treatment with 2 mg daily, with slow titration to a maximum of 36 mg is recommended. Crucially, monitoring of liver function should be performed monthly for the first 6 months of treatment and periodically thereafter. Gabapentin comprises another alternative to baclofen and tizanidine, with acceptable safety profile; however, there are scarce data regarding its efficacy in MSS, while head to head comparisons between gabapentin and other pharmacological therapies for MSS are missing. Gabapentin may be particularly considered for patients with MSS and neuropathic pain, or fluctuating MSS with paroxysmal components of spastic dystonia. Given the increased risk of side effects associated with the use of benzodiazepines, including the increased risk for addiction and misuse, diazepam should be reserved for patients that experience severe MSS and have failed alternative treatment options. Dantrolene and nabiximols may be indicated for selected patients who experience MSS despite combined use of other non-pharmacological and pharmacological treatments. Finally, a stepwise approach to MSS therapy is preferable, favoring monotherapy over drug combinations, although combination of drugs may be clinically useful, but requires careful titration to establish a both effective and tolerable treatment regimen. A summary of the presented recommendations is provided in Figure 2.

8b. *Intrathecal therapies*

8b-1. *Intrathecal baclofen*

Baclofen does not effectively cross the blood-brain barrier when administered orally; thus, intrathecal baclofen (ITB) achieves much higher concentrations in the CSF [192]. A surgically implanted pump with reservoir achieves a 4 times higher concentration of the drug at the 1% of oral dosage [136]. In clinical practice, pump implantation may be considered only after testing responsiveness and determining optimal individual doses. Typically, treatment is started at a dose of 25 μg/day, increasing over the first 6 months up to an average of 400 to 500 μg daily.

A systematic review assessing RCTs on ITB for MSS, identified 3 RCTs [193-195] that examined the effect of ITB infused by programmable infusion pumps, after having asserted responsiveness to treatment. A long-term multicenter placebo-controlled trial comprising 22 patients who underwent ITB [194], found significant improvements in the AS scores in the active treatment group, as well as significant improvements in the spasms score and the self-reported pain score (class I evidence). These results were corroborated in a larger multicenter trial [193] (class III evidence), and in a short-term placebo-controlled crossover trial [195] (class II evidence). Similar results were also obtained by an independent systematic review [40] that based on the results of 2 RCTs assessing the effects of ITS on AS scores [194, 195], concluded that, despite the low quality of identified studies, there was strong consensus for the use of ITS for MSS treatment.

ITB can be an effective treatment alternative to oral medications in patients who have severe MSS and a suboptimal response to oral medications, or poor tolerance due to side effects of oral pharmacotherapies. Side effects caused by the drug itself are uncommon [136], with the most common being drowsiness, dizziness, blurred vision and slurred speech. Technical complications are mainly related to the surgical procedure, while pump and catheter dysfunction have also been reported in clinical studies [193, 195]. ITB may be considered especially in patients with lower limb spasticity, while the effects of ITB should be assessed prior to implantation, with an external pump that infuses baclofen and allows assessment for responsiveness, including the effects on walking ability [2]. Recently, several studies have argued that ITB therapy may be underutilized in the MS population due to to underestimation of the impact of MSS on QoL and to concerns about the cost and safety of ITB therapy [2]. Delivery of ITB therapy requires expertly trained staff and proper facilities for pump management; there is strong expert consensus that ITB should be considered in patients with persisting MSS despite conventional treatments [191], while a careful selection of patients and establishment of realistic and mutually agreed treatment goals are recommended [136]. The efficacy of ITB in functional status improvement and pain reduction in patients with severe MSS or spinal cord injury has been also shown in a Greek cohort [67].

8b-2. *Intrathecal phenol*

In the systematic review of Otero-Romero et al.

[136], no RCTs evaluating the effect of intrathecal phenol on MSS were identified. Four identified observational studies were reviewed [196-199]. Of those, two studies reported descriptive results in terms of general relief of MSS (class IV evidence) [196, 197]. A cross-sectional observational study compared the effects of initial phenol injection (initial group) versus subsequent injections (serial group) in different muscle groups, showing a significant reduction in the AS scores in both groups (class IV evidence) [198]. Finally, in a retrospective observational study comprising 34 MS patients, intrathecal phenol was associated with MSS improvement assessed by a simple rating scale and by attainment of rehabilitation goals (class IV evidence) [199]. Thus, there is insufficient evidence to support the use of phenol intrathecal injections for MSS treatment, while the very low quality of the aforementioned studies precludes any meaningful inferences regarding the potential utility of intrathecal phenol in the MS patient population.

8c. *Botulinum neurotoxin therapy (BoNT)*

BoNT acts by inhibiting acetylcholine release from nerve endings, thereby causing presynaptic neuromuscular block and impeding muscle contraction [200]. The neurotoxin is produced by anaerobic Gram-positive bacteria of the Clostridium genus. Local injection of BoNT in isolated muscles has effects that typically last for several weeks to months, while the blockage of neurotransmitter release by BoNT is irreversible [201]. Neuromuscular function has been shown to recover by sprouting of nerve terminals and formation of new synaptic contacts [201]. So far, BoNTs have been classified into 8 different serotypes denoted with different alphabetical letters (A to H). Among these, serotype A is almost exclusively used for therapeutic purposes, as it provides the most consistent efficacy [202]. In total, 3 type A and one type B botulinum toxins have been approved by the FDA (U.S. Food and Drug Administration) for clinical use. Botulinum toxins type A include onabotulinumtoxin A (Botox®), incobotulinumtoxin A (Xeomin®) and abobotulinumtoxin A (Dysport®). The type B is rimabotulinum toxin (Neurobloc®). The following bioequivalent units between these toxins have been suggested in RCTs: 1 unit of Onabotulinum toxin A = 1 unit of incobotulinum toxin A =3 abobotulinum toxin A units = 40-50 units of rimabotulinum [203]. Nevertheless, there are substantial variations in bioequivalence among different BoNT across different muscles [204].

Upper and lower limb spasticity, regardless of the underlying cause of spasticity, are now FDA-approved indications for BoNTs based on data provided by large multicenter studies, which also included MS patients [205]. Although current SPCs of BoNTs approved in Greece do not include MSS in the indications for BoNT treatment, there is expert consensus that BoNT can be safely and effectively utilized in the treatment of upper and lower limb spasticity in MS, similar with the provided recommendations for BoNT use in the treatment of post-stroke spasticity [40, 51, 136, 206]. According to currently approved SPCs, the BoNT regimens available in Greece for treatment of post-stroke upper and lower limb spasticity include onabotulinumtoxin A (Botox®) and abobotulinumtoxin A (Dysport®) (Table 7). It is worth noting, that recommendations regarding the therapeutic use of BoNT for the management of post-stroke upper and lower limb spasticity have been previously published in a consensus document of the Hellenic Neurological Society, the Hellenic Society of Cerebrovascular Diseases, and Hellenic Society of Physical and Rehabilitation Medicine [207]. In the following sections, the data regarding the therapeutic use of BoNT for MSS treatment will be presented, along with recommendations of an expert panel regarding their implementation in clinical practice for the treatment of upper and lower limb spasticity in MS patients.

A recent systematic review including clinical studies on BoNT for MSS treatment [136], identified a total of 5 studies, 3 of which were excluded from subsequent analysis due to methodological reasons [case-series design [208], MS patients representing less than half of the sample [209], and open-label uncontrolled design [210]. The two available placebo-controlled RCTs studied the commercial preparations Botox® or Dysport® [47, 211]. The first RCT [211], published more than 30 years ago, demonstrated the efficacy of onabotulinumtoxin A (Botox®) in MSS of leg adductors by using a double-blind, placebo-controlled crossover study design. Nine patients, who were either chair-bound or bed-bound with chronically stable MS were included. Adductor brevis, longus, and magnus muscles were injected with 100, 100, and 200 mouse units (MU) of onabotulinumtoxin A, respectively. The study demonstrated that BoNT was associated with a significant reduction in spasticity and a significant improvement in the ease of nursing care, while no adverse effects were reported (class III evidence). In the second RCT [199], 74 patients with definite or probable MS, and disabling MSS affecting the hip adductor muscles of both legs, were randomized to one of 4 groups, to receive abobotulinumtoxin A (Dysport®) (500, 1000 or 1500 Units), or placebo by intramuscular injection in the hip adductor muscles. The study found a significant improvement in the measured distance between the knees during passive movements for the 1500-Unit group compared to placebo, and significant improvements in hygiene for the 1000- and 1500-Unit groups. Pain and spasm frequency improved to a similar extent in all 4 groups, but significant changes in muscle tone

Table 7. Recommendations regarding intramuscular injections of onabotulinumtoxinA and abobotulinumA for MS-related spasticity (MSS)

Muscle group		Botulinum toxin agents			
		Onabotulinum toxin		Abobotulinum toxin	
Clinical Pattern	Muscles	*Range of dose (Units)*	*Max. No of injection sites per muscle*	*Range of dose (Units)*	*Max. No of injection sites per muscle*
Flexed Wrist	Flexor Carpi Radialis	50-75	2	100-200	
	Flexor Carpi Ulnaris	25-50	2	100-150	
Clenched Fist	Flexor Digitorum Superficialis	40-50	2	100-150	
	Flexor Digitorum Profundus	25-60	2	100-200	
	Flexor Pollicis Brevis	10-15	1		
	Flexor Pollicis Longus	25-30	2	100-200	
	Adductor Pollicis Longus	10-12.5	1	25-50	
Flexed fingers	Flexor Digitorum Superficialis	25-60	2	100-200	
	Flexor Digitorum Profundus	25-75	2	100-200	
Flexed elbow	Brachioradialis	25-50	2	100-200	
	Biceps Brachii	10-50	4	200-300	
	Brachialis	50-100	2	100-200	
Pronated forearm	Pronator Quadratus	10-25	1		
	Pronator Teres	45-60	2	100-200	
Thumb in palm	Flexor Pollicis Longus	40-50	2	50-100	
	Adductor Pollicis	10-20	1		
	Flexor Pollicis Brevis	12.5-20	1		
Adducted Shoulder	Pectoralis complex	75-100	4	100-200	
	Latissimus Dorsi	75	4		
Adducted Thigh	Adductor Magnus	75-150	2	100-150	
	Adductor Longus	75-80	2	100-150	
	Adductor Brevis	20-25	2		
	Gracilis	25-40			
	Iliopsoas	25-150			
	Medial Hamstrings	50			
Flexed knee	Medial Hamstrings	125	4		
	Lateral Hamstrings	75	4		
	Gastrocnemius	50-200		100-450	1-3
	Iliopsoas	40-150			
	Gracilis	50			

Table 7. Continuity

Extended knee	Rectus Femoris	80-125	4		
	Vastus Medialis	50	2		
	Vastus Lateralis	50-70	2		
	Vastus Intermedius	35-75			
	Gluteus Maximus	40			
Equinovarus Foot	Tibialis Posterior	100	2	100-250	1-3
	Gastrocnemius	125	4	200-300	
	Soleus	75-100	4	150-200	
	Tibialis Anterior	75			
	Flexor Digitorum Longus	20-75		50-200 50-100	1-2
	Flexor Digitorum Brevis	13-38		50-200	1-2
	Flexor Hallucis Longus	25-38		50-200	1-2
	Extensor Hallucis Longus	13-50			
Plantar Flexed Foot Ankle	Gastrocnemius	125	4	100-300	1-3
	Soleus	75	4	150-200	2-4
	Tibialis Posterior	25-75		100-200	
	Long Toe Flexor	20			
Striatal Toe	Extensor Hallucis Longus	50		50	
	Extensor Hallucis Longus Motor Point	38	2		
	Extensor Digitorum Longus	25-30			
Flexed Toe	Flexor Digitorum Longus	50-80	2	50-200 100-150	1-2
	Flexor Digitorum Brevis	25	1	50-200	1-2
	Flexor Hallucis Longus	40-50	2	50-200 50-100	1-2
	Flexor Hallucis Brevis	13		50-100	1-2

were only observed in the botulinum toxin groups. Time to re-treatment was significantly longer for all treatment doses compared to placebo (class I evidence). Concerning side effects, the frequency of muscle weakness was found to be higher in the 1500-Unit treatment group (36%) compared to the placebo group (6%). The authors concluded that the optimal dose for hip adductor spasticity seems to be 500-1000 Units abobotulinumtoxin A (Dysport®), divided between both legs [199].

Despite the small number of patients and the short duration of the previous RCTs, the observed effects on MSS and the safety profile of BoNT (similar to placebo with the exception of muscle weakness) have prompted independent research groups and expert panels to support the use of BoNT for the treatment of MSS [40, 51, 136]. In another systematic review, 4 controlled trials were included in a GRADE analysis: the two previously presented RCTs [47, 211], and two single-blind randomized trials [97, 212]. Giovanelli et al. [97] conducted a single-blind, pilot RCT over a 12-week study period, including 38 patients with progressive MS and focal spasticity of the upper and lower limbs. The aim of this study was to assess whether combined physiotherapy can improve the response to BoNT. All patients included in this study received onabotulinumtoxinA (Botox®), whereas the treatment group received additional physiotherapy with strengthening and stretch exercises. MSS outcomes were evaluated at baseline, 2, 4, and 12 weeks

post-treatment by the use of MAS and VAS scales. Patients with focal MSS of the upper or lower limb were treated with Botox® 100 U diluted (50 U/mL), which was injected in upper limb muscles affected by MSS as follows: in flexor digitorum superficialis (two sites), flexor carpi radialis (two sites) and flexor carpi ulnaris (two sites). Accordingly, in the lower limb muscles, Botox® 100-300 U diluted (50 U/mL) was injected in the tibialis posterior (one site), gastrocnemius medial and lateral (three sites) and soleus (two sites). A significant decrease in MAS scores was observed in the treatment group at all study time points, while combined treatment was more effective as reflected by the significant decrease in VAS measures. Crucially, this study underscored the role of physiotherapy, which in combination with BoNT, can significantly improve the overall response to BoNT in MS patients. Another single-blind, RCT [212], including 42 patients with secondary progressive MS and knee/ankle MSS, suggested that, besides physiotherapy, segmental muscle vibration may have additive effects to BoNT [onabotulinumtoxinA, Botox® 100-300 U diluted (50 U/mL) in the rectus femoris, gastrocnemius medial and lateral, and soleus muscles] and can effectively reduce MSS while improving fatigue in the medium-term follow-up. Importantly, none of the previous studies reported any adverse events from BoNT in MS patients [97, 212]. Taken together, the previous findings have led the authors of the systematic review to conclude [40] that despite the small sample size from clinical studies - with a total of 134 patients treated with BoNT - the quality of evidence was moderate. Therefore, this panel of experts reached a consensus to recommend the use of BoNT for MSS treatment [40].

It should be noted, that despite the compelling data on the efficacy of BoNT in MSS treatment, there is an ongoing controversy in the literature with respect to the magnitude of response to BoNT therapy in MSS compared to stroke-related spasticity [205]. In a study of 99 patients with spasticity [33 MS, 33 stroke, 33 cerebral palsy (CP)], the investigators found that MSS patients required substantially higher doses of BoNT to achieve a significant clinical response [213]. By contrast, a large prospective registry of 508 patients found no differences with respect to dose and magnitude of response to BoNT between different types of spasticity (stroke, traumatic brain injury, MS, CP) [214]. Individualized titration of BoNT is recommended for MSS treatment, while physicians that utilize BoNT should adhere to the approved/recommended dosages of local authorities' guidelines. Table 7 summarizes the recommended dosages per muscle based on expert consensus and in accordance with the recommendations for post-stroke spasticity [207, 215].

Data from clinical studies indicate that even high BoNT doses (e.g., onabotulinumtoxinA doses of ≥600, abobotulinumtoxinA 500-1000 U) are generally well tolerated, causing mostly transient side-effects (most frequently muscle weakness) without any life-threatening complications [216-218]. It should be noted, however, that the maximum total botulinum toxin dose per session should not exceed 400 Units for onabotulinumtoxin A (with possibility to increase to 600 Units per session depending on treatment response) and 1500 Units for abobotulinumtoxin A.

Based on the results of RCTs and meta-analyses, the American Academy of Neurology has recently updated their guidelines on the use of botulinum toxin for the treatment of patients with spasticity [219]. Accordingly, abobotulinumtoxin A, onabotulinumtoxin A and incobotulinumtoxin A are recommended as first line treatment options for upper-limb spasticity (Level of Evidence A), whereas rimabotulinum B should be considered as an alternative treatment (Level of Evidence B) [219]. With respect to lower-limb spasticity, these guidelines suggest that abobotulinumtoxin A and onabotulinumtoxin A are established as effective and should be offered for spasticity treatment (Level of Evidence A). Notably, there is evidence from a randomised, double-blind, placebo-controlled trial comparing BoNT (onabotulinumtoxinA, Botox®) injected into spastic upper limb muscles with oral tizanidine or placebo, showing that BoNT was superior to tizanidine for improving wrist and finger flexor tone, whereas tizanidine showed no benefit over placebo [220]. Moreover, a high incidence of adverse effects with tizanidine in this RCT limited its dose titration [220]. Based on these findings, the American Academy of Neurology recommends that BoNT (with onabotulinumtoxinA) should be considered as a treatment option before tizanidine for treating adult upper extremity spasticity (Level B) [219]. It should be noted, however, that these guidelines do not differentiate between underlying causes of spasticity, and do not provide specific guidelines for MSS treatment.

Perhaps the most robust evidence so far for the use of BoNT has been provided by a consensus paper of the IAB (Interdisziplinärer Arbeitskreis Bewegungsstörungen) – Interdisciplinary Working Group for Movement Disorders task force [206]. In this position paper, the authors performed a systematic literature search, identifying a total of 55 publications (3 RCTs as cited above, 3 interventional studies, 11 observational studies, 2 case studies, 35 reviews, 1 guideline), all of which unanimously favored the use of BoNT for MSS treatment. The committee concluded that based on the reviewed data, there is no reason to assume that BT is less effective or safe in MSS than in post-stroke spasticity; thus, MS specialists should consider BoNT for MSS treatment. In addition, the committee advocated for expansion of

BoNT indications to include all types of spasticity regardless of its etiology, and stressed that SPCs should be promptly updated and approved by national and international regulatory authorities.

Finally, it should be stressed that BoNT for MSS treatment should be applied by physicians trained in its use. The number of injection sites per muscle dependents on their size, the severity of hypertonia, the degree of muscle weakness, and the response to previous injections. Administration of multiple injections may allow for a more uniform contact with the sites of muscle innervation, particularly in larger muscles. Additionally, in extremities that preserve a certain degree of voluntary movement, BoNT injections in selected muscles may contribute to the development of the appropriate conditions for the upper and lower limb that will enable a patient to participate in specialized rehabilitation programs, using for example guided plasticity techniques. In case of insufficient treatment responses, expert panels recommend: 1) increasing dose at a subsequent session, 2) increasing the number of injected muscles, 3) modifying dilution of the product [221]. In addition, ultrasound, electromyography, and electrical stimulation may all be used for guided and more accurate delivery of BoNT, since guided BoNT clearly outweighs the non-guided delivery in various patient groups, including MS patients [222, 223]. Moreover, adherence to a minimum of 12 weeks intervals between injection sessions is recommended to reduce tolerance and prevent formation of neutralizing antibodies (NAbs) against botulinum toxin [224, 225].

Recommendations regarding the use of BoNT in anticoagulated patients have been previously published in the consensus document of the Hellenic Neurological Society, the Hellenic Society of Cerebrovascular Diseases, and the Hellenic Society of Physical and Rehabilitation Medicine on post-stroke spasticity [207]. Briefly, intramuscular BoNT injections for the treatment of spasticity in anticoagulated patients should not be withheld regardless of the localization of targeted muscles [207, 215, 226, 227]. Moreover, it is suggested using 25G sized or smaller needles when injecting into deep compartment muscles of the lower limbs, and the International Normalized Ratio (INR) value should be ≤3.5. In cases of fluctuating INR values or suspected coagulopathy, a recent INR value should be available (last 2-3 days). For cases on direct oral anticoagulants (DOACs), the same precautions as for patients on warfarin and normal INR range should be taken. No dosage modification of DOACs before treatment is recommended [227].

Besides the utility of BoNT in MSS treatment, another indication of BoNT that merits mention involves the treatment of neurogenic bladder dysfunction in MS patients. Although the treatment of overactive bladder requires endoscopic BoNT injections and should be performed strictly by trained urologists or gynecologists, it is important in the context of the present consensus paper to stress that there is level A of evidence (effectiveness in two or more class I studies) supporting that the injection of onabotulinumtoxin A into the bladder's detrusor muscle improves MS-related neurogenic detrusor overactivity (NDO) and MS-related overactive (OA) bladder symptoms [205]. The FDA has approved the use of onabotulinumtoxinA for the treatment of NDO based on the results of two large multicenter studies [228, 229], which included a total of 691 patients, and demonstrated that BoNT can significantly reduce the frequency of urge urinary incontinence and improve urodynamic parameters in patients with NDO. These results have been recently confirmed by independent meta-analyses, indicating that onabotulinumtoxin A is both effective and safe for treating patients with NDO compared to placebo [230-232]. Thus, neurologists, urologists and physical medicine and rehabilitation physicians should be aware of the safety and efficacy of BoNT in the treatment of OA, and refer accordingly MS patients suffering from OA symptoms to allied medical specialties for clinical assessment.

Finally, there are emerging data mostly, based on retrospective class IV studies, demonstrating a potential efficacy of BoNTs in other MS symptoms, including focal myokymia, spastic dysphagia, and double vision due to internuclear ophthalmoplegia [205, 233]. Safarpour et al. have recently reviewed the literature, presenting single observational studies with promising results for the previous conditions [179], whilst they concluded that there is no data to support the use of BoNT for MS-related trigeminal neuralgia and sialorrhea. Even though some small observational studies have provided encouraging results, there is no evidence to date to support the utility of BoNT from large, well-designed RCTs for any of the previous indications. Therefore, no evidence-based recommendations can be formulated for the use of BoNT in MS patients with such symptoms.

9. Conclusions

The present consensus paper of the Hellenic Neurological Society, the Hellenic Academy of Neuroimmunology and the Hellenic Society of Physical and Rehabilitation Medicine provided a summary of the current evidence on pharmacological and non-pharmacological MSS treatments. This document underscores the importance of engaging interdisciplinary groups in MSS management and aims to raise awareness among clinicians for the early recognition and treatment of MSS. Proposed practical algorithms for the diagnostic approach and therapeutic management of MSS have been provided in Figure 1 and Figure 2, respectively.

The main steps of these algorithms are summarized below:

- All MS patients with upper or lower limb paresis/paralysis should be clinically evaluated for the possible presence of MSS using both clinically standardized (AS scale, MAS, Tardieu, or REPAS scale) and functional scales that incorporate patient-relevant symptoms and QoL measures. In addition, the implementation of combined scales is advisable for patient follow-up and monitoring of responsiveness to MSS therapies.
- The initial assessment of MSS should entail thorough assessment of different functional domains (including use of MSFC and EDSS scales), but also of different organ systems to identify possible complications of MSS, including bladder/bowel dysfunction, dysphagia, contractures and limb deformities, as well as pressure sores.
- Before initiation of MSS treatments it is important to assess potential risk factors, including immobility, pain, noxious stimuli, emotional tension, infections, thromboses and fractures, along with potential adverse effects of concomitant treatments; moreover, regular assessment of DMTs is warranted to ensure that disease activity does not contribute to MSS aggravation.
- Establishment of treatment goals should be decided jointly with the patients and their caregivers, considering the patient's daily activities and functional impairment due to MSS.
- In patients with motor deficits and MSS, rehabilitation sessions (including, physical and occupational therapy) are of fundamental importance for the preservation of mobility and functional independence.
- With respect to non-pharmacological approaches, physical activity programs can be used in combination with other interventions against MSS (pharmacological or non-pharmacological). Among non-pharmacological interventions, the use of intermittent/repetitive magnetic stimulation (iTBS/rTMS) with or without adjuvant exercise therapy has the highest level of evidence for improving MSS. Conversely, the use of TDCS, TENS, sports climbing and vibration therapy is not sufficiently supported by evidence from RCTs; however, their implementation in clinical practice, given their good safety profile, may be considered on an individual patient basis.
- Similarly, other non-pharmacological therapies, including hydrotherapy, cryotherapy, thermotherapy, neurodevelopmental inhibitory techniques orthoses/splints and robotic rehabilitation should be performed only in experienced therapeutic centers, as appropriate, and ideally within the settings of clinical trials and as adjunctive to other first-line spasticity treatments.
- With respect to pharmacological therapies, due to the narrow therapeutic range of oral antispastics, a careful titration of dosing is recommended. First-line treatments include oral baclofen and tizanidine, while gabapentin, diazepam, nabiximols and dantrolene may be considered in selected patients under close monitoring for potential side-effects. In addition, intrathecal baclofen pumps may be indicated especially for patients with serious side-effects from oral pharmacotherapies and generalized MSS, whereas phenol pumps have no indication for MSS treatment.
- Intramuscular BoNT injections should be considered in MS patients with upper and/or lower limb spasticity, on the condition that BoNT treatment is delivered by appropriately trained and experienced physicians. The recommendation of BoNT injections appears to have higher level of evidence compared to oral pharmacotherapies for the treatment of focal, multifocal and segmental spasticity.
- Importantly, BoNT treatment should be combined with rehabilitation sessions, as well as with orthoses/splints/casts, electrical nerve stimulation or vibration therapy, as appropriate. The simultaneous use of other techniques, like robotic technology, depends on the experience of each therapeutic center, and is recommended as appropriate, ideally within the settings of clinical trials.
- We recommend adherence to the approved BoNTs dosages according to the respective SPCs. Since MSS has not been included into currently approved BoNT indications, we recommend that muscles/BoNT dosing schemes should be aligned with those approved for post-stroke spasticity. Currently, the approved botulinumtoxin A regimens for both upper and lower limp post-stroke spasticity management in Greece are onabotulinumtoxin A and abobotulinumtoxin A.
- The maximum total botulinum toxin dose per session should not exceed 400 Units for onabotulinumtoxin A (with possibility to increase to 600 Units per session depending on treatment response) and 1500 Units for abobotulinumtoxin A. Ultrasound-guided or electromyography-guided injections are recommended; the needle size should be preferably ≥27G. Anticoagulant treatment is not a contraindication for BoNT injections.
- Finally, BoNT may be indicated for patients with neurogenic bladder dysfunction, and treating physicians should refer early MS patients to allied specialties for consultation and treatment assessment.

References

[1] Frohman EM, Racke MK, Raine CS. Multiple sclerosis-the plaque and its pathogenesis. N Engl J Med. 2006;354(9):942-55.

[2] Erwin A, Gudesblatt M, Bethoux F, Bennett SE, Koelbel S, Plunkett R, et al. Intrathecal baclofen in multiple sclerosis: too little, too late? Mult Scler. 2011;17(5):623-9.
[3] Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler. 2004;10(5):589-95.
[4] Oreja-Guevara C, González-Segura D, Vila C. Spasticity in multiple sclerosis: results of a patient survey. Int J Neurosci. 2013;123(6):400-8.
[5] Sanger TD, Delgado MR, Gaebler-Spira D, Hallett M, Mink JW. Classification and definition of disorders causing hypertonia in childhood. Pediatrics. 2003;111(1):e89-97.
[6] Henze T, Rieckmann P, Toyka KV. Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society. Eur Neurol. 2006;56(2):78-105.
[7] Trompetto C, Marinelli L, Mori L, Pelosin E, Currà A, Molfetta L, et al. Pathophysiology of spasticity: implications for neurorehabilitation. Biomed Res Int. 2014;2014:354906.
[8] Petropoulou KB, Panourias IG, Rapidi CA, Sakas DE. The phenomenon of spasticity: a pathophysiological and clinical introduction to neuromodulation therapies. Acta Neurochir Suppl. 2007;97(Pt 1):137-44.
[9] Norbye AD, Midgard R, Thrane G. Spasticity, gait, and balance in patients with multiple sclerosis: A cross-sectional study. Physiother Res Int. 2020;25(1):e1799.
[10] Sammarco A, Orasanu B, Mahajan S. The bladder in MS: a review. J Neurol Neurophysiol. 2014;5:200.
[11] Preziosi G, Gordon-Dixon A, Emmanuel A. Neurogenic bowel dysfunction in patients with multiple sclerosis: prevalence, impact, and management strategies. Degener Neurol Neuromuscul Dis. 2018;8:79-90.
[12] Merson RM, Rolnick MI. Speech-language pathology and dysphagia in multiple sclerosis. Phys Med Rehabil Clin N Am. 1998;9(3):631-41.
[13] Ghai A, Garg N, Hooda S, Gupta T. Spasticity - Pathogenesis, prevention and treatment strategies. Saudi J Anaesth. 2013;7(4):453-60.
[14] Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(3):269-85.
[15] Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler. 2020;26(14):1816-21.
[16] Stevenson VL, Gras A, Bárdos JI, Broughton J. The high cost of spasticity in multiple sclerosis to individuals and society. Mult Scler. 2015;21(12):1583-92.
[17] Lance JW. Pathophysiology of spasticity and clinical experience with baclofen. Spasticity: disordered motor control. 1980:185-204.
[18] Young RR. Treatment of spastic paresis. N Engl J Med. 1989;320(23):1553-5.
[19] Bhimani R, Anderson L. Clinical understanding of spasticity: implications for practice. Rehabil Res Pract. 2014;2014:279175.
[20] Stevenson VL. Rehabilitation in practice: Spasticity management. Clin Rehabil. 2010;24(4):293-304.
[21] Hugos CL, Cameron MH. Assessment and Measurement of Spasticity in MS: State of the Evidence. Curr Neurol Neurosci Rep. 2019;19(10):79.
[22] Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of neurology. 2011;69(2):292-302.
[23] Wattjes MP, Ciccarelli O, Reich DS, Banwell B, de Stefano N, Enzinger C, et al. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. The Lancet Neurology. 2021.
[24] Young RR. Treatment of spastic paresis. Mass Medical Soc; 1989.
[25] Dietz V, Sinkjaer T. Spastic movement disorder: impaired reflex function and altered muscle mechanics. Lancet Neurol. 2007;6(8):725-33.
[26] McLachlan EM, Chua M. Rapid adjustment of sarcomere length in tenotomized muscles depends on an intact innervation. Neuroscience Letters. 1983;35(2):127-33.
[27] Dietz V, Quintern J, Berger W. Electrophysiological studies of gait in spasticity and rigidity. Evidence that altered mechanical properties of muscle contribute to hypertonia. Brain. 1981;104(3):431-49.
[28] Puce L, Currà A, Marinelli L, Mori L, Capello E, Di Giovanni R, et al. Spasticity, spastic dystonia, and static stretch reflex in hypertonic muscles of patients with multiple sclerosis. Clinical Neurophysiology Practice. 2021;6:194-202.
[29] Marinelli L, Currà A, Trompetto C, Capello E, Serrati C, Fattapposta F, et al. Spasticity and spastic dystonia: the two faces of velocity-dependent hypertonia. J Electromyogr Kinesiol. 2017;37:84-9.
[30] Gracies JM. Pathophysiology of spastic paresis. II: Emergence of muscle overactivity. Muscle Nerve. 2005;31(5):552-71.
[31] Waubant E, Alizé P, Tourbah A, Agid Y. Paroxysmal dystonia (tonic spasm) in multiple sclerosis. Neurology. 2001;57(12):2320-1.

[32] Wissel J, Manack A, Brainin M. Toward an epidemiology of poststroke spasticity. Neurology. 2013;80(3 Suppl 2):S13-9.
[33] Kister I, Bacon TE, Chamot E, Salter AR, Cutter GR, Kalina JT, et al. Natural history of multiple sclerosis symptoms. Int J MS Care. 2013;15(3):146-58.
[34] Burke D, Gillies JD, Lance JW. The quadriceps stretch reflex in human spasticity. J Neurol Neurosurg Psychiatry. 1970;33(2):216-23.
[35] Kamper D, Schmit B, Rymer W. Effect of muscle biomechanics on the quantification of spasticity. Annals of Biomedical Engineering. 2001;29(12):1122-34.
[36] Tardieu G, Tardieu C, Colbeau-Justin P, Bret M. Effects of muscle length on an increased stretch reflex in children with cerebral palsy. Journal of Neurology, Neurosurgery & Psychiatry. 1982;45(4):348-52.
[37] Flachenecker P, Henze T, Zettl UK. Spasticity in patients with multiple sclerosis--clinical characteristics, treatment and quality of life. Acta Neurol Scand. 2014;129(3):154-62.
[38] Puce L, Currà A, Marinelli L, Mori L, Capello E, Di Giovanni R, et al. Spasticity, spastic dystonia, and static stretch reflex in hypertonic muscles of patients with multiple sclerosis. Clin Neurophysiol Pract. 2021;6:194-202.
[39] Williams G, Singer BJ, Ashford S, Brian H, Hastings-Ison T, Fheodoroff K, et al. A synthesis and appraisal of clinical practice guidelines, consensus statements and Cochrane systematic reviews for the management of focal spasticity in adults and children. Disabil Rehabil. 2020:1-11.
[40] Comi G, Solari A, Leocani L, Centonze D, Otero-Romero S. Italian consensus on treatment of spasticity in multiple sclerosis. Eur J Neurol. 2020;27(3):445-53.
[41] Platz T, Eickhof C, Nuyens G, Vuadens P. Clinical scales for the assessment of spasticity, associated phenomena, and function: a systematic review of the literature. Disabil Rehabil. 2005;27(1-2):7-18.
[42] Emre M, Leslie GC, Muir C, Part NJ, Pokorny R, Roberts RC. Correlations between dose, plasma concentrations, and antispastic action of tizanidine (Sirdalud). J Neurol Neurosurg Psychiatry. 1994;57(11):1355-9.
[43] Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther. 1987;67(2):206-7.
[44] Ashworth B. PRELIMINARY TRIAL OF CARISOPRODOL IN MULTIPLE SCLEROSIS. Practitioner. 1964;192:540-2.
[45] Haugh AB, Pandyan AD, Johnson GR. A systematic review of the Tardieu Scale for the measurement of spasticity. Disabil Rehabil. 2006;28(15):899-907.
[46] Platz T, Vuadens P, Eickhof C, Arnold P, Van Kaick S, Heise K. REPAS, a summary rating scale for resistance to passive movement: item selection, reliability and validity. Disability and rehabilitation. 2008;30(1):44-53.
[47] Hyman N, Barnes M, Bhakta B, Cozens A, Bakheit M, Kreczy-Kleedorfer B, et al. Botulinum toxin (Dysport®) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. Journal of Neurology, Neurosurgery & Psychiatry. 2000;68(6):707-12.
[48] Petropoulou K. Managing Spasticity with a Focus on Rehabilitation. Available at: https://www.neuromodulation.com/fact_sheet_spasticity.
[49] Hobart JC, Riazi A, Thompson AJ, Styles IM, Ingram W, Vickery PJ, et al. Getting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88). Brain. 2006;129(Pt 1):224-34.
[50] Wissel J, Schelosky LD, Scott J, Christe W, Faiss JH, Mueller J. Early development of spasticity following stroke: a prospective, observational trial. Journal of neurology. 2010;257(7):1067-72.
[51] Platz T, Wissel J, Donauer E. Therapie des spastischen Syndroms, S2k-Leitlinie. Leitlinien für Diagnostik und Therapie in der Neurologie www dgn org/leitlinien (abgerufen am 288 2019). 2018.
[52] Tyson S, Connell L. The psychometric properties and clinical utility of measures of walking and mobility in neurological conditions: a systematic review. Clinical rehabilitation. 2009;23(11):1018-33.
[53] Brashear A, Zafonte R, Corcoran M, Galvez-Jimenez N, Gracies J-M, Gordon MF, et al. Inter-and intrarater reliability of the Ashworth Scale and the Disability Assessment Scale in patients with upper-limb poststroke spasticity. Archives of physical medicine and rehabilitation. 2002;83(10):1349-54.
[54] Ertzgaard P, Ward AB, Wissel J, Borg J. Practical considerations for goal attainment scaling during rehabilitation following acquired brain injury. Journal of rehabilitation medicine. 2011;43(1):8-14.
[55] Ashford S, Turner-Stokes L, Siegert R, Slade M. Initial psychometric evaluation of the Arm Activity Measure (ArmA): a measure of activity in the hemiparetic arm. Clinical rehabilitation. 2013;27(8):728-40.
[56] Ashford S, Williams H, Nair A, Orridge S, Turner-Stokes L. Categorisation of goals set using Goal Attainment Scaling for treatment of leg

spasticity: a multicentre analysis. Disability and rehabilitation. 2019;41(16):1925-30.
[57] Shakespeare D, Boggild M, Young CA. Anti-spasticity agents for multiple sclerosis. Cochrane Database of Systematic Reviews. 2003(4).
[58] Meca-Lallana JE, Hern-ndez-Clares R, Carre-n-Guarnizo E. Spasticity in multiple sclerosis and role of glatiramer acetate treatment. Brain Behav. 2015;5(9):e00367.
[59] Pozzilli C. Overview of MS spasticity. Eur Neurol. 2014;71 Suppl 1:1-3.
[60] Pozzilli C. Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice. Expert Rev Neurother. 2013;13(12 Suppl):49-54.
[61] Donzé C, De Sèze J. Spasticity and everyday life in multiple sclerosis. Revue neurologique. 2012;168:S51-6.
[62] Flachenecker P, Henze T, Zettl U. Spasticity in patients with multiple sclerosis-clinical characteristics, treatment and quality of life. Acta Neurologica Scandinavica. 2014;129(3):154-62.
[63] Milonas I, Tsounis S, Logothetis I. Epidemiology of multiple sclerosis in northern Greece. Acta Neurol Scand. 1990;81(1):43-7.
[64] Papathanasopoulos P, Gourzoulidou E, Messinis L, Georgiou V, Leotsinidis M. Prevalence and incidence of multiple sclerosis in western Greece: a 23-year survey. Neuroepidemiology. 2008;30(3):167-73.
[65] Argyriou AA, Karanasios P, Makridou A, Makris N. F-wave characteristics as surrogate markers of spasticity in patients with secondary progressive multiple sclerosis. J Clin Neurophysiol. 2010;27(2):120-5.
[66] Barbalias GA, Nikiforidis G, Liatsikos EN. Vesicourethral dysfunction associated with multiple sclerosis: clinical and urodynamic perspectives. J Urol. 1998;160(1):106-11.
[67] Boviatsis EJ, Kouyialis AT, Korfias S, Sakas DE. Functional outcome of intrathecal baclofen administration for severe spasticity. Clin Neurol Neurosurg. 2005;107(4):289-95.
[68] Wissel J, Verrier M, Simpson DM, Charles D, Guinto P, Papapetropoulos S, et al. Post-stroke spasticity: predictors of early development and considerations for therapeutic intervention. Pm r. 2015;7(1):60-7.
[69] Cheung J, Rancourt A, Di Poce S, Levine A, Hoang J, Ismail F, et al. Patient-identified factors that influence spasticity in people with stroke and multiple sclerosis receiving botulinum toxin injection treatments. Physiotherapy Canada. 2015;67(2):157-66.
[70] Haselkorn JK, Balsdon Richer C, Fry Welch D, Herndon RM, Johnson B, Little JW, et al. Overview of spasticity management in multiple sclerosis. Evidence-based management strategies for spasticity treatment in multiple sclerosis. J Spinal Cord Med. 2005;28(2):167-99.
[71] Giovannoni G, Turner B, Gnanapavan S, Offiah C, Schmierer K, Marta M. Is it time to target no evident disease activity (NEDA) in multiple sclerosis? Mult Scler Relat Disord. 2015;4(4):329-33.
[72] Hegen H, Bsteh G, Berger T. 'No evidence of disease activity' - is it an appropriate surrogate in multiple sclerosis? Eur J Neurol. 2018;25(9):1107-e101.
[73] Rotstein DL, Healy BC, Malik MT, Chitnis T, Weiner HL. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol. 2015;72(2):152-8.
[74] Tsivgoulis G, Katsanos AH, Grigoriadis N, Hadjigeorgiou GM, Heliopoulos I, Papathanasopoulos P, et al. The Effect of Disease Modifying Therapies on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis. PLoS One. 2015;10(12):e0144538.
[75] Beard S, Hunn A, Wight J. Treatments for spasticity and pain in multiple sclerosis: a systematic review. Health Technol Assess. 2003;7(40):iii, ix-x, 1-111.
[76] Lublin F, Whitaker J, Eidelman B, Miller A, Arnason B, Burks J. Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference. Neurology. 1996;46(1):12-8.
[77] Leary SM, Thompson AJ. The effect of interferon beta-1a on spasticity in primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2004;75(3):508-9.
[78] Stolp-Smith KA, Wainberg MC. Antidepressant exacerbation of spasticity. Archives of physical medicine and rehabilitation. 1999;80(3):339-42.
[79] Del Real M, Hernandez A, Vaamonde J, Gudin M. Exacerbation of spasticity induced by serotonin reuptake inhibitors. Letter. Neurologia (Barcelona, Spain). 1996;11(7):272.
[80] Algahtani HA, Aldarmahi AA, Al-Rabia MW, Almalki WH, Bryan Young G. Generalized myoclonus and spasticity induced by lamotrigine toxicity: a case report and literature review. Clin Neuropharmacol. 2014;37(2):52-4.
[81] Phadke CP, Balasubramanian CK, Ismail F, Boulias C. Revisiting physiologic and psychologic triggers that increase spasticity. Am J Phys Med Rehabil. 2013;92(4):357-69.
[82] Marshall O, Lu H, Brisset J-C, Xu F, Liu P, Herbert J, et al. Impaired cerebrovascular reactivity in multiple sclerosis. JAMA neurology. 2014;71(10):1275-81.
[83] Tseng CH, Huang WS, Lin CL, Chang YJ. In-

creased risk of ischaemic stroke among patients with multiple sclerosis. European journal of neurology. 2015;22(3):500-6.
[84] Hatate J, Miwa K, Matsumoto M, Sasaki T, Yagita Y, Sakaguchi M, et al. Association between cerebral small vessel diseases and mild parkinsonian signs in the elderly with vascular risk factors. Parkinsonism Relat Disord. 2016;26:29-34.
[85] Bot JC, Barkhof F, Lycklama à Nijeholt G, van Schaardenburg D, Voskuyl AE, Ader HJ, et al. Differentiation of multiple sclerosis from other inflammatory disorders and cerebrovascular disease: value of spinal MR imaging. Radiology. 2002;223(1):46-56.
[86] Major EO, Yousry TA, Clifford DB. Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned. The Lancet Neurology. 2018;17(5):467-80.
[87] Huntsman R, Lemire E, Norton J, Dzus A, Blakley P, Hasal S. The differential diagnosis of spastic diplegia. Archives of disease in childhood. 2015;100(5):500-4.
[88] Klebe S, Stevanin G, Depienne C. Clinical and genetic heterogeneity in hereditary spastic paraplegias: from SPG1 to SPG72 and still counting. Rev Neurol (Paris). 2015;171(6-7):505-30.
[89] Vivancos-Matellano F, Pascual-Pascual SI, Nardi-Vilardaga J, Miquel-Rodriguez F, de Miguel-Leon I, Martinez-Garre MC, et al. [Guide to the comprehensive treatment of spasticity]. Rev Neurol. 2007;45(6):365-75.
[90] Brainin M, Norrving B, Sunnerhagen KS, Goldstein LB, Cramer SC, Donnan GA, et al. Post-stroke chronic disease management: towards improved identification and interventions for poststroke spasticity-related complications. Int J Stroke. 2011;6(1):42-6.
[91] Patzold T, Schwengelbeck M, Ossege LM, Malin JP, Sindern E. Changes of the MS functional composite and EDSS during and after treatment of relapses with methylprednisolone in patients with multiple sclerosis. Acta Neurol Scand. 2002;105(3):164-8.
[92] Amatya B, Khan F, La Mantia L, Demetrios M, Wade DT. Non pharmacological interventions for spasticity in multiple sclerosis. Cochrane Database Syst Rev. 2013(2):Cd009974.
[93] Thompson AJ, Jarrett L, Lockley L, Marsden J, Stevenson VL. Clinical management of spasticity. J Neurol Neurosurg Psychiatry. 2005;76(4):459-63.
[94] O'Brien CF, Seeberger LC, Smith DB. Spasticity after stroke. Epidemiology and optimal treatment. Drugs Aging. 1996;9(5):332-40.
[95] Gallien P, Gich J, Sánchez-Dalmau BF, Feneberg W. Multidisciplinary management of multiple sclerosis symptoms. Eur Neurol. 2014;72 Suppl 1:20-5.
[96] Khan F, Amatya B, Bensmail D, Yelnik A. Non-pharmacological interventions for spasticity in adults: An overview of systematic reviews. Ann Phys Rehabil Med. 2019;62(4):265-73.
[97] Giovannelli M, Borriello G, Castri P, Prosperini L, Pozzilli C. Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spasticity in patients with multiple sclerosis. Clinical rehabilitation. 2007;21(4):331-7.
[98] Mori F, Ljoka C, Magni E, Codecà C, Kusayanagi H, Monteleone F, et al. Transcranial magnetic stimulation primes the effects of exercise therapy in multiple sclerosis. J Neurol. 2011;258(7):1281-7.
[99] Schyns F, Paul L, Finlay K, Ferguson C, Noble E. Vibration therapy in multiple sclerosis: a pilot study exploring its effects on tone, muscle force, sensation and functional performance. Clin Rehabil. 2009;23(9):771-81.
[100] Velikonja O, Curi- K, Ozura A, Jazbec SS. Influence of sports climbing and yoga on spasticity, cognitive function, mood and fatigue in patients with multiple sclerosis. Clin Neurol Neurosurg. 2010;112(7):597-601.
[101] Tupimai T, Peungsuwan P, Prasertnoo J, Yamauchi J. Effect of combining passive muscle stretching and whole body vibration on spasticity and physical performance of children and adolescents with cerebral palsy. Journal of physical therapy science. 2016;28(1):7-13.
[102] Dettmers C, Teske U, Hamzei F, Uswatte G, Taub E, Weiller C. Distributed form of constraint-induced movement therapy improves functional outcome and quality of life after stroke. Arch Phys Med Rehabil. 2005;86(2):204-9.
[103] Platz T, van Kaick S, Mehrholz J, Leidner O, Eickhof C, Pohl M. Best conventional therapy versus modular impairment-oriented training for arm paresis after stroke: a single-blind, multicenter randomized controlled trial. Neurorehabil Neural Repair. 2009;23(7):706-16.
[104] Lannin NA, Cusick A, McCluskey A, Herbert RD. Effects of splinting on wrist contracture after stroke: a randomized controlled trial. Stroke. 2007;38(1):111-6.
[105] Gracies JM, Marosszeky JE, Renton R, Sandanam J, Gandevia SC, Burke D. Short-term effects of dynamic lycra splints on upper limb in hemiplegic patients. Arch Phys Med Rehabil. 2000;81(12):1547-55.
[106] Pizzi A, Carlucci G, Falsini C, Verdesca S, Grippo A. Application of a volar static splint in poststroke spasticity of the upper limb. Arch Phys Med Rehabil. 2005;86(9):1855-9.

[107] Iwata M, Kondo I, Sato Y, Satoh K, Soma M, Tsushima E. An ankle-foot orthosis with inhibitor bar: effect on hemiplegic gait. Arch Phys Med Rehabil. 2003;84(6):924-7.
[108] Mills PB, Finlayson H, Sudol M, O'Connor R. Systematic review of adjunct therapies to improve outcomes following botulinum toxin injection for treatment of limb spasticity. Clin Rehabil. 2016;30(6):537-48.
[109] Stoeckmann T. Casting for the person with spasticity. Top Stroke Rehabil. 2001;8(1):27-35.
[110] Müller-Dahlhaus F, Ziemann U, Classen J. Plasticity resembling spike-timing dependent synaptic plasticity: the evidence in human cortex. Front Synaptic Neurosci. 2010;2:34.
[111] Ziemann U. TMS induced plasticity in human cortex. Rev Neurosci. 2004;15(4):253-66.
[112] Suppa A, Huang YZ, Funke K, Ridding MC, Cheeran B, Di Lazzaro V, et al. Ten Years of Theta Burst Stimulation in Humans: Established Knowledge, Unknowns and Prospects. Brain Stimul. 2016;9(3):323-35.
[113] Lefaucheur JP, Aleman A, Baeken C, Benninger DH, Brunelin J, Di Lazzaro V, et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018). Clin Neurophysiol. 2020;131(2):474-528.
[114] Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of evidence and strength of recommendations. Bmj. 2004;328(7454):1490.
[115] Centonze D, Koch G, Versace V, Mori F, Rossi S, Brusa L, et al. Repetitive transcranial magnetic stimulation of the motor cortex ameliorates spasticity in multiple sclerosis. Neurology. 2007;68(13):1045-50.
[116] Boutière C, Rey C, Zaaraoui W, Le Troter A, Rico A, Crespy L, et al. Improvement of spasticity following intermittent theta burst stimulation in multiple sclerosis is associated with modulation of resting-state functional connectivity of the primary motor cortices. Multiple Sclerosis Journal. 2017;23(6):855-63.
[117] Mori F, Codecà C, Kusayanagi H, Monteleone F, Boffa L, Rimano A, et al. Effects of intermittent theta burst stimulation on spasticity in patients with multiple sclerosis. European journal of neurology. 2010;17(2):295-300.
[118] Mori F, Ljoka C, Magni E, Codecà C, Kusayanagi H, Monteleone F, et al. Transcranial magnetic stimulation primes the effects of exercise therapy in multiple sclerosis. Journal of neurology. 2011;258(7):1281-7.
[119] Nielsen JF, Sinkjaer T, Jakobsen J. Treatment of spasticity with repetitive magnetic stimulation; a double-blind placebo-controlled study. Multiple Sclerosis Journal. 1996;2(5):227-32.
[120] Kumru H, Benito-Penalva J, Valls-Sole J, Murillo N, Tormos JM, Flores C, et al. Placebo-controlled study of rTMS combined with Lokomat(®) gait training for treatment in subjects with motor incomplete spinal cord injury. Exp Brain Res. 2016;234(12):3447-55.
[121] Nardone R, Langthaler PB, Orioli A, Höller P, Höller Y, Frey VN, et al. Effects of intermittent theta burst stimulation on spasticity after spinal cord injury. Restor Neurol Neurosci. 2017;35(3):287-94.
[122] Beaulieu LD, Schneider C. Effects of repetitive peripheral magnetic stimulation on normal or impaired motor control. A review. Neurophysiol Clin. 2013;43(4):251-60.
[123] Momosaki R, Yamada N, Ota E, Abo M. Repetitive peripheral magnetic stimulation for activities of daily living and functional ability in people after stroke. Cochrane Database Syst Rev. 2017;6(6):Cd011968.
[124] Iodice R, Dubbioso R, Ruggiero L, Santoro L, Manganelli F. Anodal transcranial direct current stimulation of motor cortex does not ameliorate spasticity in multiple sclerosis. Restorative neurology and neuroscience. 2015;33(4):487-92.
[125] Pandyan AD, Granat MH, Stott DJ. Effects of electrical stimulation on flexion contractures in the hemiplegic wrist. Clin Rehabil. 1997;11(2):123-30.
[126] Chen SC, Chen YL, Chen CJ, Lai CH, Chiang WH, Chen WL. Effects of surface electrical stimulation on the muscle-tendon junction of spastic gastrocnemius in stroke patients. Disabil Rehabil. 2005;27(3):105-10.
[127] Fernández-Tenorio E, Serrano-Mu-oz D, Avendaño-Coy J, G-mez-Soriano J. Transcutaneous electrical nerve stimulation for spasticity: A systematic review. Neurologia (Engl Ed). 2019;34(7):451-60.
[128] Shaygannejad V, Janghorbani M, Vaezi A, Haghighi S, Golabchi K, Heshmatipour M. Comparison of the effect of baclofen and transcutaneous electrical nerve stimulation for the treatment of spasticity in multiple sclerosis. Neurological research. 2013;35(6):636-41.
[129] Mills PB, Dossa F. Transcutaneous Electrical Nerve Stimulation for Management of Limb Spasticity: A Systematic Review. Am J Phys Med Rehabil. 2016;95(4):309-18.
[130] Yan T, Hui-Chan CW, Li LS. Functional electrical stimulation improves motor recovery of the lower extremity and walking ability of subjects with first acute stroke: a randomized placebo-controlled trial. Stroke. 2005;36(1):80-5.

[131] Cai Y, Zhang CS, Liu S, Wen Z, Zhang AL, Guo X, et al. Electroacupuncture for Post-stroke Spasticity: A Systematic Review and Meta-Analysis. Arch Phys Med Rehabil. 2017;98(12):2578-89.e4.
[132] Chen JC, Liang CC, Shaw FZ. Facilitation of sensory and motor recovery by thermal intervention for the hemiplegic upper limb in acute stroke patients: a single-blind randomized clinical trial. Stroke. 2005;36(12):2665-9.
[133] Huang M, Liao LR, Pang MY. Effects of whole body vibration on muscle spasticity for people with central nervous system disorders: a systematic review. Clin Rehabil. 2017;31(1):23-33.
[134] Sadeghi M, Sawatzky B. Effects of vibration on spasticity in individuals with spinal cord injury: a scoping systematic review. Am J Phys Med Rehabil. 2014;93(11):995-1007.
[135] Yang E, Lew HL, Özçakar L, Wu CH. Recent Advances in the Treatment of Spasticity: Extracorporeal Shock Wave Therapy. J Clin Med. 2021;10(20).
[136] Otero-Romero S, Sastre-Garriga J, Comi G, Hartung HP, Soelberg S-rensen P, Thompson AJ, et al. Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. Mult Scler. 2016;22(11):1386-96.
[137] Montané E, Vallano A, Laporte JR. Oral antispastic drugs in nonprogressive neurologic diseases: a systematic review. Neurology. 2004;63(8):1357-63.
[138] Wade DT, Collin C, Stott C, Duncombe P. Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult Scler. 2010;16(6):707-14.
[139] Olvey EL, Armstrong EP, Grizzle AJ. Contemporary pharmacologic treatments for spasticity of the upper limb after stroke: a systematic review. Clin Ther. 2010;32(14):2282-303.
[140] Lakhan SE, Rowland M. Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review. BMC Neurol. 2009;9:59.
[141] Russo M, Calabrò RS, Naro A, Sessa E, Rifici C, D'Aleo G, et al. Sativex in the management of multiple sclerosis-related spasticity: role of the corticospinal modulation. Neural Plast. 2015;2015:656582.
[142] Meythaler JM, Guin-Renfroe S, Johnson A, Brunner RM. Prospective assessment of tizanidine for spasticity due to acquired brain injury. Arch Phys Med Rehabil. 2001;82(9):1155-63.
[143] Lindsay C, Kouzouna A, Simcox C, Pandyan AD. Pharmacological interventions other than botulinum toxin for spasticity after stroke. Cochrane Database Syst Rev. 2016;10(10):Cd010362.
[144] Bass B, Weinshenker B, Rice GP, Noseworthy JH, Cameron MG, Hader W, et al. Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis. Can J Neurol Sci. 1988;15(1):15-9.
[145] Stien R, Nordal HJ, Oftedal SI, Sletteb- M. The treatment of spasticity in multiple sclerosis: a double-blind clinical trial of a new anti-spastic drug tizanidine compared with baclofen. Acta Neurol Scand. 1987;75(3):190-4.
[146] Hinderer SR, Liberty K. Effects of baclofen on oral counting, arithmetic, and symbol decoding: An explorative multiple-baseline design across subjects. International Journal of Rehabilitation and Health. 1996;2(1):41-55.
[147] Jamous A, Kennedy P, Psychol C, Grey N. Psychological and emotional effects of the use of oral baclofen: a preliminary study. Paraplegia. 1994;32(5):349-53.
[148] Chou R, Peterson K, Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J Pain Symptom Manage. 2004;28(2):140-75.
[149] Taricco M, Pagliacci MC, Telaro E, Adone R. Pharmacological interventions for spasticity following spinal cord injury: results of a Cochrane systematic review. Eura Medicophys. 2006;42(1):5-15.
[150] Pinder RM, Brogden RN, Speight TM, Avery GS. Dantrolene sodium: a review of its pharmacological properties and therapeutic efficacy in spasticity. Drugs. 1977;13(1):3-23.
[151] Brainin M, Barnes M, Baron JC, Gilhus NE, Hughes R, Selmaj K, et al. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces-revised recommendations 2004. Eur J Neurol. 2004;11(9):577-81.
[152] Brar SP, Smith MB, Nelson LM, Franklin GM, Cobble ND. Evaluation of treatment protocols on minimal to moderate spasticity in multiple sclerosis. Arch Phys Med Rehabil. 1991;72(3):186-9.
[153] Cartlidge N, Hudgson P, Weightman D. A comparison of baclofen and diazepam in the treatment of spasticity. Journal of the neurological sciences. 1974;23(1):17-24.
[154] Feldman RG, Kelly-Hayes M, Conomy JP, Foley JM. Baclofen for spasticity in multiple sclerosis Double-blind crossover and three-year study. Neurology. 1978;28(11):1094.
[155] From A, Heltberg A. A double-blind trial with baclofen (LIORESAL®) and diazepam in spastic-

ity due to multiple sclerosis. Acta Neurologica Scandinavica. 1975;51(2):158-66.
[156] Hudgson P, Weightman D. Baclofen in the treatment of spasticity. Br Med J. 1971;4(5778):15-7.
[157] Larsen T, Ravnborg M. Effect of baclofen on gait in spastic MS patients. Acta Neurol Scand. 2000;101:244-8.
[158] Roussan M, Terrence C, Fromm G. Baclofen versus diazepam for the treatment of spasticity and long-term follow-up of baclofen therapy. Pharmatherapeutica. 1985;4(5):278-84.
[159] Sachais BA, Logue JN, Carey MS. Baclofen, a new antispastic drug: a controlled, multicenter trial in patients with multiple sclerosis. Archives of Neurology. 1977;34(7):422-8.
[160] Sawa G, Paty D. The use of baclofen in treatment of spasticity in multiple sclerosis. Canadian Journal of Neurological Sciences. 1979;6(3):351-4.
[161] Levine I, Jossmann P, DeAngelis V. Liorseal, a new muscle relaxant in the treatment of spasticity--a double-blind quantitative evaluation. Diseases of the nervous system. 1977;38(12):1011-5.
[162] Dario A, Tomei G. A benefit-risk assessment of baclofen in severe spinal spasticity. Drug safety. 2004;27(11):799-818.
[163] Nance P, Sheremata W, Lynch S, Vollmer T, Hudson S, Francis G, et al. Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis. Archives of neurology. 1997;54(6):731-6.
[164] Vakhapova V, Auriel E, Karni A. Nightly sublingual tizanidine HCl in multiple sclerosis: clinical efficacy and safety. Clinical neuropharmacology. 2010;33(3):151-4.
[165] Smith C, Birnbaum G, Carter JL, Greenstein J, Lublin FD. Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group. Neurology. 1994;44(11 Suppl 9):S34-42; discussion S.
[166] Lapierre Y, Bouchard S, Tansey C, Gendron D, Barkas W, Francis G. Treatment of spasticity with tizanidine in multiple sclerosis. Canadian Journal of Neurological Sciences. 1987;14(S3):513-7.
[167] A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. United Kingdom Tizanidine Trial Group. Neurology. 1994;44(11 Suppl 9):S70-8.
[168] Rinne U, UK R. Tizanidine treatment of spasticity in multiple sclerosis and chronic myelopathy. 1980.
[169] Eyssette M, Rohmer F, Serratrice G, Warter J, Boisson D. Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis. Current medical research and opinion. 1988;10(10):699-708.
[170] Hoogstraten M, Van der Ploeg R, Burg Wv, Vreeling A, Van Marle S, Minderhoud J. Tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patients. Acta neurologica scandinavica. 1988;77(3):224-30.
[171] Newman P, Nogues M, Newman P, Weightman D, Hudgson P. Tizanidine in the treatment of spasticity. European journal of clinical pharmacology. 1982;23(1):31-5.
[172] Bass B, Weinshenker B, Rice G, Noseworthy J, Cameron M, Hader W, et al. Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis. Canadian journal of neurological sciences. 1988;15(1):15-9.
[173] Smolenski C, Muff S, Smolenski-Kautz S. A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis. Current medical research and opinion. 1981;7(6):374-83.
[174] Stien R, Nordal H, Oftedal S, Sletteboø M. The treatment of spasticity in multiple sclerosis: a double-blind clinical trial of a new anti-spastic drug tizanidine* compared with baclofen. Acta neurologica scandinavica. 1987;75(3):190-4.
[175] Wagstaff AJ, Bryson HM. Tizanidine. Drugs. 1997;53(3):435-52.
[176] Nance PW, Sheremata WA, Lynch SG, Vollmer T, Hudson S, Francis GS, et al. Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis. Arch Neurol. 1997;54(6):731-6.
[177] Smith C, Birnbaum G, Carter JL, Greenstein J, Lublin FD. Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group. Neurology. 1994;44(11 Suppl 9):S34-42; discussion S-3.
[178] Vakhapova V, Auriel E, Karni A. Nightly sublingual tizanidine HCl in multiple sclerosis: clinical efficacy and safety. Clin Neuropharmacol. 2010;33(3):151-4.
[179] Schmitz A. Benzodiazepine use, misuse, and abuse: a review. Mental Health Clinician. 2016;6(3):120-6.
[180] Schmidt R, Lee R, Spehlmann R. Comparison of dantrolene sodium and diazepam in the treatment of spasticity. Journal of Neurology, Neurosurgery & Psychiatry. 1976;39(4):350-6.
[181] Basmajian J, Shankardass K, Russell D, Yucel V. Ketazolam treatment for spasticity: double-

blind study of a new drug. Archives of physical medicine and rehabilitation. 1984;65(11):698-701.
[182] Basmajian JV, Shankardass K, Russell D. Ketazolam once daily for spasticity: double-blind cross-over study. Archives of physical medicine and rehabilitation. 1986;67(8):556-7.
[183] Cutter NC, Scott DD, Johnson JC, Whiteneck G. Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial. Archives of physical medicine and rehabilitation. 2000;81(2):164-9.
[184] Mueller ME, Gruenthal M, Olson WL, Olson WH. Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. Archives of physical medicine and rehabilitation. 1997;78(5):521-4.
[185] Gelenberg AJ, Poskanzer DC. The effect of dantrolene sodium on spasticity in multiple sclerosis. Neurology. 1973;23(12):1313-.
[186] Tolosa ES, Soll RW, Loewenson RB. Treatment of spasticity in multiple sclerosis with dantrolene. Jama. 1975;233(10):1046-.
[187] Fragoso YD, Carra A, Macias MA. Cannabis and multiple sclerosis. Expert Rev Neurother. 2020;20(8):849-54.
[188] Novotna A, Mares J, Ratcliffe S, Novakova I, Vachova M, Zapletalova O, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®)), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol. 2011;18(9):1122-31.
[189] Wang T, Collet J-P, Shapiro S, Ware MA. Adverse effects of medical cannabinoids: a systematic review. Cmaj. 2008;178(13):1669-78.
[190] UK NCGC. Multiple sclerosis: Management of multiple sclerosis in primary and secondary care. 2014.
[191] Haselkorn J, Richer CB, Welch DF. Multiple Sclerosis Council for Clinical Practice Guidelines. Overview of spasticity management in multiple sclerosis. Evidence-based management strategies for spasticity treatment in multiple sclerosis. J Spinal Cord Med. 2005;28(2):167-99.
[192] Sallerin B, Lazorthes Y. [Intrathecal baclofen. Experimental and pharmacokinetic studies]. Neurochirurgie. 2003;49(2-3 Pt 2):271-5.
[193] Coffey RJ, Cahill D, Steers W, Park T, Ordia J, Meythaler J, et al. Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter study. Journal of neurosurgery. 1993;78(2):226-32.
[194] Middel B, Kuipers-Upmeijer H, Bouma J, Staal M, Oenema D, Postma T, et al. Effect of intrathecal baclofen delivered by an implanted programmable pump on health related quality of life in patients with severe spasticity. Journal of Neurology, Neurosurgery & Psychiatry. 1997;63(2):204-9.
[195] Penn RD, Savoy SM, Corcos D, Latash M, Gottlieb G, Parke B, et al. Intrathecal baclofen for severe spinal spasticity. New England Journal of Medicine. 1989;320(23):1517-21.
[196] Browne R, Catton D. The use of intrathecal phenol for muscle spasms in multiple sclerosis. Canadian Anaesthetists' Society Journal. 1975;22(2):208-18.
[197] Cain HD. Subarachnoid phenol block in the treatment of pain and spasticity. Spinal Cord. 1965;3(2):152-60.
[198] Jarrett L, Nandi P, Thompson A. Managing severe lower limb spasticity in multiple sclerosis: does intrathecal phenol have a role? Journal of Neurology, Neurosurgery & Psychiatry. 2002;73(6):705-9.
[199] Pinder C, Bhakta B, Kodavali K. Intrathecal phenol: an old treatment revisited. Disability and rehabilitation. 2008;30(5):381-6.
[200] Das TK, Park DM. Effect of treatment with botulinum toxin on spasticity. Postgrad Med J. 1989;65(762):208-10.
[201] Nigam PK, Nigam A. Botulinum toxin. Indian journal of dermatology. 2010;55(1):8.
[202] Tehran DA, Pirazzini M. Novel Botulinum Neurotoxins: Exploring Underneath the Iceberg Tip. Toxins (Basel). 2018;10(5).
[203] Jabbari B. History of Botulinum Toxin Treatment in Movement Disorders. Tremor Other Hyperkinet Mov (N Y). 2016;6:394.
[204] S-awek J, Car H, Bonikowski M, Bogucki A, Koziorowski D, Potulska-Chromik A, et al. [Are botulinum toxin type A preparations really the same medication? A comparison of three botulinum toxin A for variations in labelled neurological indications]. Neurol Neurochir Pol. 2010;44(1):43-64.
[205] Safarpour Y, Mousavi T, Jabbari B. Botulinum Toxin Treatment in Multiple Sclerosis-a Review. Curr Treat Options Neurol. 2017;19(10):33.
[206] Dressler D, Bhidayasiri R, Bohlega S, Chahidi A, Chung TM, Ebke M, et al. Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force. J Neurol. 2017;264(1):112-20.
[207] Tsivgoulis G, Kargiotis O, Vadikolias K, Tsivgoulis A, Karapanayiotides T, Karavasili A, et al. Management of post-stroke upper and lower limb spasticity: a consensus document of the Hellenic Neurological Society, Hellenic Society of Cerebrovascular Diseases and Hellenic So-

ciety of Physical and Rehabilitation Medicine Neurologia 2019;28(1):28-57.
[208] Borg-Stein J, Pine ZM, Miller JR, Brin MF. Botulinum toxin for the treatment of spasticity in multiple sclerosis. New observations. Am J Phys Med Rehabil. 1993;72(6):364-8.
[209] Grazko MA, Polo KB, Jabbari B. Botulinum toxin A for spasticity, muscle spasms, and rigidity. Neurology. 1995;45(4):712-7.
[210] Finsterer J, Fuchs I, Mamoli B. Automatic EMG-guided botulinum toxin treatment of spasticity. Clinical neuropharmacology. 1997;20(3):195-203.
[211] Snow BJ, Tsui JK, Bhatt MH, Varelas M, Hashimoto SA, Calne DB. Treatment of spasticity with botulinum toxin: a double-blind study. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society. 1990;28(4):512-5.
[212] Paoloni M, Giovannelli M, Mangone M, Leonardi L, Tavernese E, Di Pangrazio E, et al. Does giving segmental muscle vibration alter the response to botulinum toxin injections in the treatment of spasticity in people with multiple sclerosis? A single-blind randomized controlled trial. Clinical rehabilitation. 2013;27(9):803-12.
[213] Fève A. Spasticity and botulinum toxin in 2003. An update. Neuro-chirurgie. 2003;49(2-3 Pt 2):265-70.
[214] Schramm A, Ndayisaba J-P, auf dem Brinke M, Hecht M, Herrmann C, Huber M, et al. Spasticity treatment with onabotulinumtoxin A: data from a prospective German real-life patient registry. Journal of Neural Transmission. 2014;121(5):521-30.
[215] Simpson DM, Patel AT, Alfaro A, Ayyoub Z, Charles D, Dashtipour K, et al. OnabotulinumtoxinA Injection for Poststroke Upper-Limb Spasticity: Guidance for Early Injectors From a Delphi Panel Process. Pm r. 2017;9(2):136-48.
[216] Baricich A, Grana E, Carda S, Santamato A, Cisari C, Invernizzi M. High doses of onabotulinumtoxinA in post-stroke spasticity: a retrospective analysis. J Neural Transm (Vienna). 2015;122(9):1283-7.
[217] Nuanthaisong U, Abraham N, Goldman HB. Incidence of adverse events after high doses of onabotulinumtoxinA for multiple indications. Urology. 2014;84(5):1044-8.
[218] Jost WH, Hefter H, Reissig A, Kollewe K, Wissel J. Efficacy and safety of botulinum toxin type A (Dysport) for the treatment of post-stroke arm spasticity: results of the German-Austrian open-label post-marketing surveillance prospective study. J Neurol Sci. 2014;337(1-2):86-90.
[219] Simpson DM, Hallett M, Ashman EJ, Comella CL, Green MW, Gronseth GS, et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016;86(19):1818-26.
[220] Simpson DM, Gracies JM, Yablon SA, Barbano R, Brashear A. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo-controlled study. J Neurol Neurosurg Psychiatry. 2009;80(4):380-5.
[221] Esquenazi A, Alfaro A, Ayyoub Z, Charles D, Dashtipour K, Graham GD, et al. OnabotulinumtoxinA for Lower Limb Spasticity: Guidance From a Delphi Panel Approach. Pm r. 2017;9(10):960-8.
[222] O'Brien CF. Injection techniques for botulinum toxin using electromyography and electrical stimulation. Muscle Nerve Suppl. 1997;6:S176-80.
[223] Grigoriu AI, Dinomais M, Rémy-Néris O, Brochard S. Impact of Injection-Guiding Techniques on the Effectiveness of Botulinum Toxin for the Treatment of Focal Spasticity and Dystonia: A Systematic Review. Arch Phys Med Rehabil. 2015;96(11):2067-78.e1.
[224] Fabbri M, Leodori G, Fernandes RM, Bhidayasiri R, Marti MJ, Colosimo C, et al. Neutralizing Antibody and Botulinum Toxin Therapy: A Systematic Review and Meta-analysis. Neurotox Res. 2016;29(1):105-17.
[225] Benecke R. Clinical relevance of botulinum toxin immunogenicity. BioDrugs. 2012;26(2):e1-9.
[226] Schrader C, Ebke M, Adib Saberi F, Dressler D. Botulinum toxin therapy in patients with oral anticoagulation: is it safe? J Neural Transm (Vienna). 2018;125(2):173-6.
[227] Boulias C, Ismail F, Phadke CP, Bagg S, Bureau I, Charest S, et al. A Delphi-Based Consensus Statement on the Management of Anticoagulated Patients With Botulinum Toxin for Limb Spasticity. Arch Phys Med Rehabil. 2018;99(11):2183-9.
[228] Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. European urology. 2011;60(4):742-50.
[229] Ginsberg D, Gousse A, Keppenne V, Sievert KD, Thompson C, Lam W, et al. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol. 2012;187(6):2131-9.

[230] Cheng T, Shuang WB, Jia DD, Zhang M, Tong XN, Yang WD, et al. Efficacy and Safety of OnabotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS One. 2016;11(7):e0159307.
[231] Cui Y, Cai T, Dong T, Zhang X, Zhou Z, Lu Y, et al. Trigonal-Sparing vs. Trigonal-Involved OnabotulinumtoxinA Injection for the Treatment of Overactive Bladder: A Systematic Review and Meta-Analysis. Front Neurol. 2021;12:651635.
[232] Zhou X, Yan HL, Cui YS, Zong HT, Zhang Y. Efficacy and safety of onabotulinumtoxinA in treating neurogenic detrusor overactivity: a systematic review and meta-analysis. Chin Med J (Engl). 2015;128(7):963-8.
[233] Di Stadio A, Bernitsas E, Restivo DA, Alfonsi E, Marchese-Ragona R. Spasmodic Dysphonia in Multiple Sclerosis Treatment With Botulin Toxin A: A Pilot Study. J Voice. 2019;33(4):550-3.

Άρθρα...

A PRACTICAL GUIDE FOR EUROPEAN STROKE ORGANIZATION (ESO) STROKE UNIT ACCREDITATION OF ACUTE STROKE-READY CLINICS IN GREECE

Apostolos Safouris MD[1, 2, 3], Jobst Rudolf MD[4], Theodore Karapanayiotides MD[5], Sotirios Giannopoulos MD[2], Maria Gryllia MD[6], Argyro Kiamili MD[7], Odysseas Kargiotis MD[1], Klearchos Psychogios MD[1, 2], Thomas Tegos MD[8], Sofia Vassilopoulou MD[9], Vasileios Tentolouris-Piperas MD[9], Eleni Bakola MD[2], Lina Palaiodimou MD[2], Konstantinos Vadikolias MD[10], Panayiotis Mitsias MD[11], Georgios Tsivgoulis, MD[2,12]

[1] Stroke Unit, Metropolitan Hospital, Piraeus
[2] 2nd Department of Neurology, National & Kapodistrian University of Athens, School of Medicine, "Attikon" University Hospital, Athens
[3] Aktios Rehabilitation Center, Koropi, Attica
[4] Department of Neurology, Papageorgiou Hospital, Thessaloniki
[5] 2nd Department of Neurology, AHEPA University Hospital, Aristotle University of Thessaloniki, School of Medicine, Thessaloniki
[6] Department of Neurology, Athens General Hospital G. Gennimatas, Athens
[7] Department of Neurology, "Korgialenio-Benakio" Hellenic Red Cross Hospital, Athens
[8] 1st Department of Neurology, AHEPA University Hospital, Aristotle University of Thessaloniki, School of Medicine, Thessaloniki
[9] 1st Department of Neurology, National and Kapodistrian University of Athens, Eginition Hospital, Athens
[10] Department of Neurology, Democritus University of Thrace, School of Medicine, Alexandroupolis
[11] Department of Neurology Medical School, University of Crete, Heraklion, Crete
[12] Department of Neurology, The University of Tennessee Health Science Center, Memphis, Tennessee, United States of America

Abstract

Recent advances in acute ischemic stroke treatment have ended, in theory, the therapeutic nihilism towards stroke. In practice, implementation of approved treatments still lags in many European countries. European Stroke Organization (ESO) Stroke Unit accreditation process is the first step for improving the quality of stroke services. The process is simple and straightforward but users unaccustomed with quality procedures may be intimidated by the requested documentation. Moreover, high variation of health systems among European countries may further complicate the presentation of an acute stroke-ready center in a way to fit the definition of an ESO-accredited stroke unit. The present narrative review may help the interested stroke physicians formulate a comprehensive presentation of their center in order to facilitate accreditation of those acute stroke-ready centers that have established high standards of stroke care. Several free online resources concerning stroke education and accreditation will be provided. This document will also address specific characteristics of the stroke health services in Greece, highlighting suboptimal practices in the hope to initiate actions to promote adherence to ESO standards. Translating recent scientific advances into current stroke care in Greece is a major challenge for Greek stroke physicians and collaboration with public health agencies is necessary to achieve high quality care for stroke patients in Greece.

Key words: stroke, stroke units, accreditation, quality of care, European Stroke Organization, Greece

ΕΝΑΣ ΠΡΑΚΤΙΚΟΣ ΟΔΗΓΟΣ ΠΙΣΤΟΠΟΙΗΣΗΣ ΩΣ ΜΟΝΑΔΕΣ ΑΓΓΕΙΑΚΩΝ ΕΓΚΕΦΑΛΙΚΩΝ ΕΠΕΙΣΟΔΙΩΝ (ΑΕΕ) ΣΤΟΝ ΕΥΡΩΠΑΪΚΟ ΟΡΓΑΝΙΣΜΟ ΕΓΚΕΦΑΛΙΚΩΝ (EUROPEAN STROKE ORGANIZATION) ΤΩΝ ΕΛΛΗΝΙΚΩΝ ΚΛΙΝΙΚΩΝ ΠΟΥ ΝΟΣΗΛΕΥΟΥΝ ΟΞΕΑ ΑΕΕ

Σαφούρης Απόστολος[1, 2, 3], Rudolf Jobst[4], Καραπαναγιωτίδης Θεόδωρος[5], Γιαννόπουλος Σωτήριος[2], Γρύλλια Μαρία[6], Κιαμίλη Αργυρώ[7], Καργιώτης Οδυσσέας[1], Ψυχογιός Κλέαρχος[1, 2], Τέγος Θωμάς[8], Βασιλοπούλου Σοφία[9], Τεντολούρης-Πιπεράς Βασίλειος[9], Ελένη Μπακόλα[2], Λίνα Παλαιοδήμου[2], Βαδικόλιας Κωνσταντίνος[10], Μήτσιας Παναγιώτης[11], Τσιβγούλης Γεώργιος[2, 12]

[1] Μονάδα Εγκεφαλικών, Ιδιωτικό Θεραπευτήριο Metropolitan, Πειραιάς
[2] Β' Πανεπιστημιακή Νευρολογική Κλινική, Εθνικό Καποδιστριακό Πανεπιστήμιο Αθηνών, ΠΓΝ «Αττικόν», Αθήνα
[3] Κέντρο Αποκατάστασης «Άκτιος», Κορωπί Αττικής
[4] Νευρολογική Κλινική, ΓΝ Παπαγεωργίου, Θεσσαλονίκη
[5] Β' Νευρολογική Κλινική, ΠΓΝ ΑΧΕΠΑ, Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης, Θεσσαλονίκη
[6] Νευρολογική Κλινική, ΓΝΑ «Γ. Γεννηματάς», Αθήνα
[7] Νευρολογική Κλινική, Γ.Ν.Α. «Κοργιαλένειο-Μπενάκειο Ελληνικός Ερυθρός Σταυρός», Αθήνα
[8] Α' Νευρολογική Κλινική, ΠΓΝ ΑΧΕΠΑ, Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης, Θεσσαλονίκη
[9] Α' Πανεπιστημιακή Νευρολογική Κλινική, Εθνικό Καποδιστριακό Πανεπιστήμιο Αθηνών, Αιγινήτειο Νοσοκομείο, Αθήνα
[10] Νευρολογική Κλινική, Δημοκρίτειο Πανεπιστήμιο Θράκης, Ιατρική Σχολή, Αλεξανδρούπολη
[11] Νευρολογική Κλινική, Ιατρική Σχολή, Πανεπιστήμιο Κρήτης, Ηράκλειο
[12] Department of Neurology, The University of Tennessee Health Science Center, Memphis, Tennessee, United States of America

Περίληψη

Οι σύγχρονες εξελίξεις της θεραπευτικής του οξέος ισχαιμικού αγγειακού εγκεφαλικού επεισοδίου (ΑΕΕ) έθεσαν ένα τέλος στη μηδενιστική προσέγγιση των ΑΕΕ, τουλάχιστον θεωρητικά. Στην πράξη, η εφαρμογή των αποδεδειγμένων αποτελεσματικών θεραπειών υστερεί σε πολλές χώρες της Ευρώπης. Η διαδικασία πιστοποίησης μονάδων ΑΕΕ από τον Ευρωπαϊκό Οργανισμό Εγκεφαλικών (European Stroke Organization, ESO) δύναται να συμβάλει στη βελτίωση της ποιότητας των υπηρεσιών υγείας για τους ασθενείς με ΑΕΕ. Η διαδικασία είναι απλή αλλά ιατροί ανεξοικείωτοι με διαδικασίες πιστοποίησης ίσως διστάσουν να προχωρήσουν σε αίτηση του κέντρου στο οποίο εργάζονται. Επιπλέον, διαφορές στην καθημέρα κλινική πρακτική μεταξύ Ευρωπαϊκών κρατών αυξάνουν την ανομοιογένεια και δυσχεραίνουν την παρουσίαση μιας κλινικής που νοσηλεύει ασθενείς με ΑΕΕ με τρόπο που να δείχνει προσαρμοσμένη στον ορισμό μιας μονάδας ΑΕΕ σύμφωνα με τον ESO. Η παρούσα περιγραφή στοχεύει να βοηθήσει τους ιατρούς που διαχειρίζονται ασθενείς με ΑΕΕ στο να δημιουργήσουν μια συνολική παρουσίαση της κλινικής τους, ώστε να ευοδωθεί η ευρωπαϊκή πιστοποίηση εκείνων των ελληνικών μονάδων που παρέχουν ήδη υψηλή ποιότητα υπηρεσιών στους ασθενείς με ΑΕΕ αλλά παρουσιάζουν ελάσσονες ελλείψεις, που δεν είναι όμως απαγορευτικές της ευρωπαϊκής πιστοποίησης. Αναφέρονται ηλεκτρονικές πηγές εκπαίδευσης και πιστοποίησης με ελεύθερη πρόσβαση. Παρουσιάζονται συνοπτικά κάποια προβλήματα που αφορούν την επείγουσα διαχείριση ασθενών με ΑΕΕ στη χώρα μας με την ελπίδα να προωθηθεί ο διάλογος που θα οδηγήσει σε πρωτοβουλίες εναρμόνισης των κλινικών πρακτικών με τις ευρωπαϊκές κατευθυντήριες οδηγίες. Η μετάφραση των επιστημονικών επιτευγμάτων στην καθημέρα κλινική πρακτική διαχείρισης των ΑΕΕ στην Ελλάδα είναι η μεγάλη πρόκληση για τους ιατρούς που διαχειρίζονται ασθενείς με ΑΕΕ στη χώρα μας. Είναι αδήριτη ανάγκη η εμβάθυνση της συνεργασίας με τις αρχές δημόσιας υγείας της χώρας προκειμένου να επιτευχθεί υψηλή ποιότητα υπηρεσιών υγείας στους Έλληνες ασθενείς με ΑΕΕ.

Λέξεις ευρετηρίου: αγγειακό εγκεφαλικό επεισόδιο, μονάδες εγκεφαλικών, πιστοποίηση, ποιότητα υπηρεσιών υγείας, European Stroke Organization, Ελλάδα

Introduction

Randomized-controlled clinical trials have long solidified the crucial role of multidisciplinary stroke units for reducing post stroke mortality and disability [1]. Although organized services exist in most European countries, there is wide variability in the translation of treatment guidelines into clinical practice, and in adherence to quality indicators [2]. The European Stroke Organisation (ESO) in cooperation with the Stroke Alliance for Europe (SAFE) prepared a European Stroke Action Plan (ESAP) that included four overarching targets for 2030:

1. Reduce the absolute number of strokes in Europe by 10%.
2. Treat >90% of stroke patients in Europe in a dedicated stroke unit as the first level of care.
3. Create national plans for stroke encompassing the entire chain of care.
4. Fully implement national strategies for multisector public health interventions.

ESO has established certification processes for stroke units and stroke centers to improve quality and reduce discrepancies in stroke care, both within and between European countries [3]. Two levels of stroke care are certified:

Stroke units (SU): basic stroke care including IV thrombolysis, neuro-intensive care, diagnostics, secondary prevention, early treatment of complications and start of rehabilitation.

Stroke center (SC): a fully equipped institution, additionally providing endovascular treatment, advanced neuroimaging and surgical interventions.

There are 7 categories of main criteria for both SU and SC: (A) Lead, (B) Personnel, (C) General infrastructure, (D) Investigations, (E) Interventions and monitoring, (F) Teaching, meetings and research, (G) Numbers and quality indicators. Most decisive criteria are defined as **must** criteria that are considered essential and should be fulfilled completely. At least one of the leading physicians of the applying SU or SC needs to be an active member of the ESO. The application is provided in English but standard operational procedures (SOP) already in use in clinical practice are accepted in native language.

Greece has one of the highest incidences of first-ever stroke in Europe (European Standard Population-adjusted incidence: 534.1 per 100 000 person-years) [4]. Although safety and efficacy of IVT and EVT have been demonstrated, their use is very limited (mean annual number of IVT in Europe: 142 per million inhabitants vs Greece: 20.5 per million inhabitants; 3.7 per million inhabitants EVTs in Greece vs. 37.1 per million inhabitants in European countries) [5-8]. Furthermore, the number of SU in both the public and private sector in Greece is limited, while only two SU have received ESO certification to date.

In view of the former considerations, the present manuscript aims to serve as a practical guide for interested vascular neurologists to apply for accreditation, a process that offers multifaceted advantages for stroke clinics (Table 1). This document may serve as a roadmap for Greek vascular neurologists, stroke physicians and interventionists during the application process of their Stroke Unit Certification by ESO. A translation in Greek of main requirements is provided in the Appendix.

Stroke Unit Certification Process

A. *Stroke Unit definition and multidisciplinary stroke teams*

According to ESO, the definition of a stroke unit comprises the following elements: 1. *A geographically dedicated clearly defined area or ward in a hospital*: stroke unit beds are exclusively used for stroke patients. As such, they cannot be provided by the ICU on demand. This is a major point that troubles low-volume centers that have difficulties acquiring stroke beds. Even if an ICU bed (with the corresponding ICU nurse) provides more advanced life support care, it cannot provide the expertise needed, as shown later in the definition. 2. *Stroke patients are admitted and cared for by a multi-professional team (medical, nursing, and therapy staff) who have specialist knowledge of cerebral function, training and skills in stroke care with well-defined individual tasks, regular interaction with other disciplines, and stroke leadership.*

In order to reach the ESO 2030 goal of admitting 90% of stroke patients in stroke units, currently available acute stroke-ready units need to be reinforced in Greece. Centralization of stroke care in one and only unit within each hospital will facilitate the creation of medical and nursing stroke care expertise and will allow the investment of resources for promoting stroke care to permit ESO SU accreditation in Greece. The recent governmental planning is to restructure hospital networks by distinguishing "hubs" that will offer advanced tertiary services and "spokes" that will treat most admissions but rapidly transfer complicated cases to hubs [11]. Stroke physicians should build on this initiative a whole country coverage map of stroke units and centers to diminish current regional variabilities in modern stroke care availability.

B. Personnel

B1. *A stroke physician (at least a junior) is present at the institution around the clock 24/7. A stroke neurologist is available around the clock 24/7.* The physical presence of a doctor trained in acute stroke is indispensable. Even though telestroke gained momentum during the current pandemic [12], ESO does not allow accreditation based on telestroke expertise. It is of

Table 1. Why should you apply for ESO certification?[9].

1.	Improve the quality of patient care by reducing variation in clinical processes. In the absence of national audits, ESO provides a unique opportunity in thrombolysis-ready stroke clinics to standardize treatment pathways and harmonize care with European standards.
2.	Provide a benchmark for quality of stroke management.
3.	Acquire an objective assessment of clinical excellence – ESO auditors have significant experience in stroke care, provide expert advice and follow well-defined criteria for evaluation based on the «European Stroke Organization recommendations to establish a stroke unit and stroke centre» [10].
4.	Creates a loyal, cohesive clinical team. The certification process provides an opportunity for staff to develop their skills and knowledge. The accreditation process involves all medical, nursing and paramedical personnel, all of which will contribute to the success of modern stroke care.
5.	Promotes a culture of excellence across the organization.
6.	Facilitates marketing, contracting and reimbursement. Promoting our work may strengthen our case for obtaining financial aid from non-profit organizations or resources from the public health system.
7.	Strengthens community confidence in the quality and safety of care, treatment and services. This is important for stroke units in the periphery.

note that stroke physician may be a junior doctor, even a physician during his specialty training and that even in non-neurology clinics, a stroke neurologist must be available around the clock, since neurological expertise may be needed in the differential diagnosis of stroke mimics or non-vascular neurological complications of acute stroke (eg seizures). The necessary documentation for B1 requirement includes *"official and authorized Work plan and CV's of all stroke staff including full time equivalents"*. The work plan needs approval by the hospital authorities with names, official function, and signatures from two different persons. Training schedules, description of stroke training and integrations may be given in the local language.

B2. *(Non-must criterion) A neurosonologist is available during regular working hours.* Neurosonology expertise varies considerably among European countries. The ESO accreditation process does not require availability of a neurosonologist. Centers with availability of a neurosonologist should describe what is exactly provided and when during the day. It is possible that the widespread use of non-invasive angiography will further limit the role of neurosonology in the future.

B3. *A radiology technician is present at the hospital around the clock, 24/7. A radiologist is present during official working hours and available 24/7. Neuroradiological or neurointerventional assistance by immediate dialogue (tele-stroke) is available 24/7 at the nearest stroke centre.* Radiology technician physically present, radiologist during working hours and available 24/7 and neuroradiologist availability in a collaborating center are prerequisites for stroke unit accreditation. Despite allowing for the absence of a neuroradiologist, a signed agreement of collaboration by neuroradiologists / neuro-interventionalists at the stroke centre must be submitted, since challenging cases may need specialist consultation at any given time.

B4. *Cardiology expertise and internist expertise are available 24/7 or assistance by immediate call is available 24/7 at the nearest stroke centre.* Cardiology and internal medicine specialists are needed in the work-up of stroke and for managing possible complications of stroke in the acute phase, but ESO allows for their absence in the hospital harboring the applicant unit, as long as a staff plan is submitted, with names of available specialists of cardiology and internal medicine available 24/7.

B5. *(Non-must criterion) A specialist for neurorehabilitation is collaborating with the team.* External collaborators may be accepted; physician's CV should be included in the application.

B6. *Patients are cared by dedicated stroke trained nursing staff.* There cannot be a stroke unit without stroke nurses. A series of documents need to be provided with every application: Training schedules for nurses, CV of the head-nurse of the SU, number of nursing personnel given in FTE (full time equivalent), and calculated number of nurse per bed/24hrs. The head nurse needs to show previous experience with stroke patients and should train any newcomer nurse to the basics of acute stroke nursing care. Recent advances in acute stroke treatment increase the responsibilities of nurses in the acute phase of stroke, as highlighted by the recent AHA guidelines [13].

Greece combines both the highest doctor-to-population ratio in the world and the lowest nurse-to-population ratio in Europe [14]. Consequently, nurses in Greece take charge of more patients but carry fewer responsibilities. This iatrocentric model of care means that treatment decisions are made by doctors, leaving only a very small opportunity for nurses to participate in the provision of multidisciplinary care [15]. Both trends are unacceptable for stroke care.

The role of stroke nurse cannot be overstated and each application to the ESO should clearly indicate the experience of the leading nurse and the accumulated experience of the stroke nursing team that needs to be adequate for the number of stroke beds.

There are several resources that may be available for nursing education in stroke. Nurses willing to deepen their knowledge in stroke care should be actively supported by stroke organizations which should invite trained nurses in their meetings. The MSc Stroke Program of the Medical School of Democritus University of Thrace accepts nurses with either a university, or a Technological Educational Institutes degree and it is currently the only way for a nurse to acquire an official certification in stroke medicine in Greece [16]. Online resources, albeit informal, are excellent to transmit the theoretical background. The ESO Angels' Initiative provides a full online certification comprising of 20 modules [17].

B7. *Stroke trained physiotherapists (PTs) are part of the stroke team. B8. (Non-must criterion) Stroke trained occupational therapists (OTs) are part of the stroke team. In case of missing OTs, specify who is doing diagnostic testing of cognitive deficits. B9. Stroke trained speech, language and swallowing therapists (SLTs) are part of the stroke team.* Rapid patient mobilization has been widely accepted as a means to hasten recovery in hospitalized stroke patients. Such an important task needs to be initiated, directed, and supervised by a trained physiotherapist that has previous experience with stroke patients. Also, part of the stroke nurse duties is to test all stroke patients for dysphagia on admission and initiate patient positioning but patients with difficulties in swallowing need assessment by a SLT that is also needed in the care of aphasic patients with prolonged hospitalization. The applicant needs to submit a detailed description of stroke training of PTs and SLTs as well as their names, FTE for PTs and SLTs as well as their numbers per stroke bed.

As described previously, the iatrocentric model of healthcare in Greece means that all paramedical specialties are underrepresented in Greek hospitals. Practically all ICUs in Greece have PTs [18], so in centers harboring an ICU, PTs in adequate numbers can also take care of stroke patients. Reported PT/ICU beds ratios range widely from 1:12 to 1:50, meaning that understaffed ICUs cannot possibly provide adequate personnel and this issue must be resolved before submitting the application. The situation is still worse with SLTs, as there will be many acute stroke-ready clinics in Greece that have no SLT coverage, especially in regional hospitals. However, this is a prerequisite for ESO accredited stroke care and incorporating external associates into the stroke team may be a solution to this problem, as long as a specialist with stroke background experience regularly visits the stroke unit and is accessible for emergencies during working hours. This must be thoroughly documented on submission.

OTs availability is not considered a must criterion. Whenever available, names of OTs, FTE for OTs and number of OTs per bed should be provided. If located outside the hospital, signed agreement and staff plan of OT expertise should be provided.

B10. *(Non-must criterion) Support by social worker (SW) is available at the institution.* When available, describe how SWs are integrated in the stroke team, provide names of SWs, FTE for patients, number of SWs per stroke bed. If located outside the hospital, provide a signed agreement and staff plan of SW expertise.

B11. *(Non-must criterion) Patients get access to neuropsychologists. Specify who, when and where, is doing testing of cognitive function for stroke victims that are still active professionally / other similar challenges.* Description of how neuropsychologists are integrated, names of neuropsychologists, FTE for patients, number of neuropsychological assessments of stroke patients during the previous year. If located outside the hospital, provide a signed agreement.

C. General Infrastructure

C1. *Stroke patient care in a discrete area in the hospital, staffed by a specialist stroke multi-professional team with regular multi-professional meetings for planning care. For this purpose the Stroke Unit consists of a geographically defined stroke ward admitting stroke and TIA patients.* This criterion is straightforward: Stroke beds are not to be shared with ICU, neurosurgery or other hospitalized patients. In the only systematic review comparing mobile stroke teams to geographically defined stroke units, no significant change in patient outcomes has been noticed [19]. However, the advantages of stroke wards have been outlined: better financial management, development of nursing expertise, facilitation of research, fundraising and volunteer support, as well as ease of implementation of guidelines and treatment protocols in clinical practice [20]. The applicant needs to submit a standard operating procedure (SOP): a document approved by the hospital authorities with names, official function and signatures from two separate individuals. SOP must include a plan of Stroke Unit facilities and a photograph of the monitoring unit/beds.

C2. *The stroke unit is located in an institution that runs an emergency department (according to international standards, such as trauma level I or higher). C3 The stroke unit is located in an institution that runs an intensive care unit.* Level 1 trauma centers are tertiary centers that include 24-hour availability of critical care coverage by all major medical specialties [21].

Emergency departments (ED) and ICUs complement the acute stroke care pathway and are indispensable to ensure continuity of care and immediate support of life-threatening stroke complications.

EDs have only recently been staffed with permanent medical personnel specialized in Emergency Medicine in Greece, while in most hospitals ED are properly staffed with trained nurses. Most physicians working in the ED are residents and attendees of different specialties that make rotating calls in the ED evaluating patients with symptoms related to their specialty. Another important consideration is the rotation in tertiary care hospitals covering medical emergencies in major urban areas in Greece. More specifically, the largest tertiary care hospitals in the capital of Greece, Athens, receive patients every four days according to the rotation system, while a similar rotation system has been implemented in Thessaloniki (second largest city in Greece) and other large cities. This rotation system may represent a source of concern regarding the continuity of stroke care in Greece and should be explicitly explained to the ESO certification committee examining the application. In particular, it should be stated that no public hospital provides continuous emergency department availability in the regions of Attica and Thessaloniki. On the other hand, it should be noted that the total number of admitted stroke cases on an annual basis exceeds ESO demands (see below) since during active ED days the workload is exceedingly high.

C4. *(Non-must criterion) The stroke unit runs an outpatient clinic for stroke and TIA patients.* In case of absence of an outpatient clinic at your hospital, specify the type of follow-up of stroke care.

D. Investigations

D1. *Emergency Computed tomography or magnetic resonance tomography are available 24/7 including imaging of cervical/intracranial vessels, access within 30 minutes for candidates of acute interventional therapy, Staff list, working plan, location plan in hospital – Access within 30 Min. provided.* Time metrics are of outmost importance when presenting the information in the application related to this specific requirement. Reducing door to needle time to less than 20 minutes is feasible for standard, non-contrast CT-based intravenous thrombolysis. Meretoja et al [22] have summarized critical steps for bringing down door-to-needle times (Table 2) and we suggest implementing these steps using standard operating procedure (SOP) documentation in SUs applying for ESO certification. Furthermore, we suggest the implementation of a practical approach regarding neuroimaging for acute ischemic stroke patients with unknown time of stroke onset that are potential candidates for both on-label and off-label acute reperfusion therapies [24-25].

D2. *Digital subtraction angiography (DSA) is available either in the own Stroke unit or within a nearby stroke centre SOP and in contact with a nearby stroke centre.* Despite having lost some of its diagnostic indications to less invasive imaging modalities, interest in DSA has exponentially increased after the publication of the positive endovascular treatment randomized-controlled clinical trials. DSA availability is not prerequisite for SU application. However, collaboration with a nearby center that can proceed with DSA 24/7 has to be proven through appropriate documentation. This is an important point, since the ESO certification process for stroke units allows for the absence of endovascular treatment in place, but demands an established pathway for transfer to a thrombectomy-capable center. It should therefore made clear that no application without provision of endovascular treatment may be accepted, since the stroke treatment paradigm using only thrombolysis as recanalization therapy is harmful for large-vessel occlusion stroke patients.

In case there is no possibility for endovascular treatment in a center that is interested in applying for ESO certification then potential collaboration with the nearest stroke center with availability of angiography lab and neurointerventionalist may be explored in order to adopt a drip-and-ship paradigm. The SOP that will be submitted after being signed by all implicated parties, has to take into consideration estimated arrival times, the necessity or not of repeating imaging and, most importantly, availability, since many thrombectomy-ready centers lack resources to provide continuous service.

D3. *Swallowing assessment is warranted 24/7, following a written procedure SOP.* Dysphagia is very common in the acute stage of stroke and needs to be screened for by a stroke nurse on admission. Each center may develop its own protocol for dysphagia assessment, which should be completed for each patient. An example of a SOP in an ESO certified SU is presented in Figure 1 and a Greek translation in Supplementary Figure 1. The Angels Initiative provides free online course for oropharyngeal dysphagia pathophysiology and management [27], while the ESO recommendations for the diagnosis and treatment of post-stroke dysphagia offer additional insight on this critical issue of stroke management [28].

D4. *Neurosonology assessment is available within 24 hours SOP.* Neurosonology has been partially shadowed by the incorporation of vessel imaging in the ED for acute ischemic stroke patients (mostly using CT angiography) but it remains a valuable tool for vascular neurologists, allowing for easily repeatable, non-invasive, real-time brain hemodynamic assessment at the bedside [29-31]. Ultrasound assessment does not need to be available on admission, but availability within 24 hours of admission needs to be shown.

Table 2. Measures to reduce DNT, adapted from Meretoja et al. [22]

1.	Emergency medical services involvement to fast-track acute stroke patients
2.	Hospital prenotification to alarm the stroke team and preorder imaging studies and laboratory tests
3.	No-delay CT interpretation: Stroke physician interprets the CT scan, not waiting for formal radiology report. A stroke physician has to exclude two major things: intracranial hemorrhage and massive (more than a third of middle cerebral artery territory) brain hypodensity
4.	Premixing of alteplase with highly suspect thrombolysis candidates.
5.	Delivery of alteplase on CT table: Bolus administered on CT table but also continue alteplase infusion with intravenous drip.
6.	CT relocated to ED: Avoid elevators between ED and CT at all costs.
7.	CT priority: CT needs to be emptied prior to patient arrival so that the patient may be transferred directly onto CT table, not ED bed. This critical step highlights the importance of involving in the discussion radiologists and emergency department physicians.
8.	Rapid neurologic evaluation
9.	Preacquisition of history: a major hurdle that could be soon ameliorated with the planned introduction of electronic personal health records [23].
10.	Point-of-care international normalized ratio (INR): a low-cost solution that may deeply impact treatment and prognosis of patients on Vitamin K antagonists, suffering either from intracranial bleeding (permitting rapid reversal) or ischemic stroke with subtherapeutic (<1.7) INR (permitting thrombolysis).
11.	Reduced imaging for patients arriving <4.5h that can be thrombolysed on standard protocol.

D5. *Investigations for establishing the aetiopathogenic diagnosis are available at the institution (Holter-monitoring at least for 24 hours, TTE, TEE, laboratory analysis, EEG).* Stroke medicine has evolved through different clinical pathways and specialties in various countries, but neurology and cardiology expertise remain indispensable in every hospital harboring a SU.

E. Interventions and Monitoring (Native language permitted – review by national auditor only)

E1. (Non-must criterion) The stroke team establishes and follows written standard operating procedures (stroke pathways or written protocols, which should be revised regularly) for diagnosis, nursing, rehabilitation, prevention, follow-up, management of critical incidents. There is a concept for pediatric stroke, which defines and enables treatment/ management 24/7 in collaboration with the nearest stroke center or a pediatric competence center).

E2. *(Non-must criterion) There are conceptual written protocols in relation to the emergency medical services, ED, and referring institutions. The concepts are revised regularly.*

E3. *(Non-must criterion) There are conceptual written protocols for all needs of rehabilitation.*

E4. *(Non-must criterion) The stroke team establishes and works after a defined concept for swallowing disorders.*

E5. *IV-thrombolysis is available 24/7. Time from EMR arrival to thrombolysis (e.g. Door to needle time, complication rate) is assessed and documented. SOP Results of door to needle time and complication rate for the last year before application.*

Applicant units should clearly present competence in thrombolysis through time metrics, to ensure timely and efficient recanalization therapy. The importance of documentation cannot be understated for the process of certification. The applicant center may opt for a retrospective analysis of time metrics, but it is strongly recommended to run a prospective registry of patients treated with thrombolysis for acute ischemic stroke. Even better, an electronic registry may be used to keep track of treatment rates, door to needle times and complication rates. The SITS-ISTR (Safe Implementation of Thrombolysis in Stroke -Thrombolysis Register) registry is a free online registry, already in use by Greek centers. SITS-ISTR was initially conceived for online documentation of acute ischemic stroke patients treated with intravenous thrombolysis in accordance with a study protocol, the SITS Monitoring Study (SITS-MOST) by the European Medicines Evaluation Agency. Currently SITS-ISTR has expanded to encompass data on ICH, atrial fibrillation and other aspects of acute stroke care [32]. SITS-ISTR registry has been endorsed by the ESO. The SITS-ISTR registry also serves a valuable resource to validate the quality of stroke care

Figure 1. An example of a nurse dysphagia screening SOP on admission of a stroke patient. Modified Massey Bedside Swallowing Screen [26], Greek translation. SOP or agreements or written protocols may be submitted in native language



both in individual centers and in Greece as a whole [6]. All European countries are registered, but reporting rates vary between countries; SITS registry has expanded to include countries from Asia, Africa and South America. In total, approximately 335,000 stroke patients from 1930 centers worldwide have been registered to SITS. In Greece, there are currently 29 active centers that have enrolled 2371 acute ischemic stroke patients treated with acute reperfusion therapies (10% mechanical thrombectomy, 90% intravenous thrombolysis).

Another important free online registry is the Res-Q (Registry of Stroke Care Quality) [33], initiated by the European Stroke Organisation- Enhancing and Accelerating Stroke Treatment (ESO East) Project to help both sites and countries improve their stroke care system. It was launched in May 2016 and targeted primarily the Eastern European countries [34]. It is designed to document the quality of stroke care through organized measurements that have been agreed by an international working group [35] and include the availability of stroke units, brain imaging, vascular imaging, cardiac arrhythmia detection, thrombolytic therapy, and other factors. Currently, there are 20 active centers and 3590 acute stroke patients registered from Greece in Res-Q.

In the absence of a national stroke registry, all interested stroke physicians are strongly advised to take advantage of available free-to-use online registries as a tool for continuous monitoring, evaluation and improvement of health care quality in their center. Collaborative contribution will help identify gaps in health care delivery at a national, regional and hospital level. Participation in registries is not requisite for ESO accreditation. However, it facilitates any center's application by easily providing multiple metrics that are needed for accreditation and highlights the center's commitment in monitoring and improving quality of care. In view of these considerations, we strongly recommend joining either SITS-ISTR, RES-Q or both international registries before preparing the application for ESO SU certification.

E6. *Neurosurgical and neurointerventional procedures are available 24/7 in collaboration with the nearest stroke center.* Neurosurgical and neurointerventional expertise may not be available in the hospital harboring the stroke unit. However, a SOP must be in place to rapidly transfer acute stroke patients in need of neurointerventions (eg acute aneurysmal subarachnoid hemorrhage) to a collaborating stroke center.

E7. *(Non-must criterion) Revascularization of the carotid artery with thrombendarterectomy or stenting is available in collaboration with a nearby stroke center 24/7.* Similarly to neurosurgical and neurointerventional procedures, treatment of symptomatic carotid disease may not be available in place but must be promptly performed in eligible patients, in collaboration with a stroke center.

E8. *The infrastructure of the stroke unit allows continuous monitoring of ECG, breathing, blood pressure, pulsoxymetry, and monitoring of glucose and temperature.* Continuous monitoring allows for early detection and treatment of complications in the unstable subacute stroke patient: stroke in progression, cerebral oedema, epileptic seizures and non-cerebral complications [10].

F. Teaching, Meetings, and Research

F1. *(Non-must criterion) Runs multidisciplinary group meetings at least once a week and documents in the chart proving that the case was discussed by the multiprofessional team.*

F2. *(Non-must criterion) Organization of ongoing teaching courses and professional education for all groups represented in the stroke team (not only the doctors) is warranted and documented.*

F3. *(Non-must criterion) Patients and their families should be regularly updated about treatment and prognosis.*

The three aforementioned non-must criteria add

Figure 2. An example of Res-Q registry annual overview of a stroke unit. The registry's dashboard can be used to monitor performance and reports in excel can be downloaded. Adapted from "How to use RES-Q tool" [36].

value to any stroke unit and would be highly appreciated in any application.

G. Numbers and quality indicators

G1. *(Non-must criterion) The stroke unit has a stroke data base for quality control.* Applicants should provide an annual report or online link or screen shot.

G2. *Minimal overall number of dedicated beds for stroke patients.* Minimal number: 6. This number refers to both monitored and non-monitored beds.

G3. *(Non-must criterion) Minimal number of beds with automated monitoring.* Minimal number: 4.

G4. *Minimal number of patients with TIA and acute stroke treated per year.* Official and organized hospital statistics with percentages of different stroke types by annual report or database or online link; Minimum: 200. This number refers to both ischemic and hemorrhagic strokes.

G5. *(Non-must criterion) Numbers on acute treatment (IV-thrombolysis, door to needle time, type and rate of complications and number of referrals to acute intra-arterial interventions per year).* Provide official and authorized hospital statistics by annual report or database with online link. Minimum IV-thrombolysis: 20. Also provide number of referrals for endovascular treatment.

G6. *(Non-must criterion) Documentation of age, sex, admission stroke severity case fatality, of discharge National Institutes of Health Stroke Scale, discharge modified Rankin Scale.* Provide official and authorized hospital statistics by annual report or database with online link.

G7. *(Non-must criterion) Documentation of quality of stroke care: % documented swallowing test, early mobilization, and prevention of DVT.* Provide relevant statistical data.

G8. *(Non-must criterion) Access to local stroke support organization.*

G9. *Numbers of the relevant diagnostics (Number of TTE/TOE., Numbers of Neurovascular Ultrasound, Number of brain CT/MRI and CTA/MRA); Official and organized hospital statistics by annual report or database with online link.*

All these metrics can be easily extracted by the RES-Q platform in case centers are actively participating in Res-Q (Figure 2). To the best of our knowledge there is currently no Greek hospital using an online local database dedicated to stroke patients. As a result, a retrospective review of patient files is needed to record all diagnostic examinations that have been performed by centers not yet participating in Res-Q. Finally, it should be mentioned that all applicants are strongly advised to start using online registries, since accreditation is a process to be repeated every 5 years and re-certification would be greatly facilitated when patient data is prospectively collected. This process represents a major advantage for a SU

applying for ESO accreditation: the process can be used as a means to further improve quality markers and advance quality of care.

Conclusions

The World Stroke Organization defines 3 levels of stroke care [37].

1. Minimum Healthcare Services: Care provided in local communities without coordination across defined geographic regions. Despite widespread availability of diagnostic studies and physicians, great variability persists in access to other healthcare workers (nurses, speech specialists) resulting in lack of basic training in swallow screens and dysphagia management in many Greek centers. The information in this manuscript does not refer to these centers since basic infrastructure is lacking to proceed to ESO SU accreditation.

2. Essential Stroke Services: Limited coordinated stroke care provided across geographically discrete regions. These clinics offer stroke expertise in medical and nursing personnel, a variety of diagnostic studies and acute intravenous thrombolysis. Many Greek clinics fulfill these criteria, and the current manuscript aims to help them proceed to the next level.

3. Advanced Stroke Services: Fully coordinated stroke care provided across geographically discrete regions. An ESO accredited stroke unit would fall in this category. There are currently only two low-volume private SU that have been accredited by ESO in Greece. Further inclusion of SU from public hospitals in ESO certification process is being incentivized and fully supported by National Scientific Societies including the Hellenic Society of Cerebrovascular Diseases and the Hellenic Neurological Society.

In conclusion, application for ESO SU certification process of Greek SUs will provide a benchmark that may assist the implementation of interventions that have been proven to advance the quality and efficiency of stroke care. It is also quite clear that in order to offer advanced stroke services to the entire Greek population and to align stroke care in Greece with European and international standards, it is not enough to create some low-volume centers of excellence, but Health Authorities need to address several long-standing fundamental issues concerning stroke care. The current iatrocentric model with rotational ED activation in major cities needs urgent update to accommodate modern stroke treatment paradigms. Communicating the need to restructure the current Health System is a task that exceeds our clinical work but deeply impacts it. Advocacy for stroke involves supporting stroke patients, building organizations, raising awareness and campaigning, but also working with, and influencing, decision makers.

References

[1] Collaborative systematic review of the randomized trials of organized inpatient (stroke unit) care after stroke Stroke Unit Trialists' Collaboration. BMJ 1997;314:1151-1159.

[2] Hillmann S, Wiedmann S, Fraser A, et al. Temporal changes in the quality of acute stroke care in five national audits across Europe. Biomed Res Int 2015;2015:432497.

[3] Waje-Andreassen U, Nabavi DG, Engelter ST, et al. European Stroke Organisation certification of stroke units and stroke centres. Eur Stroke J. 2018 Sep;3(3):220-226.

[4] Tsivgoulis G, Patousi A, Pikilidou M, et al. Stroke Incidence and Outcomes in Northeastern Greece: The Evros Stroke Registry. Stroke 2018;49:288-295.

[5] Rudolf J, Tsivgoulis G, Deretzi G, et al. Feasibility and safety of intravenous thrombolysis for acute ischaemic stroke in northern Greece. Int J Stroke 2011;6:91-92.

[6] Tsivgoulis G, Kargiotis O, Rudolf J, et al. Intravenous thrombolysis for acute ischemic stroke in Greece: the Safe Implementation of Thrombolysis in Stroke registry 15-year experience. Ther Adv Neurol Disord 2018;11:1756286418783578.

[7] Tsivgoulis G, Mantatzis, M, Vadikolias K, et al. Mechanical thrombectomy for acute ischemic stroke due to large vessel occlusion: a two year experience in Greek Centers of SITS Registry. Nevrologia 2017;26:4-17.

[8] Aguiar de Sousa D, von Martial R, Abilleira S, et al. Access to and delivery of acute ischaemic stroke treatments: A survey of national scientific societies and stroke experts in 44 European countries. Eur Stroke J 2019;4:13-28.

[9] Adapted from the ESO certification website. https://eso-certification.org/node/23 Accessed January 26, 2022.

[10] Ringelstein EB, Chamorro A, Kaste M, et al; ESO Stroke Unit Certification Committee. European Stroke Organisation recommendations to establish a stroke unit and stroke center. Stroke 2013;44:828-840.

[11] Greek government announces new roadmap for hospital organization. Available at https://www.ethnos.gr/politiki/159530_epanashediasmotoy-esy-proaniggeile-o-mitsotakis-neos-hartis-nosokomeion Accessed January 26, 2022.

[12] Guzik AK, Martin-Schild S, Tadi P, et al. Telestroke Across the Continuum of Care: Lessons from the COVID-19 Pandemic. J Stroke Cerebrovasc Dis 2021;30:105802.

[13] Rodgers ML, Fox E, Abdelhak T, et al; American Heart Association Council on Cardiovascular and Stroke Nursing and the Stroke Council.

Care of the Patient With Acute Ischemic Stroke (Endovascular/Intensive Care Unit-Postinterventional Therapy): Update to 2009 Comprehensive Nursing Care Scientific Statement: A Scientific Statement From the American Heart Association. Stroke. 2021;52:e198-e210.
[14] OECD (2019), Health at a Glance 2019: OECD Indicators, OECD Publishing, Paris, https://doi.org/10.1787/4dd50c09-en Accessed January 26, 2022.
[15] Rafferty A, Busse R, Zander-Jentsch B, et al. Strengthening health systems through nursing: Evidence from 14 European countries. European Observatory on Health Systems and Policies; 2019, No. 52.
[16] Master Program "Stroke" – Medical School – Democritus University of Thrace http://strokeduth.gr/home-en/ Accessed January 26, 2022.
[17] https://www.angels-initiative.com/angels-academy/educational-courses/stroke-nurse-certification Accessed January 26, 2022.
[18] Grammatopoulou E, Charmpas TN, Strati EG, et al. The scope of physiotherapy services provided in public ICUs in Greece: A pilot study. Physiother Theory Pract 2017;33:138-146.
[19] Langhorne P, Dey P, Woodman M, Kalra L, Wood-Dauphinee S, Patel N, Hamrin E. Is stroke unit care portable? A systematic review of the clinical trials. Age Ageing. 2005 ;34:324-330.
[20] Langhorne P. Organisation of acute stroke care. Br Med Bull. 2000;56(2):436-43.
[21] https://www.eso.com/blog/explainer-the-five-trauma-center-levels/ Accessed January 26, 2022.
[22] Meretoja A, Strbian D, Mustanoja S, Tatlisumak T, Lindsberg PJ, Kaste M. Reducing in-hospital delay to 20 minutes in stroke thrombolysis. Neurology. 2012;79:306-313.
[23] https://www2.deloitte.com/gr/en/pages/life-sciences-and-healthcare/articles/Health-4_0.html Accessed January 26, 2022.
[24] Magoufis G, Safouris A, Raphaeli G, Kargiotis O, Psychogios K, Krogias C, et al. Acute reperfusion therapies for acute ischemic stroke patients with unknown time of symptom onset or in extended time windows: an individualized approach. Ther Adv Neurol Disord 2021;14:17562864211021182.
[25] Tsivgoulis G, Kargiotis O, De Marchis G, Kohrmann M, Sandset EC, Karapanayiotides T, et al. Off-label use of intravenous thrombolysis for acute ischemic stroke: a critical appraisal of randomized and real-world evidence. Ther Adv Neurol Disord 2021;14:1756286421997368.
[26] Massey R, Jedlicka D. The Massey Bedside Swallowing Screen. J Neurosci Nurs 2002;34:257-260.
[27] https://www.angels-initiative.com/academy/post-acute/learnings-assessments Accessed January 26, 2022.
[28] Dziewas R, Michou E, Trapl-Grundschober M, Lal A, Arsava EM, Bath PM, et al. European Stroke Organisation and European Society for Swallowing Disorders guideline for the diagnosis and treatment of post-stroke dysphagia. Eur Stroke J 2021;6:LXXXIX-CXV.
[29] Psychogios K, Magoufis G, Kargiotis O, et al. Ultrasound Assessment of Extracranial Carotids and Vertebral Arteries in Acute Cerebral Ischemia. Medicina (Kaunas). 2020;56:711.
[30] Tsivgoulis G, Alexandrov AV. Ultrasound in Neurology. Continuum (Minneap Minn). 2016;22:1655-1677.
[31] Alexandrov AV, Sloan MA, Tegeler CH, Newell DN, Lumsden A, Garami Z, et al. American Society of Neuroimaging Practice Guidelines Committee. Practice standards for transcranial Doppler (TCD) ultrasound. Part II. Clinical indications and expected outcomes. J Neuroimaging 2012;22:215-24.
[32] https://sitsinternational.org/registry/ Accessed on January 26, 2022.
[33] https://qualityregistry.eu Accessed on January 26, 2022.
[34] Mikulík R, Caso V, Bornstein NM, Svobodov- V, Pezzella FR, Grecu A, et al. Enhancing and accelerating stroke treatment in Eastern European region: Methods and achievement of the ESO EAST program. Eur Stroke J 2020;5:204-212.
[35] Norrving B, Bray BD, Asplund K, et al; European Implementation Score Collaboration. Cross-National Key Performance Measures of the Quality of Acute Stroke Care in Western Europe. Stroke 2015;46:2891-2895.
[36] https://qualityregistry.eu/seafile/f/e2f46fc0475449fdaa27/?dl=1 Accessed January 26, 2022.
[37] World Stroke Organization Global Stroke Guidelines and Action Plan: A Road Map for Quality Stroke Care. Available at https://www.world-stroke.org/assets/downloads/Global_Stroke_Guidelines_and_Action_Plan_All_in_one.pdf accessed on January 26, 2022.

Appendix

Supplement 1 – Greek Translation of Main Requirements

A1. *A dedicated geographically clearly defined area or ward in a hospital.*

Αποκλειστική, σαφώς γεωγραφικά καθορισμένη περιοχή ή κλινική σε νοσοκομείο.

A2. *Stroke patients are admitted and cared for by a multi-professional team (medical, nursing, and therapy staff) who have specialist knowledge of cerebral func-*

tion, training and skills in stroke care with well-defined individual tasks, regular interaction with other disciplines, and stroke leadership.

Οι ασθενείς με Αγγειακά Εγκεφαλικά Επεισόδια (ΑΕΕ) εισάγονται και παρακολουθούνται από μία διεπιστημονική ομάδα (ιατροί, νοσηλευτές και θεραπευτές) με εξειδικευμένες γνώσεις των εγκεφαλικών λειτουργιών, εκπαίδευση και κατάρτιση στη φροντίδα του ΑΕΕ, με σαφώς καθορισμένες αρμοδιότητες, τακτική αλληλεπίδραση με άλλες ειδικότητες, και με ηγετικό ρόλο στην αντιμετώπιση των ΑΕΕ.

B1. *A stroke physician (at least a junior) is present at the institution around the clock 24/7. A stroke neurologist is available around the clock 24/7.*

Να είναι συνεχώς παρών ένας ιατρός με εμπειρία στα ΑΕΕ (έστω άρτι εκπαιδευμένος). Να είναι συνεχώς διαθέσιμος ένας αγγειακός νευρολόγος.

B2. *(Non-must criterion) A neurosonologist is available during regular working hours.* (Προαιρετικό) Να υπάρχει διαθέσιμος νευροϋπερηχογραφιστής κατά τις εργάσιμες ημέρες και ώρες.

B3. *A radiology technician is present at the hospital around the clock, 24/7. A radiologist is present during official working hours and available 24/7. Neuroradiological or neurointerventional assistance by immediate dialogue (tele-stroke) is available 24/7 at the nearest stroke centre.*

Να είναι συνεχώς παρών ένας τεχνολόγος ακτινολογικού στο νοσοκομείο. Να είναι παρών ένας ακτινολόγος κατά τις εργάσιμες ώρες, και να είναι συνεχώς διαθέσιμος. Να διατίθεται συνεχής νευροακτινολογική ή νευροεπεμβατική βοήθεια με άμεση επικοινωνία (tele-stroke) στο πλησιέστερο Κέντρο ΑΕΕ.

B4. *Cardiology expertise and internist expertise are available 24/7 or assistance by immediate dialogue is available 24/7 at the nearest stroke centre.*

Να υπάρχει διαθέσιμη συνεχής εξειδικευμένη καρδιολογική και παθολογική υποστήριξη ή αντίστοιχη βοήθεια με άμεση επικοινωνία στο πλησιέστερο Κέντρο ΑΕΕ.

B5. *(Non-must criterion) A specialist for neurorehabilitation is collaborating with the team.*

(Προαιρετικό) Η ομάδα να συνεργάζεται με ειδικό στην νευροαποκατάσταση.

B6. *Patients are cared by dedicated stroke trained nursing staff.*

Να παρέχεται νοσηλευτική φροντίδα στους ασθενείς από αποκλειστικό νοσηλευτικό προσωπικό, εκπαιδευμένο στα ΑΕΕ.

B7. *Stroke trained physiotherapists (PTs) are part of the stroke team.*

Να αποτελούν μέρος της ομάδας ΑΕΕ φυσιοθεραπευτές εκπαιδευμένοι στα ΑΕΕ.

B8. *(Non-must criterion) Stroke trained occupational therapists (OTs) are part of the stroke team. In case of missing OTs, specify who is when doing diagnostic testing of cognitive deficits.*

(Προαιρετικό) Να αποτελούν μέρος της ομάδας ΑΕΕ εργοθεραπευτές εκπαιδευμένοι στα ΑΕΕ. Σε περίπτωση απουσίας εργοθεραπευτών, να προσδιοριστεί ποιος διαγιγνώσκει τα νοητικά ελλείμματα.

B9. *Stroke trained speech, language and swallowing therapists (SLTs) are part of the stroke team.*

Να αποτελούν μέρος της ομάδας ΑΕΕ λογοθεραπευτές εκπαιδευμένοι στα ΑΕΕ.

B10. *(Non-must criterion) Support by social worker (SW) is available at the institution.*

(Προαιρετικό) Να υπάρχει υποστήριξη από κοινωνικούς λειτουργούς στο ίδρυμα.

B11. *(Non-must criterion) Patients get access to neuropsychologists. Specify who is, when and where, doing testing of cognitive function for stroke victims that are still following their professional careers / other similar challenges.*

(Προαιρετικό) Οι ασθενείς να έχουν πρόσβαση σε νευροψυχολόγους. Να προσδιορίζεται ποιος, που, και πότε διεξάγει νευροψυχολογικές δοκιμασίες στους ασθενείς με ΑΕΕ που εξακολουθούν να έχουν επαγγελματική δραστηριότητα ή άλλες παρόμοιες προκλήσεις.

C1. *Stroke patient care in a discrete area in the hospital, staffed by a specialist stroke multi-professional team with regular multi-professional meetings for planning care. For this purpose the Stroke Unit dispose of an geographically defined stroke ward admitting stroke and TIA patients.*

Η φροντίδα των ασθενών με ΑΕΕ να λαμβάνει χώρα σε διακριτή περιοχή του νοσοκομείου, στελεχωμένη από εξειδικευμένη διεπιστημονική ομάδα ΑΕΕ με τακτικές διεπιστημονικές συναντήσεις για τον προγραμματισμό της φροντίδας. Για αυτό το λόγο η Μονάδα ΑΕΕ να περιλαμβάνει μια γεωγραφικά καθορισμένη κλινική ΑΕΕ που δέχεται ασθενείς με ΑΕΕ και παροδικό ισχαιμικό επεισόδιο.

C2. *The stroke unit is located in an institution that runs an emergency department (according to international standards, such as trauma level I or higher).*

Η Μονάδα ΑΕΕ ανήκει σε ίδρυμα που διαθέτει Τμήμα Επειγόντων Περιστατικών (ανάλογο μονάδας τραύματος επιπέδου 1 σύμφωνα με τα διεθνή πρότυπα)

C3. *The stroke unit is located in an institution that runs an intensive care unit.*

Η Μονάδα ΑΕΕ ανήκει σε ίδρυμα που διαθέτει Μονάδα Εντατικής Θεραπείας.

C4. *(Non-must criterion) The stroke unit runs an outpatient clinic for stroke and TIA patients.*

(Προαιρετικό) Η Μονάδα ΑΕΕ λειτουργεί Τμήμα Εξωτερικών Ιατρείων για ασθενείς με ΑΕΕ ή παροδικό ισχαιμικό επεισόδιο.

D1. *Emergency Computed tomography or magnetic resonance tomography are available 24/7 including imaging of cervical/intracranial vessels, access within 30 minutes for candidates of acute interventional therapy .*

Να υπάρχει συνεχώς δυνατότητα επείγουσας αξο-

νικής ή μαγνητικής τομογραφίας, συμπεριλαμβανομένων απεικονίσεων τραχηλικών/ενδοκράνιων αγγείων, με πρόσβαση εντός 30 λεπτών για ασθενείς που είναι υποψήφιοι για επείγουσες παρεμβατικές θεραπείες.

D2. *Digital subtraction angiography (DSA) is available either in the own Stroke unit or within a nearby stroke centre.*

Να υπάρχει διαθεσιμότητα για ψηφιακή αγγειογραφία στην ίδια Μονάδα ΑΕΕ ή σε παρακείμενο Κέντρο ΑΕΕ.

D3. *Swallowing assessment is warranted 24/7, following a written procedure.*

Εξασφαλίζεται συνεχής δυνατότητα δοκιμασίας κατάποσης, βάσει γραπτού πρωτοκόλλου.

D4. *Neurosonology assessment is available within 24 hours.*

Υπάρχει διαθέσιμος νευροϋπερηχογραφικός έλεγχος εντός 24 ωρών.

D5. *Investigations for establishing the aetiopathogenic diagnosis are available at the institution (Holter-monitoring at least for 24 hours, TTE, TEE, laboratory analysis, EEG).*

Υπάρχει στο ίδρυμα δυνατότητα διενέργειας διαγνωστικών εξετάσεων για αιτιοπαθογενετική διάγνωση (Holter ρυθμού τουλάχιστον 24 ωρών, διαθωρακικό υπερηχογράφημα καρδιάς, διοισοφάγειο υπερηχογράφημα καρδιάς, εργαστηριακός έλεγχος, ηλεκτροεγκεφαλογράφημα).

E1. *(Non-must criterion) The stroke team establishes and follows written standard operating procedures (stroke pathways or written protocols, which should be revised regularly) for diagnosis, nursing, rehabilitation, prevention, follow-up, management of critical incidents. There is a concept for pediatric stroke, which defines and enables treatment/ management 24/7 in collaboration with a at the nearest stroke center or a pediatric competence center).*

(Προαιρετικό) Η ομάδα ΑΕΕ καθορίζει και να ακολουθεί γραπτώς διατυπωμένες τυποποιημένες διαδικασίες λειτουργίας (αλγόριθμος ΑΕΕ ή γραπτά πρωτόκολλα, που επικαιροποιούνται τακτικά) για τη διάγνωση, τη νοσηλεία, την αποκατάσταση, την πρόληψη, την παρακολούθηση, και την αντιμετώπιση οξέων συμβαμάτων. Υπάρχει σχέδιο θεραπείας παιδιατρικού ΑΕΕ, που επιτρέπει και καθορίζει την αδιάκοπη αντιμετώπιση σε συνεργασία με το πλησιέστερο Κέντρο ΑΕΕ ή το αρμόδιο παιδιατρικό νοσοκομείο.

E2. *(Non-must criterion) There are conceptual written protocols in relation to the emergency medical services, ED, and referring institutions. The concepts are revised regularly.*

(Προαιρετικό) Υπάρχουν γραπτά πρωτόκολλα συνεργασίας με τις επείγουσες ιατρικές υπηρεσίες (ΕΚΑΒ), το Τμήμα Επειγόντων Περιστατικών (ΤΕΠ) και τα παραπέμποντα ιδρύματα. Τα πρωτόκολλα επικαιροποιούνται τακτικά.

E3. *(Non-must criterion) There are conceptual written protocols for all needs of rehabilitation.*

(Προαιρετικό) Να υπάρχουν γραπτώς διατυπωμένα πρωτόκολλα για όλες τις ανάγκες αποκατάστασης.

E4. *(Non-must criterion) The stroke team establishes and works after a defined concept for swallowing disorders.*

(Προαιρετικό). Η Ομάδα ΑΕΕ εφαρμόζει ένα προκαθορισμένο σχέδιο για τις διαταραχές κατάποσης.

E5. *IV-thrombolysis is available 24/7. Time from EMR arrival to thrombolysis (e.g. Door to needle time, complication rate) is assessed and documented.*

Υπάρχει αδιάκοπη δυνατότητα ενδοφλέβιας θρομβόλυσης. Μετράται και καταγράφεται ο χρόνος από την άφιξη μέχρι τη θρομβόλυση (χρόνος door-to-needle) καθώς και τα ποσοστά επιπλοκών.

E6. *Neurosurgical and neurointerventional procedures are available 24/7 in collaboration with nearest stroke center.*

Να υπάρχει αδιάκοπη δυνατότητα νευροχειρουργικών και νευροεπεμβατικών παρεμβάσεων σε συνεργασία με το πλησιέστερο Κέντρο ΑΕΕ.

E7. *(Non-must criterion) Revascularisation of the carotid artery with thrombendarterectomy or stenting is available in collaboration with a nearby stroke center 24/7.*

(Προαιρετικό) Υπάρχει αδιάκοπη δυνατότητα για επαναγγείωση έσω καρωτίδας με ενδαρτηρεκτομή ή τοποθέτηση ενδοπρόθεσης, σε συνεργασία με παρακείμενο Κέντρο ΑΕΕ.

E8. *The infrastructure of the stroke unit allows continuous monitoring of ECG, breathing, blood pressure, pulsoxymetry, and monitoring of glucose and temperature.*

Οι υποδομές της Μονάδας ΑΕΕ επιτρέπουν συνεχή παρακολούθηση ΗΚΓ, αναπνοών, αρτηριακής πίεσης, παλμικής οξυμετρίας, και απλή παρακολούθηση θερμοκρασίας και γλυκόζης αίματος.

F1. *(Non-must criterion) Runs multidisciplinary group meetings at least once a week and documents in the chart that the case was discussed by the multiprofessional team.*

(Προαιρετικό) Να διενεργούνται διεπιστημονικές συναντήσεις τουλάχιστον μία φορά την εβδομάδα όπου να συζητούνται τα περιστατικά, και να καταγράφεται αυτό στον φάκελο κάθε ασθενούς.

F2. *(Non-must criterion) Organizes ongoing teaching courses and professional education for all groups represented in the stroke team (not only the doctors) is warranted and documented*

(Προαιρετικό) Οργανώνονται συνεχιζόμενα μαθήματα, εξασφαλίζεται και καταγράφεται η επαγγελματική εκπαίδευση για όλα τα μέλη που συγκροτούν την Ομάδα ΑΕΕ (όχι μόνο των ιατρών).

F3. *(Non-must criterion) Patients and their families should be regularly updated about treatment and prognosis.*

(Προαιρετικό) Οι ασθενείς και οι οικογένειές τους ενημερώνονται τακτικά για τη θεραπεία και την πρόγνωση.

G1. *(Non-must criterion) The stroke unit has a stroke data base for quality control.*

(Προαιρετικό) Η Μονάδα ΑΕΕ διατηρεί βάση δεδομένων ΑΕΕ για έλεγχο της ποιότητας.

G2. *Minimal overall number of dedicated beds for stroke patients. Minimum: 6.*

Ελάχιστος συνολικός αριθμός κλινών αποκλειστικά για ασθενείς με ΑΕΕ: 6.

G3. *(Non-must criterion) Minimal number of beds with automated monitoring. Minimum: 4.*

(Προαιρετικό) Ελάχιστος αριθμός κλινών με αυτόματη συνεχή καταγραφή: 4.

G4. *Minimal number of patients with TIA and acute stroke treated per year. Minimum: 200.*

Ελάχιστος αριθμός ασθενών με παροδικό ισχαιμικό επεισόδιο και οξύ ΑΕΕ που αντιμετωπίζονται ανά έτος: 200.

G5. *(Non-must criterion) Numbers of acute treatment (IV-thrombolysis, door to needle time, type and rate of complications and number of referrals to acute intra-arterial interventions per year).*

(Προαιρετικό) Καταγράφεται ο αριθμός οξέων θεραπειών που διενεργούνται (ενδοφλέβια θρομβόλυση, χρόνος door-to-needle, είδος και ποσοστό επιπλοκών, και αριθμός παραπομπών προς οξείες ενδαρτηριακές παρεμβάσεις ανά έτος).

G6. *(Non-must criterion) Documentation of age, sex, admission stroke severity case fatality, of discharge National Institutes of Health Stroke Scale, discharge modified Rankin Scale.*

(Προαιρετικό) Καταγράφονται ηλικία, φύλο, βαρύτητα ΑΕΕ κατά την εισαγωγή, θνητότητα, NIHSS εξόδου, mRS εξόδου.

G7. *(Non-must criterion) Documentation of quality of stroke care: % documented swallowing test, early mobilization, and prevention of DVT.*

(Προαιρετικό) Καταγράφεται η ποιότητα της παρεχόμενης φροντίδας για το ΑΕΕ: % καταγεγραμμένων δοκιμασιών κατάποσης, πρώιμη κινητοποίηση, και πρόληψη της εν τω βάθει φλεβικής θρόμβωσης.

G8. *(Non-must criterion) Access to local stroke support organization.*

(Προαιρετικό) Να υπάρχει πρόσβαση σε τοπικές οργανώσεις υποστήριξης ασθενών με ΑΕΕ.

G9. *Number of the relevant diagnostics (Number of TTE/TOE., Numbers of Neurovascular Ultrasound, Number of brain CT/MRI and CTA/MRA).*

Καταγράφεται ο αριθμός των σχετικών διαγνωστικών εξετάσεων που διενεργούνται (διαθωρακικά/διοισοφάγεια υπερηχογραφήματα, νευροαγγειακά υπερηχογραφήματα, CT/MRI εγκεφάλου και CTA/MRA).

Supplementary Figure 1



SAFETY OF INTRAVENOUS THROMBOLYSIS IN AN ACUTE ISCHEMIC STROKE PATIENT WITH SEVERE HEMOPTYSIS DUE TO UNDERLYING BRONCHIECTASIS

Aikaterini Theodorou MD[1], Vasiliki Kotsali-Peteinelli MD[1], Marianna Bregianni MD[1], Lina Palaiodimou MD[1], Marianna Papadopoulou MD[1] Maria Maili MD[1], Anastasios Bonakis MD[1], Konstantinos Voumvourakis MD, PhD[1], Georgios Tsivgoulis, MD, PhD, MSc, FESO, FEAN, FAAN[1, 2]

[1] 2nd Department of Neurology, National and Kapodistrian University of Athens, School of Medicine, "Attikon" University Hospital, Athens
[2] Department of Neurology, The University of Tennessee Health Science Center, Memphis, TN, USA

Abstract

Introduction: Despite that bronchiectasis has been mentioned in patients with even fatal complications of intravenous thrombolysis (IVT) for myocardial infarction, the safety of IVT administration in patients with known bronchiectasis and acute ischemic stroke (AIS) is not established.

Methods: We present the case of a 74-year-old woman who received intravenous thrombolysis for AIS despite recent hemoptysis due to underlying bronchiectasis.

Results: A 74-year-old patient with recent (8 hours) hemoptysis due to extensive underlying bronchiectasis presented with acute left hemiplegia, dysarthria, gaze deviation and decreased level of consciousness (NIHSS-Score on admission: 22) within 75 min from symptom onset. She was treated successfully with IVT, resulting in substantial neurological improvement. (Discharge-NIHSS: 2). Neuroimaging studies disclosed infarctions in different arterial territories, without hemorrhagic complications, while cardiac monitoring revealed paroxysmal atrial fibrillation (AF) as the underlying stroke etiology.

Discussion: The present case highlights that systemic thrombolysis for AIS despite recent hemoptysis due to underlying bronchiectasis appears to be safe.

Key words: hemoptysis, bronchiectasis, brain MRI, acute ischemic stroke, intravenous thrombolysis

ΑΣΦΑΛΕΙΑ ΤΗΣ ΕΝΔΟΦΛΕΒΙΑΣ ΘΡΟΜΒΟΛΥΣΗΣ ΣΕ ΑΣΘΕΝΗ ΜΕ ΟΞΥ ΙΣΧΑΙΜΙΚΟ ΑΓΓΕΙΑΚΟ ΕΓΚΕΦΑΛΙΚΟ ΕΠΕΙΣΟΔΙΟ ΚΑΙ ΠΡΟΣΦΑΤΗ ΣΟΒΑΡΗ ΑΙΜΟΠΤΥΣΗ ΛΟΓΩ ΥΠΟΚΕΙΜΕΝΩΝ ΒΡΟΓΧΕΚΤΑΣΙΩΝ

Αικατερίνη Θεοδώρου MD[1], Βασιλική Κότσαλη-Πετεινέλλη MD[1], Μαριάννα Μπρέγιαννη MD[1], Λίνα Παλαιοδήμου MD[1], Μαριάννα Παπαδοπούλου MD[1], Μαρία Μαΐλη MD[1], Αναστάσιος Μπονάκης MD, PhD[1], Κωνσταντίνος Βουμβουράκης MD, PhD[1], Γεώργιος Τσιβγούλης MD, PhD, MSc, FESO, FEAN, FAAN[1, 2]

[1] Β΄ Νευρολογική Κλινική, Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών, Ιατρική Σχολή, Πανεπιστημιακό Γενικό Νοσοκομείο «ΑΤΤΙΚΟΝ»
[2] Department of Neurology, The University of Tennessee Health Science Center, Memphis, TN, USA

Περίληψη

Εισαγωγή: Σε υπάρχουσες βιβλιογραφικές αναφορές, οι βρογχεκτασίες του πνευμονικού παρεγχύματος έχουν συνδεθεί με θανατηφόρες επιπλοκές σε ασθενείς που έλαβαν ενδοφλέβια θρομβόλυση λόγω εμφράγματος του μυοκαρδίου. Η ασφάλεια όμως της ενδοφλέβιας θρομβόλυσης σε ασθενείς με οξύ ισχαιμικό αγγειακό εγκεφαλικό επεισόδιο (ΑΕΕ) και προϋπάρχουσα βρογχεκτασία μένει να διερευνηθεί.

Μέθοδοι: Στην παρούσα μελέτη παρουσιάζουμε ένα περιστατικό, που αφορά γυναίκα 74 χρονών, η οποία έλαβε ενδοβλέβια θρομβόλυση λόγω οξέος ισχαιμικού ΑΕΕ παρά την αναφερόμενη πρόσφατη αιμόπτυση σε έδαφος γνωστών βρογχεκτασιών.

Αποτελέσματα: Ασθενής 74 ετών με αναφερόμενη αιμόπτυση προ 8ώρου σε έδαφος γνωστών εκτεταμένων βρογχεκτασιών, προσήλθε στο τμήμα επειγόντων περιστατικών μετά από οξεία εγκατάσταση αριστερής ημιπληγίας, δυσαρθρίας, στροφής βλέμματος προς τα δεξιά και μειωμένου επιπέδου επικοινωνίας

(NIHSS-Score-εισόδου:22), εντός 75 λεπτών από την έναρξη των συμπτωμάτων. Η ασθενής έλαβε επιτυχώς ενδοφλέβια θρομβόλυση, οδηγώντας σε σαφή βελτίωση της νευρολογικής της συμπτωματολογίας (NIHSS-Score-εξιτηρίου:2). Τα απεικονιστικά ευρήματα αποκάλυψαν πολλαπλά έμφρακτα σε διαφορετικές αρτηριακές κατανομές, χωρίς αιμορραγική μετατροπή. Ο καρδιολογικός έλεγχος με 24ώρο monitoring του καρδιακού ρυθμού ανέδειξε παροξυσμική κολπική μαρμαρυγή, ως υποκείμενη αιτία των ισχαιμικών εγκεφαλικών.

Συζήτηση: Η εμπειρία μας από το παραπάνω περιστατικό δεικνύει την ασφάλεια της ενδοφλέβιας θρομβόλυσης ακόμα και σε περιπτώσεις ασθενών με πρόσφατη αιμόπτυση λόγω υποκείμενων βρογχεκτασιών.

Λέξεις ευρετηρίου: αιμόπτυση, βρογχεκτασίες, μαγνητική τομογραφία εγκεφάλου, οξύ ισχαιμικό αγγειακό εγκεφαλικό επεισόδιο, ενδοφλέβια θρομβόλυση

Manuscript

Introduction

Bronchiectasis, consisting an independent risk factor for ischemic stroke and coronary heart disease has been associated with severe complications of IVT in patients with acute myocardial infarction. However, there are scarce data regarding the safety of IVT in acute ischemic stroke.

Methods

We present the case of a 74-year-old woman who received intravenous thrombolysis for AIS despite recent hemoptysis due to underlying bronchiectasis.

Case Report

We describe the interesting case of a 74-year-old woman with medical history of extensive bronchiectasis due to multiple pulmonary infections in younger age and frequent episodes of hemoptysis (about 3 per month). The patient presented with acute onset of left hemiplegia and hemihypesthesia, dysarthria, gaze deviation and decreased level of consciousness (NIHSS-Score on admission: 22) within 75 min from symptom onset and a recent hemoptysis, about 8 hours ago, was also mentioned. Baseline axial brain CT scan on hospital admission (Figure; Panel A) disclosed right hyperdense middle cerebral artery (MCA) sign due to an underlying proximal MCA occlusion and values of hematologic/ coagulation testing was normal.

The patient was treated with systemic thrombolysis using alteplase standard dose (0.9 mg/kg over 60 minutes with initial 10% of dose given as bolus over 1 minute) with an onset-to-treatment-time of 110 minutes. During the first 30 min of alteplase infusion, substantial neurological improvement was documented (NIHSS-score 7), while Transcranial Color-coded Duplex disclosed complete recanalization of right M1-MCA (Thrombolysis in Brain Infarction grade 5). However, during administration and after having received about 70% of the total dose, alteplase-infusion had been interrupted due to recurrent transient hemoptysis. Contrast-enhanced chest-CT scan (Figure; Panel B) revealed the extensive cystic bronchiectasis, without any signs of active hemorrhage.

The patient experienced substantial clinical improvement and symptom resolution and her NIHSS-score at discharge was 2. During hospitalization paroxysmal atrial fibrillation (AF) was detected as the underlying cause of stroke, using cardiac monitoring.

Brain-MRI disclosed acute cardioembolic infarctions in different arterial territories including right MCA (Figure; Panels D-F) without hemorrhagic complications. The patient was treated with antiplatelet therapy for the first 8 days of symptom onset and was then switched to weight-adjusted therapeutic dose of enoxaparin-sodium under regular control of the Anti-Factor-Xa level. The modified-Rankin-Scale Score was 1 at three months.

Discussion

Recent studies indicate, that bronchiectasis consists an independent risk factor for AIS and coronary heart diseases [1-2]. Chen et.al reported through a population-based cohort study from Asian population an incidence rate of 9.18 per 1000 person-years of ischemic stroke in patients with bronchiectasis compared to an incidence rate of 4.66 per 1000 person-years in patients without bronchiectasis [3]. Furthermore bronchiectasis coexisting with diabetes, AF, or hypertension represents a multiplicative risk of ischemic stroke.

However there are only rare case-reports, which describe severe complications in patients with bronchiectasis after administration of systemic thrombolysis for acute myocardial infarction, while international recommendations for the early acute ischemic stroke management of those patients are unavailable [4-6]. Additional, severe hemoptysis is not listed as a contraindication in the current SPC of Actilyse, despite this could be considered as a recent "severe" bleeding. Consequently, the decision to deliver IVT in a patient with acute ischemic stroke and a history of bronchiectasis with recent hemoptysis is an extremely

Figure. Neuroimaging-Findings in an acute ischemic stroke patient due to right middle cerebral artery occlusion with extensive bronchiectasis and recent hemoptysis



Axial brain CT scan on hospital admission disclosing right hyperdense MCA-sign (red arrow-A). Axial chest-CT scan of chest revealing extensive cystic bronchiectasis (B). Axial brain CT scan following r-tPA administration revealing resolution of hyperdense MCA-sign (red arrow-C). Diffusion-weighted imaging (DWI) reveals multiple acute cerebral infarctions in different arterial territories: right middle cerebral artery, left middle cerebral artery and left posterior inferior cerebellar artery (D-F)

demanding task for the treating neurologist, requiring a very quick analysis of the benefit/risk ratio of alteplase treatment for the individual patient.

To the best of our knowledge this is the first report, describing the IVT-administration despite the recent hemoptysis in an AIS patient with extensive known bronchiectasis. Our patient, despite our concerns, achieved significant clinical improvement and was discharged with minimal neurological deficits. Based on our experience this management appears to be not only effective, but also safe. However it is meaningful that these patients or their legal representatives should be informed about the higher risk of hemorrhagic complications following IVT-administration and signed informed consent should be obtained.

Concluding, additional publications are needed to clarify the safety of IVT in AIS with bronchiectasis with or without recent hemoptysis, given the high risk of pulmonary hemorrhage with possible fatal outcomes.

Declarations

Ethics approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Consent to participate

Not applicable.

Consent for publication

The participant has given informed consent to the submission of the case report to the journal.

Availability of data and material

All data are presented in the manuscript.
Conflicts of interest/Competing interests.

Dr Theodorou reports no disclosures.
Dr Kotsali-Peteinelli reports no disclosures.
Dr Bregianni reports no disclosures.
Dr Palaiodimou reports no disclosures.
Dr Papadopoulou reports no disclosures.
Dr Maili reports no disclosures.
Dr Bonakis reports no disclosures.
Dr Voumvourakis reports no disclosures.
Dr Tsivgoulis reports no disclosures.

Funding

No funds, grants, or other support was received.

Authors' contributions

Study conception and design: GT.
Data collection, analysis and interpretation: AT, VKP, MB, LP.
Drafting and revising the manuscript: AT and GT.
Critical comments during manuscript revision: VKP, MP, AB, KV.
All authors read and approved the final manuscript.

Acknowledgments

None.

List of Abbreviations

IVT: intravenous thrombolysis.
AIS: acute ischemic stroke.
MCA**:** middle cerebral artery.
AF: atrial fibrillation.

References

[1] Phua C.S., Wijeratne T., Wong C., Jayaram L., Neurological and Sleep Disturbances in Bronchiectasis. J. Clin. Med. 2017, 6, 114.
[2] Navaratnam V., Millett E. RC, Hurst J., Thomas S., Smeeth L., Hubbard R., et.al., Bronchiectasis and the risk of cardiovascular disease: a population-based study. Thorax 2017;72:161-166.
[3] Chen Y-Fu., Lin H-H., Lin C-S., Turbat B., Wang K-A., Chung W-S., Bronchiectasis and increased risk of ischemic stroke: a nationwide population-based cohort study. International Journal of COPD 2017:12 1375-1383.
[4] O'Reilly SC, Taylor PM, O'Driscoll BR., Occult bronchiectasis presenting as streptokinase-induced hemoptysis. Respir Med 1994; 88:393-395.
[5] Basher AW, Oduwole A., Bhalodkar NC, Mohideen B., Sy E., Sehonanda A., Fatal Hemoptysis during Coronary Thrombolysis. Journal of Thrombosis and Thrombolysis 1996; 3:87-89.
[6] Powers W., Rabinstein A, Ackerson T., Adeoye O., Bambakidis N., Becker K., et.al. on behalf of the American Heart Association Stroke Council. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke. A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2019;50:e344-e418.

ΠΑΡΟΔΙΚΗ ΑΙΜΟΔΥΝΑΜΙΚΗ ΑΣΤΑΘΕΙΑ ΚΑΤΑ ΤΗ ΔΙΑΡΚΕΙΑ ΕΝΔΟΦΛΕΒΙΑΣ ΘΡΟΜΒΟΛΥΣΗΣ ΣΕ ΟΞΥ ΙΣΧΑΙΜΙΚΟ ΑΕΕ- ΠΑΡΟΥΣΙΑΣΗ ΠΕΡΙΣΤΑΤΙΚΟΥ

Ελένη Κρασνίκοβα MD[1, 2], Αικατερίνη Θεοδώρου MD[2], Βασιλική Πετεινέλλη-Κότσαλη MD[2], Γεωργία Καλούδη MD[2], Μαρία Μαΐλη MD[2], Μαρία Χονδρογιάννη MD[2], Χρύσα Αρβανίτη MD[2], Κωνσταντίνος Μελάνης MD[2], Ιωάννα Τσαντζαλή MD[2], Γεωργία Παπαγιαννοπούλου MD[2], Γεώργιος Τσιβγούλης MD[2, 3], Ελένη Μπακόλα, MD[2]

[1] Νευρολογικό Τμήμα, Γενικό Νοσοκομείο Βόλου «Αχιλλοπούλειο»
[2] Β΄ Νευρολογική Κλινική, Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών, Ιατρική Σχολή, Νοσοκομείο «Αττικόν», Αθήνα
[3] Department of Neurology, The University of Tennessee Health Science Center, Memphis, Tennessee, United States of America

Περίληψη

Ασθενής 59 ετών με ιστορικό αρτηριακής υπέρτασης υπό αγωγή με αναστολέα μετατρεπτικού ενζύμου της αγγειοτενσίνης (α-ΜΕΑ) εμφάνισε αιφνιδίως δυσαρθρία και αριστερή ημιπάρεση στα πλαίσια οξέος ισχαιμικού εμφράκτου και αντιμετωπίστηκε με χορήγηση ενδοφλέβιας θρομβόλυσης με αλτεπλάση. Λίγο πριν την ολοκλήρωση της έγχυσης της θρομβολυτικής αγωγής η ασθενής εμφάνισε παροδική αιμοδυναμική αστάθεια με βραδυκαρδία και εκσεσημασμένη υπόταση που αντιμετωπίστηκαν επιτυχώς με ενδοφλέβια χορήγησης ατροπίνης, υγρών και αγγειοσυσπαστικών. Ο έλεγχος για στοματογλωσσικό αγγειοοίδημα ήταν αρνητικός. Η παροδική αιμοδυναμική αστάθεια κατά τη διάρκεια ή αμέσως μετά τη θεραπεία με αλτεπλάση σε ασθενείς με οξύ ισχαιμικό ΑΕΕ που λαμβάνουν α-ΜΕΑ υποδηλώνει αγγειοδιαστολή λόγω της συσσώρευσης της βραδυκινίνης, τελικού προϊόντος ενός καταρράκτη πρωτεολύσεων πυροδοτούμενου από την αλτεπλάση που μπορεί επίσης να προκαλέσει σε κάποιες περιπτώσεις στοματογλωσσικό αγγειοοίδημα. Η παρούσα περιγραφή περιστατικού αναδεικνύει αυτή την σπάνια επιπλοκή και αναλύει υποκείμενους μηχανισμούς και τρόπους αντιμετώπισης.

Λέξεις ευρετηρίου: ισχαιμικό εγκεφαλικό, αλτεπλάση, αιμοδυναμική αστάθεια, βραδυκινίνη, αγγειοοίδημα

TRANSIENT CARDIOVASCULAR INSTABILITY DURING INTRAVENOUS THROMBOLYTIC THERAPY IN ACUTE ISCHEMIC STROKE – CASE REPORT

Eleni Krasnikova MD[1, 2], Aikaterini Theodorou MD[2], Vassiliki Peteinelli-Kotsali MD[2], Georgia Kaloudi MD[2], Maria Maili MD[2], Maria Chondrogianni MD[2], Chryssa Arvaniti MD[2], Konstantinos Melanis MD[2], Ioanna Tsantzali MD[2], Georgia Papagiannopoulou MD[2], GeorgiosTsivgoulis MD[2, 3], Eleni Bakola, MD[2]

[1] Department of Neurology, General Hospital of Volos, "Achilopouleio"
[2] Second Department of Neurology, National and Kapodistrian University of Athens, School of Medicine, "Attikon" Hospital, Athens
[3] Department of Neurology, The University of Tennessee Health Science Center, Memphis, Tennessee, United States of America

Abstract

A 59-year-old woman on antihypertensive treatment with Angiotensin-Converting-Enzyme (ACE) inhibitor was transferred to our hospital with acute onset dysarthria and left hemiparesis due to acute ischemic stroke. Before the end of treatment with intravenous alteplase infusion, she developed transient bradycardia with subsequent severe hypotension without orolingual angioedema and was treated successfully with fluids and vasopressors without any neurological deterioration. Transient hemodynamic instability during or right after alteplase treatment in acute ischemic stroke patients pretreated with ACE inhibitors may be caused by vasodilatation due to bradykinin accumulation induced by tissue plasminogen activator. This very uncommon complication may also be accompanied by orolingual angioedema. The present case report highlights potential underlying mechanisms and suggested approaches.

Key words: cerebral infarction, alteplase, bradykinin, hemodynamic instability

Εισαγωγή

Η ενδοφλέβια (ΕΦ) θρομβόλυση με αλτεπλάση (ιστικό ενεργοποιητή του πλασμινογόνου- rtPA) αποτελεί την ενδεδειγμένη, ασφαλή και αποτελεσματική θεραπευτική αντιμετώπιση του οξέος ισχαιμικού Αγγειακού Εγκεφαλικού Επεισοδίου (ΑΕΕ) εντός 4,5 ωρών από την έναρξη συμπτωμάτων [1]. Η χορήγηση της θρομβολυτικής αγωγής θα πρέπει να γίνεται ταυτοχρόνως με παρακολούθηση των ζωτικών σημείων (αρτηριακή πίεση, καρδιακή συχνότητα, οξυμετρία) προκειμένου να διαγνωστούν και να αντιμετωπιστούν έγκαιρα ενδεχόμενες επιπλοκές της θεραπείας.

Στην παρούσα εργασία παρουσιάζουμε μία ασθενή με οξύ ισχαιμικό ΑΕΕ που έλαβε ΕΦ θρομβόλυση και παρουσίασε προ της ολοκλήρωσης έγχυσης του φαρμάκου παροδική αιμοδυναμική αστάθεια με σημαντική αρτηριακή υπόταση και βραδυκαρδία.

Παρουσίαση περιστατικού

Γυναίκα 59 ετών με ατομικό αναμνηστικό αρτηριακής υπέρτασης υπό αγωγή με αναστολέα του μετατρεπτικού ενζύμου της αγγειοτενσίνης (περινδοπρίλη) διακομίσθηκε στο Τμήμα Επειγόντων Περιστατικών με αιφνίδιας έναρξης αριστερή ημιπάρεση, ημιϋπαισθησία και δυσαρθρία (NIHSS 10) από 90 λεπτών. Η αξονική τομογραφία εγκεφάλου δεν ανέδειξε οξεία παθολογία. Διενεργήθηκε ενδοφλέβια θρομβόλυση (ΕΦΘ) 120 λεπτά από την έναρξη των συμπτωμάτων. Ταυτοχρόνως με τη κλινική βελτίωση της νευρολογικής της σημειολογίας η ασθενής εμφάνισε σταδιακή πτώση της αρτηριακής πίεσης κατά τη διάρκεια της θεραπείας. Δέκα λεπτά προ ολοκλήρωσης της ΕΦΘ κι ενώ ήταν πλέον ασυμπτωματική, παρουσίασε σημαντική βραδυκαρδία (32 σφύξεις/λεπτό) και υπόταση (54/32mmHg) που αντιμετωπίστηκαν επιτυχώς με ενδοφλέβια χορήγηση ατροπίνης, φυσιολογικού ορού και αγγειοσυσπαστικών (νοραδρεναλίνης). Η ασθενής ελέγχθηκε άμεσα για στοματογλωσσικό αγγειοοίδημα, το οποίο και αποκλείστηκε. Το διαθωρακικό υπερηχογράφημα καρδίας που διενεργήθηκε επίσης άμεσα δεν ανέδειξε παθολογία και οι αξονικές τομογραφίες και αγγειογραφίες που ακολούθησαν (αξονική θώρακος, κοιλίας, αγγειογραφία αορτής) απέκλεισαν το ενδεχόμενο αιμορραγίας ή διαχωρισμού.

Η μαγνητική τομογραφία της ασθενούς που διενεργήθηκε τη δεύτερη μέρα της νοσηλείας της ήταν αρνητική για οξύ ισχαιμικό έμφρακτο ως επί αποφευχθέντος ισχαιμικού ΑΕΕ (averted stroke) μετά από επιτυχή ΕΦ θρομβόλυση. Μετά από πενθήμερη νοσηλεία η ασθενής εξήλθε σε άριστη κλινική κατάσταση (NIHSS 0).

Συζήτηση

Στις επιπλοκές της ενδοφλέβιας θρομβόλυσης στο οξύ ισχαιμικό ΑΕΕ περιλαμβάνονται αντιδράσεις υπερευαισθησίας και αιμορραγικές εκδηλώσεις. Η εμφάνιση αναφυλακτικής αντίδρασης με αιμοδυναμική αστάθεια ή/και στοματογλωσσικό αγγειοοίδημα είναι αρκετά σπάνια (2%), αλλά αποτελεί δυνητικά θανατηφόρα επιπλοκή [1] και είναι συχνότερη σε ασθενείς που λαμβάνουν αντιϋπερτασική αγωγή με αναστολείς μετατρεπτικού ενζύμου αγγειοτενσίνης και ανταγωνιστές υποδοχέων αγγειοτενσίνης ΙΙ [2].

Η παροδική αιμοδυναμική αστάθεια και το αγγειοοίδημα είναι επακόλουθα αγγειοδιαστολής και αυξημένης αγγειακής διαπερατότητας λόγω δράσης ενός αγγειοδιασταλτικού πεπτιδίου, της βραδυκινίνης. Η βραδυκινίνη είναι το τελικό αποτέλεσμα ενός καταρράκτη πρωτεολύσεων που μπορεί να λάβει χώρα κατά τη διάρκεια της ενδοφλέβιας θρομβόλυσης με αλτεπλάση [3] (εικόνα 1). Ο καταρράκτης των πρωτεολύσεων ξεκινά με τη μετατροπή του πλασμινογόνου σε πλασμίνη από την αλτεπλάση, η οποία με τη σειρά της διασπά την προκαλλικρεΐνη σε καλλικρεΐνη [4]. Η καλλικρεΐνη τελικά υδρολύει το κινινογόνο υψηλού μοριακού βάρους στο πλάσμα σε βραδυκινίνη [5], η οποία συνδεόμενη με τους υποδοχείς βραδυκινίνης τύπου Β2 στα τοιχώματα των αγγείων προκαλεί τη διαστολή τους. Υπεύθυνο για την αποδόμηση της βραδυκινίνης είναι το μετατρεπτικό ένζυμο. Σε ασθενείς που λαμβάνουν αναστολείς μετατρεπτικού ενζύμου και στους οποίους χορηγείται αλτεπλάση η αποδόμηση της βραδυκινίνης είναι αργή με αποτέλεσμα την παρατεταμένη δράση της καθώς αυτή συσσωρεύεται [6].

Σε μεγάλη σειρά 923 ασθενών που έλαβαν ενδοφλέβια θρομβόλυση με αλτεπλάση το αγγειοοίδημα ως αποτέλεσμα της δράσης της βραδυκινίνης εμφανίστηκε 15 έως 105 λεπτά μετά την έναρξη της θρομβολυτικής αγωγής με έναν μέσο χρόνο τα 70 λεπτά [7]. Και στην περίπτωση της ασθενούς που παρουσιάζουμε η παροδική αιμοδυναμική αστάθεια ως αποτέλεσμα της αγγειοδιαστολής που προκάλεσε η συσσώρευση της βραδυκινίνης εμφανίστηκε 50 λεπτά μετά την έναρξη της θρομβολυτικής αγωγής.

Επίσης στην ίδια μελέτη φάνηκε η συσχέτιση του στοματογλωσσικού αγγειοοιδήματος με έμφρακτο στη νήσο του Reil. Αυτό είχε ήδη διαφανεί και σε παλαιότερη μελέτη [2] με υψηλό σχετικό κίνδυνο εμφάνισης στοματογλωσσικού αγγειοοιδήματος σε οξύ ισχαιμικό έμφρακτο της νήσου του Reil και του μετωπιαίου λοβού προσθίως της σχισμής του Sylvius.

Είναι γνωστό ότι η νήσος του Reil σχετίζεται με τη λειτουργία του αυτόνομου νευρικού συστήματος. Δομικές βλάβες όπως ισχαιμικά ή αιμορραγικά ΑΕΕ ή ηλεκτροφυσιολογικές αλλαγές στην περιοχή στα πλαίσια επιληπτικών κρίσεων μπορεί να προκαλέσουν σημαντικές καρδιακές δυσλειτουργίες έως και ξαφνικό θάνατο [8]. Στην ασθενή μας, καθώς επρόκειτο για αποφευχθέν έμφρακτο, δεν ανεδείχθη ισχαιμική βλάβη στην εν λόγω περιοχή.

Η διάρκεια της δράσης της βραδυκινίνης κατά τη χορήγηση της αλτεπλάσης εξαρτάται από το ρυθμό παραγωγής της καθώς ο χρόνος ημίσειας ζωής της είναι μόλις 17 δευτερόλεπτα [6]. Συνεπώς και η αιμο-

Εικόνα 1. Καταρράκτης πρωτεολύσεων πυροδοτούμενος από ιστικό ενεργοποιητή του πλασμινογόνου (rtPA) (τροποποιημένο από *Gauberti, M.et al.*, 2018)



HMWK : υψηλού μοριακού βάρους κινινογόνο, Bradykinin : βραδυκινίνη, Prekallikrein: προκαλλικρεΐνη, Kallikrein: καλλικρεΐνη, Plasminogen: πλασμινογόνο, Plasmin: πλασμίνη, tPA: ιστικός ενεργοποιητής των πλασμινογόνου, fibrin:ινώδες, fibrinogen: ινωδογόνο, FDPs: προϊόντα αποδόμησης ινώδους

δυναμική αστάθεια που προκαλείται είναι παροδική όπως στην περίπτωση που παρουσιάζουμε και ενίοτε αυτοπεριοριζόμενη [9].

Συμπέρασμα

Κατά η διάρκεια της ΕΦ θρομβόλυσης οι ασθενείς θα πρέπει να παρακολουθούνται στενά και να καταγράφονται λεπτομερώς και συνεχώς τα ζωτικά τους σημεία, ώστε στην περίπτωση αιμοδυναμικής αστάθειας να γίνεται άμεση παρέμβαση. Η πρώτη ενέργεια στην εμφάνιση αιμοδυναμικής αστάθειας θα πρέπει είναι πάντα ο έλεγχος βατότητας του αεραγωγού, ο αποκλεισμός δηλαδή στοματογλωσσικού αγγειοοιδήματος ως αποτέλεσμα εκσεσημασμένης αγγειοδιαστολής προκαλούμενης από τη συσσώρευση βραδυκινίνης. Η δεύτερη ενέργεια είναι η άμεση χορήγηση υγρών και αγγειοσυσπαστικών. Τέλος, η θεραπευτική αντιμετώπιση στοματογλωσσικού αγγειοοιδήματος κατά της διάρκεια ενδοφλέβιας θρομβόλυσης συνοψίζεται στον πίνακα 1 [10-13]. Ειδική αναφορά θα πρέπει να γίνει σε φάρμακα που στοχεύουν ειδικά στη παθοφυσιολογία του αγγειοοιδήματος όπως είναι η ικατιβάντη (icatibant) ως εκλεκτικός ανταγωνιστής του υποδοχέα βραδυκινίνης τύπου 2 και ο αναστολεάς της C1-εστεράσης.

Πίνακας 1. Αντιμετώπιση στοματογλωσσικού αγγειοοιδήματος κατά τη χορήγηση ΕΦ rtPA

ΓΕΝΙΚΑ ΜΕΤΡΑ
• Διατήρηση αεραγωγού • Ενδοτραχειακή διασωλήνωση μπορεί να μην είναι απαραίτητη αν το οίδημα περιορίζεται στο πρόσθιο τμήμα γλώσσας και στα χείλη • Αν το οίδημα είναι σε λάρυγγα, υπερώα, έδαφος στοματικής κοιλότητας ή στον ρινοφάρυγγα και επιδεινώνεται ταχέως (μέσα σε 30min) → υψηλού κινδύνου → πιθανώς αναγκαία η διασωλήνωση • **Διακοπή** ΕΦ αλτεπλάσης • **Απαγορεύεται** η χορήγηση ACEIs, ARBs
ΦΑΡΜΑΚΕΥΤΙΚΗ ΑΝΤΙΜΕΤΩΠΙΣΗ
• Χορήγηση Solucortef 100mg iv (υδροκορτιζόνη), εναλλακτικά Solumedrol 125mg iv (μεθυλπρεδνιζολόνη) • Χορήγηση Fenistil 4mg iv (1 amp σε 100ml N/S 0,9%) • Αν επιδείνωση αγγειοοιδήματος → αδρεναλίνη (1mg/ml) im στο μηρό σε δόση 0,3-0,6ml [Εναλλακτικά νεφελοποίηση 0,5ml (1/2 amp) αδρεναλίνης] • Icatibant (Fyrazyr)* 3ml (30mg) σε προγεμισμένη σύριγγα sc. στην κοιλιακή χώρα Αν χρειαστεί: 2η χορήγηση μετά από 6h (*προσοχή*: όχι πάνω από 3 ενέσεις /24ωρο) • Αναστολέας C1-εστεράσης (Berinert) (20IU/kg) ΕΦ, αργή έγχυση 4ml/min

* Εκλεκτικός ανταγωνιστής του υποδοχέα βραδυκινίνης τύπου Β2.

Βιβλιογραφία

[1] Τσιβγούλης Γ., Μήτσογλου Α., Φλαμουρίδου Μ., Τσακαλδήμη Σ., Ντάλος Π., Χαραλαμπόπουλος Κ. και συν. Ενδοφλέβια θρομβόλυση στο οξύ ισχαιμικό: ΑΕΕ από την θεωρία στην πράξη. Ειδική έκδοση του περιοδικού Νευρολογία, Τόμος 21 – Τεύχος 5, Ειδική έκδοση 1, Δεκέμβριος 2012, σελ.17,24.

[2] Hill MD, Lye T, Moss H, Barber PA, Demchuk AM, Newcommon NJ, Green TL, Kenney C, Cole-Haskayne A, Buchan AM. Hemi-orolingual angioedema and ACE inhibition after alteplase treatment of stroke. Neurology. 2003;60:1525-1527.

[3] Gauberti M, Potzeha F, Vivien D, Martinez de Lizarrondo S. Impact of Bradykinin Generation During Thrombolysis in Ischemic Stroke. Front Med (Lausanne). 2018;5:195.

[4] Molinaro G, Gervais N, Adam A. Biochemical basis of angioedema associated with recombinant tissue plasminogen activator treatment: an in vitro experimental approach. Stroke 33: 1712-1716, 2002.

[5] Kaplan AP, Joseph K, Shibayama Y, et al. Bradykinin formation. Plasma and tissue pathways and cellular interactions. Clin Rev Allergy Immunol 16:403-429,1998.

[6] Ferreira SH, Vane JR. The disappearance of bradykinin and eledoisin in the circulation and vascular beds of the cat. Br J Pharmacol Chemother 30: 417-424, 1967.

[7] Myslimi F, Caparros F, Dequatre-Ponchelle N, et al. Orolingual Angioedema During or After Thrombolysis for Cerebral Ischemia. Stroke. 2016;47(7):1825-1830.

[8] Oppenheimer S, Cechetto D. The Insular Cortex and the Regulation of Cardiac Function. Compr Physiol. 2016;6(2):1081-1133.

[9] Kageyama T, Okanoue Y, Takai R, Suenaga T. Cardiovascular Instability Preceded by Orolingual Angioedema after Alteplase Treatment. Intern Med. 2016;55(4):409-412.

[10] Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association [published correction in Stroke. 2019 Dec;50(12):e440-e441]. Stroke.2019;50(12):e344-e418.

[11] Cheong E, Dodd L, Smith W, Kleinig T. Icatibant as a potential treatment of life-treating alteplase-induced angioedema. J Stroke Cerebrovasc Dis. 2018;27(2):e36-e37.

[12] Pahs L, Droege C, Kneale H, Pancioli A. A novel approach to the treatment of orolingual angioedema after tissue plasminogen activator administration. Ann Emerg Med. 2016;68(3):345-348.

[13] Riha HM, Summers BB, Rivera JV, Van Berkel MA. Novel therapies for angiotensin-converting enzyme inhibitor-induced angioedema: A systematic review of current evidence. J Emerg Med. 2017;53(5):662-679.

INTRAVASCULAR LARGE B-CELL LYMPHOMA: A RARE CAUSE OF STROKE-LIKE EPISODES, COMBINED WITH COGNITIVE DECLINE AND MYELOPATHY

Marianna Bregianni MD[1], Anastasios Bonakis MD, PhD[1], Chistina Zompola[1], Periklis Foukas MD, PhD[2], Matilda Papathanasiou MD, PhD[3], Efstathios Boviatsis MD, PhD[4], Georgios Tsivgoulis MD, PhD, FESO[1, 5], Konstantinos Voumvourakis MD, PhD[1]

[1] 2nd Department of Neurology, National and Kapodistrian University of Athens, School of Medicine, "Attikon" University Hospital, Athens
[2] 2nd Department of Pathology, National and Kapodistrian University of Athens, School of Medicine, "Attikon" University Hospital, Athens
[3] 2nd Department of Radiology, University of Athens, School of Medicine, "Attikon" University Hospital, Athens
[4] Department of Neurosurgery, National and Kapodistrian University of Athens, School of Medicine, "Attikon" University Hospital, Athens
[5] Department of Neurology, The University of Tennessee Health Science Center, Memphis, Tennessee, United States of America

Abstract

Intravascular large B-cell lymphoma (IVBCL) is an extremely rare, frequently fatal, extranodal, non-Hodgkin lymphoma. Diagnostic delay is common, mainly due to the variety of atypical clinical symptoms and signs. Early intervention improves outcome, although response to chemotherapeutic agents remains poor. We present a case of IVBCL with rapidly progressive dementia, myelopathy and stroke-like episodes. MRI showed typical findings of subcortical white matter lesions with restricted diffusion and gadolinium enhancement and a thoracic spine lesion. Awareness should be raised among clinicians for this extremely rare, life-threatening clinical entity, because of the potentially treatable clinical outcome in the grounds of timely diagnosis.

Key words: stroke-like episodes, intravascular lymphoma, brain biopsy, immunohistochemistry

ΕΝΔΑΓΓΕΙΑΚΟ ΛΕΜΦΩΜΑ ΑΠΟ ΜΕΓΑΛΑ Β-ΚΥΤΤΑΡΑ: ΜΙΑ ΣΠΑΝΙΑ ΝΟΣΟΣ, ΜΙΜΟΥΜΕΝΗ ΕΓΚΕΦΑΛΙΚΑ ΕΠΕΙΣΟΔΙΑ, ΤΑΧΕΩΣ ΕΞΕΛΙΣΣΟΜΕΝΗ ΑΝΟΙΑ ΚΑΙ ΜΥΕΛΟΠΑΘΕΙΑ

Μαριάννα Μπρέγιαννη[1], Αναστάσιος Μπονάκης[1], Χριστίνα Ζόμπολα[1], Περικλής Φούκας[2], Ματίλντα Παπαθανασίου[3], Ευστάθιος Μποβιάτσης[4], Κωνσταντίνος Βουμβουράκης[1], Γεώργιος Τσιβγούλης[1, 5]

[1] Β' Πανεπιστημιακή Νευρολογική Κλινική, Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών, Ιατρική Σχολή, «Αττικόν» Πανεπιστημιακό Νοσοκομείο, Αθήνα
[2] Β' Παθολογική Ανατομική, Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών, Ιατρική Σχολή, «Αττικόν» Πανεπιστημιακό Νοσοκομείο, Αθήνα
[3] Β' Εργαστήριο Ακτινολογίας, Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών, Ιατρική Σχολή, «Αττικόν» Πανεπιστημιακό Νοσοκομείο, Αθήνα
[4] Β' Νευροχειρουργική Κλινική, Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών, Ιατρική Σχολή, «Αττικόν» Πανεπιστημιακό Νοσοκομείο, Αθήνα
[5] Department of Neurology, The University of Tennessee Health Science Center, Memphis, Tennessee, United States of America

Περίληψη

Το ενδαγγειακό λέμφωμα από μεγάλα Β-κύτταρα είναι ένα εξαιρετικά σπάνιο και συχνά θανατηφόρο, εξωλεμφαδενικό, non-Hodgin λέμφωμα. Χαρακτηρίζεται από την ανεύρεση λεμφωματωδών κυττάρων στον τριχοειδικό αυλό, χωρίς την παρουσία λεμφαδενοπάθειας ή συμπαγούς όγκου. Η μέση ηλικία εμφάνισης είναι τα 67 έτη. Η προσβολή είναι πολυσυστηματική, με άτυπα συμπτώματα όπως εμπύρετο, κακουχία, ανορεξία, απώλεια βάρους, ενώ η διήθηση του Κεντρικού Νευρικού Συστήματος (ΚΝΣ) είναι συχνά η πρώτη εκδήλωση της νόσου. Εμφανίζεται με σύγχυση, διαταραχές μνήμης και βάδισης, επιληπτικές κρίσεις, και εγκεφαλικά

επεισόδια. Τα απεικονιστικά ευρήματα είναι μη ειδικά, ενδεικτικά νόσου μικρών αγγείων, εμβολικών ΑΕΕ, αγγειίτιδας ΚΝΣ, μηνιγγίτιδας ή μυελοπάθειας. Το παρόν άρθρο αφορά σε περιστατικό ενδαγγειακής λεμφωμάτωσης, με ταχέως εξελισσόμενη άνοια, μυελοπάθεια και εγκεφαλικά επεισόδια, με εκτενή αναφορά στα κύρια χαρακτηριστικά της νόσου, στη διαφορική διάγνωση και στα ευρήματα της ιστολογικής εξέτασης του εγκεφάλου. Σκοπός αυτού είναι η ευαισθητοποίηση σχετικά με αυτή τη σπάνια, αλλά δυνητικά θεραπεύσιμη, πολυσυστηματική κακοήθεια.

Λέξεις ευρετηρίου: ενδαγγειακό λέμφωμα, εγκεφαλικά επεισόδια, βιοψία εγκεφάλου, ανοσοϊστοχημεία

Introduction

Intravascular large B-cell lymphoma (IVLBCL) is a rare, usually fatal, high-grade, extranodal non-Hodgkin lymphoma. It is characterized by the selective growth of neoplastic lymphoid B-cells within the lumen of small vessels [1]. Clinical presentation is characterized by atypical signs and symptoms, making diagnostic approach challenging. Not uncommonly, diagnosis is only made postmortem. Here, we present a case of IVBCL in which stroke-like episodes, rapidly progressive dementia and myelopathy prevailed throughout the disease course.

Case description

A 73-year-old man presented with a 3-month history of gait disturbance, numbness of lower limbs and trunk, incontinence and constipation. Family reported of anorexia, memory deficits and personality change over the last 8 months. No fever or skin alterations were reported. The medical history included hypertension and hypercholesterolemia, treated with amlodipine, valsartan, simvastatin and clopidogrel for stroke prevention. The patient was a former smoker (37 pack-years) and denied alcohol consumption.

The neurological examination revealed emotional lability, disinhibition and cognitive deficits (mMSE 14/30). Spastic right hemiparesis with spastic paresis of the left leg, T7 level of hypoesthesia, incontinence and constipation were present. During his hospitalization, the patient exhibited an acute left hemiparesis with complete paralysis of left lower limb, confusion, irritability and hallucinations. Brain MRI revealed lesions of high T2 signal with restricted diffusion and gadolinium enhancement in centra semiovale bilaterally and right temporal lobe (Figure 1). Thoracic spine MRI revealed a small, non-enhancing intramedullary lesion (<1cm in diameter) at T7 level, on the right of the midline, close to the dorsal column (Figure 1).

Differential diagnosis included embolic strokes, primary CNS angiitis, demyelinating and autoimmune diseases, infectious and neoplastic CNS invasion and paraneoplastic encephalomyelitis.

Complete autoantibody panel (ANA, anti- dsDNA, anti-Scl, ACA, ENA, anti-SM, anti-RNP, anti- SSA/Ro, anti-SSB/La, anti-cardiolipin IgM & IgG, anti-β2GP1, anti-MPO, anti-PR3, anti-M2 and lupus anticoagulants) were negative. Antibodies against HIV, RPR test for syphilis and IGRA for tuberculosis were also negative. Mild anemia and ESR elevation (32mm/hr) were the only abnormal blood values. LDH was within normal levels at presentation. CSF analysis showed mild pleocytosis (7 WBC/mm3) and elevated total protein (654mg/l). Nested Multiplex PCR in the CSF was negative for Escherichia Coli, Heamophilus Influenza, Listeria Monocytogenes, Neisseria Meningitidis, Streptococcus Agalactiae, Streptococcus Pneumoniae, Cytomegalovirus, Enterovirus, Herpes Simplex 1 and 2, Human Herpesvirus 6 (HHV-6) Human Parechovirus, Varicella Zoster virus and Cryptococcus Neoformans/gattii. CSF cultures for bacteria, fungi and mycobacteria were also sterile. A thorough search for cancer was performed, with no pathological findings; whole-body CT scan and PET-CT scan, scrotal ultrasound, GI endoscopy and serum antineuronal antibodies (anti- Ri, Yo, Hu, Ma2, CV2, amphiphysin) were negative. Digital substraction angiography of the brain, 24-hour cardiac rhythm monitoring, transthoracic, transesophageal echocardiography and transcranial doppler bubble study did not reveal any pathology. Considering the inconclusive work up and the patient's severe disability and rapid deterioration, a trial of pulse dose intravenous methylprednisolone (1gr/day x3 days) was administered, with no clinical response.

Further diagnostic approach included stereotactic brain biopsy. Sample tissue was obtained from the right temporal lobe lesion. Photomicroscopy revealed infiltration of the lumen of brain capillaries with large atypical lymphoid cells and CD 20. Pax5 immunohistochemistry demonstrated the B-cell immunophenotype of the intravascular lymphoid cells. The Ki-67 proliferation index was almost 100% (Figure 2). At this point, diagnosis of intravascular B cell lymphoma was made. The patient underwent 1 cycle of treatment with rituximab 375mg/m^2, high dose intravevous methotrexate 2500mg/m^2 and cytarabine 3gr/m^2/d. His poor medical condition did not allow him to receive any further cycles of chemotherapy, as he became septic from hospital acquired infections and died.

Figure 1. MRI lesions with typical findings of IVBCL

T2, FLAIR hyperintense lesions (A, B) with contrast enhancement (C) and restricted dif-fusion (D, E). Thoracic spine MRI with small, non-enhancing, lesion of less than 1cm, located right and posteriorly at T7 level (F)



Figure 2. Brain biopsy with typical histopathology findings of IVBCL

Photomicrography of brain biopsy (x40), stain H&E, shows the presence of large atypical lymphoid cells in the lumen of a brain capillary (A). CD20 and Pax5 immunohistochemistry, demonstrates the B-cell immunophenotype of the intravascular atypical lymphoid cells, (B, C respectively). The Ki67 proliferation index is almost 100% (D)



Discussion

Intravascular large B-cell lymphoma is a rare subtype of non-Hodgkin lymphoma, characterized by intracapillary proliferation, without capillary infiltration, of malignant B-cells. Mean age of onset is 67 years old (41-85 years). IVLBCL is a multisystemic disease, mainly involving the skin and the CNS. Random skin and muscle biopsy, from unaffected regions are diagnostically valuable, with sensitivity ranging from 67% to 100% in different studies [3, 4].

Systemic symptoms, such as low-grade fever, general malaise, anorexia, weight loss and respiratory symptoms may be present. Characteristically, there is absence of lymphadenopathy and extranodal mass lesions, although infiltration of bone marrow may occur. Involvement of the CNS is evident in 60% of patients, presenting as encephalopathy, rapidly progressive dementia, gait disturbance, seizures and stroke-like episodes. Myelitis of conus medullaris and infiltration of cauda equina are typical, but spinal cord lesions may also present as a longitudinally extensive spinal lesion. Brain MRI findings are non-specific, resembling small vessel disease, embolic strokes or CNS angiitis. Multifocal T2/FLAIR hyperintense lesions with restricted diffusion in subcortical white matter and cortex are mainly encountered. Gadolinium enhancement lacks typical pattern and is both parenchymal and meningeal. Enhancement may reverse with treatment initiation, although it is not considered as a prognostic marker of treatment response [5].

In most cases, CSF shows pleocytosis with elevated protein. An elevated β2- microglobulin[6] in the CSF is a marker of intrathecal invasion. In our case, diagnosis could only be made with brain biopsy. Differential diagnosis of IVBCL includes other types of lymphomas (lymphomatoid granulomatosis, CD5+ diffuse large B-cell lymphoma, primary CNS lymphoma, reactive lymphoid hyperplasia), and leukemias. Therapeutic strategies are rituximab-combined chemotherapeutic agents and autologous stem cell transplantation [2].

Conclusion

The absence of typical features and the rarity of the disease leads to diagnostic and therapeutic delay. However, early intervention improves morbidity and mortality rates. Thus, intravascular large B-cell lymphoma, although rare, should be suspected in cases with watershed strokes in MRI, especially when associated with other, unexplained, neurological and systemic symptoms.

Declarations

Ethics approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Abbreviations

IVBCL	intravascular B-cell lymphoma
mMSE	mini-mental state examination
MRI	magnetic resonance imaging
CNS	central nervous system
ESR	estimated sedimentation rate
CSF	cerebrospinal fluid
PCR	polymerase chain reaction
FLAIR	fluid attenuated inversion recovery

REFERENCES

[1] Nakamura S, Ponzoni M, Campo E. Intravascular large B-cell lymphoma, In: Swerlow SH *et. al.* (eds) (2017). WHO classification of tumours of the haematopoietic and lymphoid tissues. IARC, Lyon, pp 317-318.

[2] Shimada K, Kiyoi H. Current progress, and future perspectives of research on intravascular large B-cell lymphoma. *Cancer Sci.* 2021;112(10):3953-3961. doi:10.1111/cas.15091.

[3] Diaz E, Ditchi Y, Roux A, Senet P, Barbaud A, Francès C, Pacanowski J, Chasset F. The value of healthy skin biopsy in the diagnosis of intravascular B-cell lymphoma: A case report and systematic literature review. *Ann Dermatol Venereol.* 2019 .

[4] Tahsili-Fahadan P, Rashidi A, Cimino PJ, Bucelli RC, Keyrouz SG. Neurologic manifestations of intravascular large B-cell lymphoma. *Neurol Clin Pract.* 2016;6(1):55-60.

[5] Baehring JM, Henchcliffe C, Ledezma CJ et al. Intravascular lymphoma: magnetic resonance imaging correlates of disease dynamics within the central nervous system *Journal of Neurology, Neurosurgery & Psychiatry* 2005;76:540-544.

[6] Caudie C, Bancel J, Dupont M, Matanza D, Poitevin F, Honnorat J. Valeurs usuelles et utilité diagnostique de la beta2-microglobuline dans le liquide céphalorachidien [CSF levels and diagnostic utility of cerebrospinal fluid beta2-microglobulin]. *Ann Biol Clin* (Paris). 2005 Nov-Dec;63(6):631-7. French. PMID: 16330382.

Εκπαιδευτικές Δράσεις της ΕΝΕ

ΕΚΠΑΙΔΕΥΤΙΚΟ ΠΡΟΓΡΑΜΜΑ ΕΛΛΗΝΙΚΗΣ ΝΕΥΡΟΛΟΓΙΚΗΣ ΕΤΑΙΡΕΙΑΣ ΓΙΑ ΤΟ ΑΚΑΔΗΜΑΪΚΟ ΕΤΟΣ 2021-2022

- **20 Νοεμβρίου 2021: «Βιοδείκτες στη διάγνωση των Ανοϊκών Συνδρόμων»**, Webinar
- **4 Δεκεμβρίου 2021: «Ιατρική βασισμένη στην τεκμηρίωση: Από τη θεωρία στην πράξη»**, Ημερίδα, Αθήνα
- **29-30 Ιανουαρίου 2022: «Γενετικός Έλεγχος στα Νευρολογικά Νοσήματα-Θεραπεύσιμα Νευρογενετικά Νοσήματα»**, Διημερίδα, Αθήνα
- **26-27 Φεβρουαρίου 2022: «Κεφαλαλγίες»**, Διημερίδα, Ηράκλειο Κρήτης
- **19-20 Μαρτίου 2022: «Απομυελίνωση και όψιμη ηλικία»**, Διημερίδα, Θεσσαλονίκη
- **9 Απριλίου 2022: «Νεότερες διαγνωστικές και θεραπευτικές εξελίξεις στο χώρο των Νευρομυϊκών Νοσημάτων»**, Μονοήμερο Σεμινάριο, Πάτρα
- **14 Μαΐου 2022: «Πρακτική διαχείριση των ασθενών με Άνοια στην καθημερινότητα»**, Μονοήμερο Σεμινάριο, Αθήνα
- **16-19 Ιουνίου 2022: 33ο Πανελλήνιο Συνέδριο Νευρολογίας**, Ηράκλειο Κρήτη

Ενημερωτικές Σελίδες...

Συνέδρια - Ημερίδες - Συμπόσια - Επιστημονικές εκδηλώσεις

2022

- **4-6 Μαΐου 2022: 8th European Stroke Organisation Conference (ESOC)**, Lyon, France
- **5-8 Μαΐου 2022: 34ο Πανελλήνιο Συνέδριο Γενικής/Οικογενειακής Ιατρικής**, Σύρος
- **4 Ιουνίου 2022: Σπάνια Νευρολογικά Νοσήματα, Ημερίδα Α΄ Νευρολογικής Κλινικής**, διαδικτυακή
- **16-19 Ιουνίου 2022: 33ο Πανελλήνιο Συνέδριο Νευρολογίας**, Ηράκλειο Κρήτης
- **25-28 Ιουνίου 2022: 8th Congress of the European Academy of Neurology**, Vienna, Austria
- **9-13 Ιουλίου 2022: 14th European Epilepsy Congress**, Geneva, Switzerland
- **8 Σεπτεμβρίου 2022: Νευρολογικές παθήσεις στην ΠΦΥ διεπιστημονικές προσεγγίσεις, Ε.ΚΟ.ΓΕΝ.ΙΑ.**, Πόρτο Χέλι
- **24-25 Σεπτεμβρίου 2022: Το ταξίδι του ασθενούς**, ΕΛΛ.Α.ΝΑ., Αθήνα
- **26-28 Οκτωβρίου 2022: ECTRIMS 2022**, Amsterdam
- **10-13 Νοεμβρίου 2022: 10ο Πανελλήνιο Συνέδριο Αγγειακών Εγκεφαλικών Νόσων**, Θεσσαλονίκη
- **8-11 Δεκεμβρίου 2022: ΕΛΛ.Α.ΝΑ.**, Θεσσαλονίκη